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Insulin resistance, part of the metabolic syndrome, is associated with type 2 
diabetes mellitus (T2DM) and increased risk for Alzheimer’s disease (AD). The !4 allele 
of APOE is the greatest genetic risk factor for sporadic, late onset AD, and is also 
associated with risk for T2DM. The thiazolidinediones (TZDs), PPAR" agonists, are 
peripheral insulin sensitisers used to treat T2DM and have been found to slow 
cognitive decline in mild to moderate AD patients. Since it is not yet clear how PPAR" 
affect insulin signalling processes in AD, I investigated the effects of the TZD, 
pioglitazone, on A# metabolism and tau phosphorylation in high fat diet (HFD)-induced 
insulin resistant mice carrying the human APOE!3 or APOE!4 genes.  
HFD reduced tau phosphorylation at specific epitopes, independent of APOE 
genotype. Pioglitazone treatment reduced tau phosphorylation, in an APOE-dependent 
manner, with the APOE!3 mice being most responsive. Examination of HFD effects on 
the cortical transcriptome revealed increased expression of the ABCA1 gene in mice 
lacking APOE and the ADRA2A gene in APOE!4 mice. ABCA1 and apoE are 
associated with A# clearance in the brain, while ADRA2A suppresses insulin secretion 
and polymorphisms in this gene is associated with T2DM risk. Erk1/2, p38, JNK, and 
calcineurin were differentially  expressed between APOE!3 and APOE!4 mice on HFD 
indicating these kinases and phosphatases may contribute to the increased risk for AD 
imparted by APOE!4.  
I have identified APOE allele-dependent effects of PPAR" agonists on tau 
phosphorylation and have identified diet and APOE allele-dependent effects on gene 
expression that relate to AD. Further work is needed to validate current findings and to 
further elucidate the mechanism. A better understanding of the relative importance of 
brain and peripheral insulin resistance will greatly improve our understanding of the 
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1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) was first described in 1906, by Alois Alzheimer, a 
German psychiatrist and neuropathologist. Alzheimer’s findings were based on a 
female patient, Auguste Deter who suffered behavioural symptoms and progressive 
memory loss at the age of 51, who subsequently died aged 55 years. Alzheimer 
correlated her behavioural features with ‘miliary foci’ and neurofibrillary tangles (NFTs) 
in the cerebral cortex.  
Today AD is the most common form of dementia, affecting 10% of the 
population who are 65 years of age and 50% of those who are over 85 years of age. It 
has been described as the pandemic of the 21st century (Jellinger, 2006). Currently it is 
estimated that 35.6 million individuals worldwide are affected with dementia, with 
820,000 in the UK alone, a figure expected to triple by 2050 (Alzheimer’s disease 
International (2010) Alzheimer’s report).  
Clinically, AD manifests initially as cognitive decline which spreads to changes 
in behaviour and as the disease progresses into full dementia, daily activities become 
impossible. Macroscopically, there is gross atrophy of the brain. Microscopically, 
amyloid beta (A#) plaques and NFTs, characteristic hallmarks of AD, are visible with 
extensive neuronal loss (Figure 1.1). These neuropathological hallmarks are observed 
in both familial early onset form of AD (FAD) and the late onset or sporadic form 
(LOAD), and begin many years before onset of clinical symptoms. Both genetic and 
environmental factors are implicated in the complex etiology of AD, with age 
considered the most important risk factor. FAD arises as a result of mutations in either 
of three genes; the amyloid precursor protein (APP), presenilin 1 (PS1) or presenilin 2 
(PS2). For LOAD, the cause is unknown, although there is a strong linkage in APOE!4 




Figure 1.1 Brain atrophy, amyloid plaques and neurofibrillary tangles  
 
 
Post-mortem brain sections reveal severe brain atrophy in AD (left) compared with a 
cognitively normal individual (right). Image was taken from (Holtzman et al., 2011). The 
neuronal lesions of AD are stained by Bielschowsky Silver Stain (a, b). Neuritic plaques 
(a) consists of A# protein, surrounded by dystrophic neurites (dark black material, 
indicated by yellow arrow). A neurofibrillary tangle is shown in (b). This image was 
taken from (O'Brien and Wong, 2011). Bar, 40 µM.  
 
 
1.1.1 Amyloid beta (A#) pathology and the discovery of amyloid precursor 
protein (APP) 
A# plaques are extracellular, compacted spherical deposits of fibrils of A# 
peptides with sizes varying between 10-100µm. A# peptides consisting of 38 to 43 
amino acids in length, are derived from proteolytic cleavage of the APP protein and can 
aggregate into fibrils as well as oligomers to form plaques. Aggregations of A# in a 
non-# sheet (non-fibrillar) conformation are deposited to form diffuse plaques and are 
detected by immunohistochemistry techniques. Aggregation of A# into a # sheet 
conformation in the extracellular space forms fibrillar deposits and can be detected 
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using stains such as Congo red and Thioflavin-S/T. Plaques are accompanied by 
degenerating neurites and gliosis, proliferation of astrocytes and reactive microglia in 
response to an inflammatory response (Holtzman et al., 2011) (for review).    
A# was first identified as the major component of A# plaques in the mid 1980s 
(Glenner and Wong, 1984; Masters et al., 1985). The amino acid sequencing of A# 
shortly after, led to the discovery of the gene encoding APP localised on chromosome 
21 (Kang et al., 1987). These findings complemented the observation that individuals 
with Down’s syndrome (or trisomy 21) inevitably develop FAD because they have an 
extra copy of the chromosome 21 gene and immediately led to the suggestion that 
overproduction of APP or its cleavage products was central to AD pathogenesis. 
  
1.1.1.1 The proteolytic processing of APP and the production of A#  
The APP gene encodes a type I transmembrane protein in which alternative 
splicing gives rise to three major isoforms APP695, APP751 and APP770 (containing 
695, 751 and 770 amino acids respectively) (Zhang et al., 2011b). These three major 
isoforms are found in human, rodents and all other mammalian species examined. The 
APP751 and APP770 isoforms contain a 56 amino acid Kunitz protease inhibitor (KPI) 
domain and are expressed in most tissues. On the other hand, the KPI domain is 
absent in the APP695 isoform which is primarily expressed in neurons within the 
central nervous system (CNS) (Kang and Muller-Hill, 1990; Rohan de Silva et al., 
1997). In AD post-mortem brain tissue, the protein and mRNA levels of KPI-containing 
APP isoforms are elevated and are associated with an increase in A# deposition, 
suggesting they may have an amyloidogenic potential (Menendez-Gonzalez et al., 
2005). Interestingly, the prolonged activation of extrasynaptic N-Methyl-D-aspartate 
(NMDA) receptors in neuronal cultures can shift the neuronal expression of APP695 to 
the expression of KPI-containing APP isoforms which was accompanied with an 
increase of A#42 production (Bordji et al., 2010). 
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Full length APP is synthesised in the endoplasmic reticulum and is transported 
to the cell surface through the Golgi apparatus and trans-Golgi network (TGN). In 
neurons, the TGN contains the highest concentration of APP at steady state and from 
here APP is transported to the cell surface via TGN derived secretory vesicles. APP 
can undergo sequential proteolysis by enzymes via two competing pathways; the non-
amyloidogenic pathway and the amyloidogenic pathway (Figure 1.2). 
 
Figure 1.2 The proteolytic processing of APP 
 
APP is processed via two pathways. In the non-amyloidogenic pathway $-secretase 
first cleaves APP to generate the soluble sAPP$ fragment and the membrane bound 
C-terminal fragment, $-CTF or C83. In the amyloidogenic pathway, APP is cleaved by 
#-secretase (BACE) at the N-terminus of the A# sequence, generating sAPP# and the 
membrane bound #-CTF or C99. Both $-CTF and #-CTF are subsequently cleaved by 
"-secretase, giving rise to the p3 and neurotoxic A# peptides respectively and the APP 
intracellular domain (AICD). A# peptides associate to form oligomers and aggregate, 
ultimately forming A# plaques. The AICD has been proposed to migrate from the 
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cytosol into the nucleus and participates in the regulation of gene transcription. This 
figure is adapted from (Sastre et al., 2008). 
 
 
In the non-amyloidogenic pathway, $-secretase cleaves APP within the A# 
domain, thus precluding the formation of A# and creates a neuroprotective sAPP$ 
fragment (Goodman and Mattson, 1994) and a membrane bound C-terminal fragment 
(CTF), $-CTF or C83. $-secretase is a zinc metalloproteinase, member of the ADAM (a 
disintegrin and metalloproteinase) family. There is more than one enzyme from the 
ADAM family that mediates $-secretase activity and the most likely candidates include 
ADAM 9, 10, 17, 19 (Asai et al., 2003; Fahrenholz et al., 2000; Tanabe et al., 2007). 
The neuroprotective roles of sAPP$ include neuronal plasticity, protection against 
excitotoxicity (Furukawa et al., 1996) and the regulation of neural stem cell proliferation 
(Caille et al., 2004; Ohsawa et al., 1999). 
In the amyloidogenic pathway, APP is first cleaved at the N-terminal of the A# 
peptide sequence by #-secretase (or #-APP cleaving enzyme (BACE)). BACE is a 
membrane-bound aspartyl protease and is thought to be the limiting factor in the 
generation of A# from APP (Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). 
This generates soluble APP# (sAPP#) and a membrane-bound #-CTF or C99. 
Interestingly, BACE2, a homolog to BACE1 is expressed in lower amounts in neurons 
(Bennett et al., 2000) and has been suggested to have a redundant role as BACE2 
knockout mice are healthy whilst knockout of both BACE1 and BACE2 are lethal 
(Dominguez et al., 2005). Additionally, although sAPP# differs from sAPP$ by the 
absence of A#1-16 region, sAPP# has been reported to act as a death receptor 6 ligand 
and mediate axonal pruning and neuronal cell death (Nikolaev et al., 2009). 
Both $-CTF and #-CTF are subject to subsequent cleavage by "-secretase, 
giving rise to the p3 peptide or neurotoxic A# peptides respectively. The p3 peptide 
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(A#17-40, or A#17-42) possesses no identified function and is rapidly degraded. In 
contrast, " cleavage of #-CTF within the A# domain is non-sequence specific, 
generating A# peptides of various lengths (A#38, A#39, A#40, A#42 and A#43) and the 
concomitant release of APP intracellular domain (AICD). A#40 is the major species 
generated whilst A#42 is the more amyloidogenic form. AICD has been proposed to 
migrate from the cytosol to the nucleus and participate in gene transcription events 
(Cao and Sudhof, 2001). These targets of AICD include: APP, GSK-3#, neprilysin, 
BACE1, EGFR (epidermal growth factor), TIP60, KAI1, LRP1 (Low density lipoprotein 
receptor-related protein 1) (Kim et al., 2003; Liu et al., 2007; Pardossi-Piquard et al., 
2005; von Rotz et al., 2004; Zhang et al., 2007). "-secretase is a multi-subunit catalytic 
complex. The subunits include PS1 or PS2, nicastrin, anterior pharynx defective 1 
(APH1) and presenilin enhancer-2 (PSENEN-2) (Kimberly et al., 2003). PS1 and PS2 
are the catalytic components of "-secretase, these contain two critically conserved 
aspartate residues indispencible for "-secretase activity (Li et al., 2000; Wolfe et al., 
1999). Nicastrin and APH1 act as scaffolding proteins for the complex whilst PSENEN-
2 regulates PS1 endoproteolysis to generate the active form of "-secretase (Ahn et al., 
2010). Under physiological conditions, non-amyloidogenic processing accounts for 
95% of all APP processing. Thus, although to a lesser extent, amyloidogenic APP 
processing takes place naturally in every human being along their life span. 
FAD is caused by the mutations in any of the three genes; APP, PS1 and PS2. 
APP mutations that cluster close to the "-secretase site in the C-terminus A# region 
promotes the generation of the more amyloidogenic A# species, A#42 (Haass et al., 
1994; Suzuki et al., 1994). Furthermore, mutations internal to the A# sequence, C-
terminal to the $-cleavage site do not elevate the A#42 to A#40 ratio but change the 
sequence of A# production with a tendency to oligomerise, fibrillise and promote 
deposition (Grabowski et al., 2001; Nilsberth et al., 2001; Van Nostrand et al., 2001). 
A# deposition occurs during normal aging to some degree but this process is 
dramatically enhanced in AD. However, mice do not normally develop A# plaques with 
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aging, unless they have been genetically modified. The amino acid sequence of APP 
between human and mice have a high degree of homology, 96.8% (Yamada et al., 
1987). Within A# region of mouse APP, there is a three amino acid difference 
compared to human APP and this may account for the absence of A# plaque formation 
in mice (Yamada et al., 1987).  
PS1 and PS2 are the products of the second (PSEN1) and third (PSEN2) 
genes located on chromosome 14 and chromosome 1 respectively. PS1 forms the 
catalytic component of "-secretase which modulates the final cleavage of APP whilst 
PS2 is a homologue of PS1 (Levy-Lahad et al., 1995). Like APP mutations, mutations 
in PS1 and PS2 also increase the generation of A#42. So far, at least 185 PSEN1 
mutations and 13 PSEN2 mutations have been identified 
(http://www.molgen.ua.ac.be/ADMutations).  
 
1.1.1.2 Intracellular A#  
Extracellular A# plaques are thought to be pathogenic by inducing neuronal cell 
death, this can be via a range of mechanisms such as tau hyperphosphorylation 
(Ghribi et al., 2003), alteration of calcium influx (Ho et al., 2001), induction of 
inflammatory responses and activation of microglia (Eikelenboom et al., 2002; Gasic-
Milenkovic et al., 2003). However in 1993, a report by Lee and Trojanowski’s group 
provided the first biochemical evidence of endogenous intracellular A# (Wertkin et al., 
1993). Subsequent research indicated increased levels of this intracellular pool of A# in 
a neuronal cell line upon neuronal maturation and with time (Skovronsky et al., 1998; 
Turner et al., 1996). Further studies on postmortem Down syndrome brain tissue 
(Busciglio et al., 2002; Gouras et al., 2000; Mori et al., 2002; Wertkin et al., 1993) and 
in APP transgenic mouse brains (Wirths et al., 2001) indicated that A#42 
immunoreactivity increased intraneuronally with aging. Additionally, in MCI patients A# 
immunoreactivity was reported to be more apparent in the entorhinal cortex and 
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hippocampus (Gouras et al., 2000), two brain regions primarily affected by AD 
pathology. Intracellular A# was also shown to precede the formation of extracellular A# 
deposits in post-mortem brain tissue of Down syndrome patients (Gyure et al., 2001; 
Mori et al., 2002), which suggests the accumulation of intracellular A# is an early event 
(Gouras et al., 2000).  
The importance of intracellular A# accumulation of was strengthened by the 
evidence that intracellular A# can cause neurotoxicity. Neurotoxicity was evident by the 
use of triple labelling of A#, TUNEL and Hoechst in post-mortem AD brain tissue (Chui 
et al., 2001). Similarly, neuronal expression of A# in mice (LaFerla et al., 1995) and the 
expression of intracellular human A# in cortical neuronal cultures from rats  (Kienlen-
Campard et al., 2002) induces neuronal apoptosis. Zhang et al also demonstrated that 
microinjections of the A#42 peptide into cultures induced significant cell death, 
specifically in human primary neurons as oppose to human primary astrocytes, 
neuronal and non-neuronal cell lines (Zhang et al., 2002). The mechanism of 
intracellular A# toxicity is unknown however, intracellular A#40 and A#42 has been 
demonstrated to directly activate the p53 promoter thereby initiating p53 dependent 
apoptosis (Ohyagi et al., 2005). This was apparent in guinea pig primary neurons after 
oxidative DNA damage, when A#42 was localised in the nucleus with increased p53 
mRNA levels. Elevation of p53 mRNA was also found in post-mortem brain tissue of 
sporadic AD patients and in Tg2576 mice (Ohyagi et al., 2005).  
Although nowadays there is no doubt about the existence of intracellular A#, a 
key question with no answer is whether part of the A# generated intracellularly is not 
secreted or if part of the secreted peptide is taken up by the cell and contribute towards 
the formation of intracellular A# pools. Some possibilities include a) retention of APP 
and production of A#42 in the ER lumen, b) the inability of A# to be secreted because 
A# may be passively leaked along any component of the secretory pathway, c) 
secreted A# is internalised into endosomes (Selkoe et al., 1996) or lysosomes (Yang et 
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al., 1998) causing increased lysosomal membrane permeability and leak into the 
cytosol, d) secreted extracellular A# can be internalised via passive diffusion across the 
plasma membrane into the cytosol or via binding to cell surface receptors such as the 
$7 nicotinic acetylcholine receptor (Nagele et al., 2002), LRP (Bu et al., 2006; 
Zerbinatti et al., 2006) and the scavenger receptor for advanced glycation end products 
(RAGE) (Deane et al., 2003; Sasaki et al., 2001; Yan et al., 1996). 
Some studies have indicated a relationship between extracellular and 
intracellular A#. Observations in various transgenic mouse models of AD supports this 
theory; the accumulation of intracellular A# occurs before the appearance of 
extracellular A# deposits (Chui et al., 1999; Li et al., 1999b; Lord et al., 2006; Oakley et 
al., 2006; Wirths et al., 2001) and the accumulation of intracellular A# correlated with 
cognitive deficits (Oddo et al., 2003). Furthermore, Oddo et al identified an inverse 
relationship between the intracellular and extracellular pools of A# in a triple transgenic 
AD model (Oddo et al., 2006a). These provide evidence that the formation of 
extracellular A# plaques may originate from a source of intracellular A#. A paper by 
D’Andrea et al demonstrated by immunohistochemistry and digital image analysis in 
post-mortem AD brain samples, that excessive accumulation of intracellular A# led to 
neuronal lysis and dispersion of intracellular A# content into the extracellular matrix 
(D'Andrea et al., 2001). Other studies using mouse models have demonstrated that 
clearance of extracellular A# plaques using immunotherapy can also reduce 
intracellular A# (Oddo et al., 2004) and improve cognition (Janus et al., 2000; Morgan 






1.1.1.3 The amyloid cascade hypothesis 
The amyloid cascade hypothesis proposed by Hardy and Allsop in 1991 (Hardy 
and Allsop, 1991), has become the dominant theory in the AD field. This hypothesis 
states that the aberrant processing of APP leads to the build-up and deposition of A#40 
and A#42 peptides, especially the more amyloidogenic form, A#42, and is thought to 
initiate a cascade of events leading to the formation of amyloid plaques, NFTs and 
consequently synaptic degeneration, neuronal death and eventually cognitive decline 
observed in patients with AD.  
Since the identification of A# as the main component of extracellular A# plaques 
by Glenner and Wong, a substantial amount of studies has supported the amyloid 
cascade hypothesis. Genetic data from FAD has provided the strongest evidence; 
mutations in either of the APP, PS1 and PS2 genes increase the generation of A# or 
the production of A#42 in many studies. Mutations in the PS1 gene causes increased 
production of the A#42 species, which is accompanied by a reduction in levels of A#40. 
This observation has led to the proposal that the ratio A#42/A#40 is a more important 
factor than the absolute levels of A#42 species and the A#42/A#40 ratio is inversely 
associated with age of AD onset. Further support for the amyloid cascade hypothesis 
comes from transgenic mice models of AD. APP transgenic mice expressing mutant 
human APP have time-dependent increase in extracellular A# that appears to correlate 
with behavioural changes, similar to AD (Hsiao, 1998). In double transgenic mice, 
expression of mutant APP and mutant tau show that the formation of NFTs is 
enhanced under the influence of A# (Lewis et al., 2001; Terwel et al., 2008). Similarly, 
injection of synthetic A# into the brains of tau transgenic mice or double transgenic 
mice (expressing mutant APP and mutant tau) induces the hyperphosphorylation of tau 
and NFT formation, therefore pointing out the role of A# upstream of tau (Gotz et al., 
2001; Lewis et al., 2001; Oddo et al., 2003; Santacruz et al., 2005). These transgenic 
models have been useful in the investigation of A# immunotherapies. In triple 
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transgenic mice displaying A# plaque and NFT pathology, A# immunisation not only 
reduced extracellular and intracellular A# accumulation but also early tau pathology 
(Oddo et al., 2004). Other amyloidogenic proteins such as Dan-amyloid which deposits 
in the brain of patients with familial Danish dementia promotes NFT lesions when Dan-
amyloid is expressed in tau transgenic mice (Coomaraswamy et al., 2010). This study 
further suggests amyloidogenic peptides drive similar pathogenic pathways.  !
Even though a vast amount of data supports the amyloid cascade hypothesis, 
the original idea that the deposition of extracellular A# plaques consisting of A# fibrils 
are pathogenic, has been challenged and modified over time. The amyloid cascade is 
currently still the leading hypothesis, however it is believed that fibrillar A# is no longer 
triggering secondary events that will lead to neurodegeneration but instead it is caused 
by the presence of soluble and oligomeric A# species. Firstly, advance development of 
imaging techniques that allows the imaging of A# plaques in vivo using Pittsburgh 
compound B have shown the presence of A# plaques in AD patients as well as in 
cognitively normal individuals. This data suggests that insoluble A# plaques may not 
actually trigger pathological events as thought but instead may be neuroprotective 
(Caughey and Lansbury, 2003). Secondly, work by Braak and Braak indicates that 
NFTs precede the appearance of A# plaques in the AD brain and is also a better 
measure of disease severity (Braak et al., 2006) (discussed in section 1.1.2). Thirdly, 
transgenic mouse models have provided further insight; mice expressing mutant 
human APP develop memory deficits prior to the onset of A# plaque deposition. 
Another group demonstrated in the PDAPP mice model, that insertion of a C-terminal 
cleavage site (Asp664) in APP which normally causes production of a toxic fragment 
C-31, prevented and improved memory deficits whilst A# production was unaltered 
(Galvan et al., 2006). Additionally in Tg2576 mice, despite the development of A# 
plaques in the brain, these mice continued to have normal memory function (Lesne et 
al., 2008). Also, in a recent clinical trial, long-term A#42 immunisation for the removal of 
A# plaques did not improve memory and cognition (Holmes et al., 2008). Thus, these 
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data suggests that A# plaques are not the root cause of disease and recent research 
has largely focused on the connection between A# neurotoxicity and soluble, non-
fibrillar A# oligomers.  
A# is present in multiple forms. A# is produced as a monomer and these can 
aggregate to form oligomers consisting of dimers and trimers. The most toxic form of 
A# is thought to be oligomers which have been shown to correlate with synaptic 
dysfunctions and disruption of learning and memory, and long-term potentiation (LTP) 
in animals (Cleary et al., 2005; Walsh et al., 2002). The formation of A# oligomers is 
thought to occur intracellularly (Oddo et al., 2006b; Takahashi et al., 2004; Walsh et al., 
2000), specifically within lipid rafts (Kawarabayashi et al., 2004; Kim et al., 2006). In 
soluble fractions of the human brain and A# plaque extracts, SDS-stable low molecular 
weight A# oligomers, dimers and trimers, have be detected and suggests that they 
could act as basic building blocks for larger oligomers and fibrils (Podlisny et al., 1995; 
Walsh et al., 2000). These A# oligomers have been shown to inhibit LTP in vivo (Cleary 
et al., 2005; Klyubin et al., 2005; Lesne et al., 2006; Trommer et al., 2005; Walsh et al., 
2002). Their high toxicity has also been supported by in vitro data, showing that dimers 
and tetramers are 3-fold and 13-fold more toxic than monomers, respectively (Ono et 
al., 2009). Furthermore, Lesne et al detected the accumulation of the A#*56 form of 
soluble A# in Tg2576 mice, which consists of SDS-stable nonamers and dodecamers 
(Lesne et al., 2006). Purification of A#*56 from memory impaired Tg2576 mice and 
subsequent administration into wild type rats induced significant memory impairment in 
spatial memory performance. Another study also demonstrated that A#*56 levels 
correlated with the cognitive decline in an APP23 mouse model (Lefterov et al., 2009).  
The amyloid cascade hypothesis is widely accepted and drives much of AD 
research however a growing consensus is that tau might actually be part of the 
pathway; tau is not just a passive target but an active component early on in the 
cascade. In hippocampal cultures obtained from wild type, tau knockout and human tau 
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transgenic mice, treatment of fibrillar A# caused neuronal degeneration in wild type and 
human tau only whilst cell death was prevented in tau knockout neurons (Rapoport et 
al., 2002). Recently an in vivo study reported that dendritic function of tau mediates A# 
toxicity as mice lacking or expressing truncated tau was protected from A#-induced 
toxicity and memory deficits (Ittner et al., 2010). Tau is associated with postsynaptic 
targeting of the Src kinase, Fyn, that mediates an interaction between NMDA receptors 
and postsynaptic density protein 95 (PSD95). This interaction is required for A# toxicity. 
Furthermore, these observations could be recapitulated by using a peptide that 
uncouples Fyn mediated interaction of NMDA and PSD95 in vivo. Thus, these data 
suggest tau has an important role in mediating A# toxicity. 
 
1.1.2 Tau pathology 
In addition to A# plaques, the second characteristic pathological hallmark of AD 
are NFTs. NFTs appear in nerve cell bodies whilst neurophil threads are present in 
neuronal processes. NFTs are aggregates of paired helical filaments (PHFs) (Kidd, 
1963), themselves composed predominately of hyperphosphorylated forms of the 
microtubule associated protein, tau (Grundke-Iqbal et al., 1986). Both A# plaques and 
NFTs are abundant in the AD brain.  However, in contrast to A# plaques, NFTs appear 
to be distributed, and to appear, in a predictable pattern. NFTs originate from the layer 
II neurons of the entorhinal cortex and spread to the outer molecular layer of the 
dentate gyrus (Braak and Braak, 1991). Studies have shown that the extent and 
distribution of NFT in AD correlate to the degree of dementia and the progressive 
cognitive decline (Arriagada et al., 1992) and also serves as a useful post-mortem 




1.1.2.1 Tau structure, isoforms and function 
Tau was first identified in 1975 (Weingarten et al., 1975). It is a highly soluble 
microtubule-associated protein (MAP) and with two other MAPs; MAP1 and MAP2, is 
mainly expressed in neurons, being predominately found within axons. All MAPs are 
involved in microtubule stabilisation to help maintain the complex neuronal morphology 
and help facilitate axonal transport along microtubules.  
Tau is preferentially expressed in the human brain and alternative splicing of 
the single gene (MAPT) on chromosome 17 (Himmler, 1989) generates the six major 
isoforms of tau (Goedert et al., 1989). The protein isoforms range from 352 to 441 
amino acids in length with molecular weights of between 45-65 kDa. They are 
distinguished by the number of microtubule binding domain repeats (R) in the C-
terminal (3 or 4 repeats) and by the presence or absence of 2 N-terminal insertions (N). 
The presence or absence of exon 10 generates the 3R or 4R isoforms respectively and 
the inclusion of exons 2 and 3 generates the zero, one or two N-terminal insertions, the 
0N, 1N or 2N isoforms. Thus, alternative splicing gives rise to three 3R isoforms of tau 
(3R0N, 3R1N and 3R2N) and three 4R isoforms (4R0N, 4R1N and 4R2N) (Figure 1.3). 
The repeat domain is known to be important for the stabilisation of microtubules and 
also in forming the core of PHFs (Wischik et al., 1988). Therefore, 4R tau isoforms are 
more efficient in promoting microtubule assembly than 3R tau isoforms (Alonso et al., 
2001b). Tau splicing is developmentally regulated; the smallest isoform, 0N3R tau is 
the only form expressed in foetal brain. By contrast all 6 isoforms are expressed in the 
mature brain. Additionally, foetal tau is highly phosphorylated compared to adult tau. 
Phosphorylation is thought to reduce the affinity of tau binding to microtubules. The 
reduced affinity of foetal tau for microtubules is thought to be required for the high level 
of plasticity occurring during early brain development. In disease, the reduced affinity of 
phosphorylated tau abolishes microtubule binding and can lead to destabilisation of the 
cytoskeleton (Drewes et al., 1995; Sengupta et al., 1998), which can impair tau-
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dependent cellular functions such as axonal growth, axonal transport and the correct 
propagation of electrical signals needed for synaptic transmission.  
 
Figure 1.3 Schematic representation of the tau isoforms in the human brain 
 
Alternative splicing of a single gene generates the six isoforms of human tau. Exons 2 
and 3 encodes the two N-terminal inserts, 1N and 2N, respectively. These give rise to 
the 1N or 2N tau isoforms whilst the absence of exons 2 and 3 gives rise to the 0N tau 
isoforms. Exon 10 encodes the microtubule binding repeat R2 and its presence or 
absence yields the 4R or 3R tau isoforms respectively. The microtubule binding 
repeats form the binding region for tau and the proline rich region has been proposed 
to increase the interaction between tau and microtubules. The number of amino acid is 







1.1.2.2 Tau phosphorylation 
All six tau isoforms are subject to phosphorylation by the addition of phosphate 
groups on three receptor amino acids; serines (Ser), threonines (Thr) and tyrosines 
(Tyr). Phosphorylation sites have been identified in vivo by a range of techniques such 
as mass spectrometry, Edman degradation and the use of phospho-specific tau 
antibodies. There are 85 putative phosphorylation sites on tau; 45 serines, 35 
threonines and 5 tyrosines (Martin et al., 2011) (for review), which may be subjected to 
phosphorylation by one or more kinases. To date, approximately 20% have been 
identified as being phosphorylated in normal brain tissue (Hanger and Noble, 2011). 
These sites are substrates for three classes of tau kinases: proline-directed protein 
kinases (PDPK), non-proline-directed protein kinases (non-PDPK) and tyrosine specific 
kinases. Amongst the PDPK are glycogen synthase kinase-3 (GSK-3) (Mandelkow et 
al., 1993), cyclin-dependent kinase 5 (Cdk5) (Baumann et al., 1993) and the mitogen-
activated protein kinases (MAPKs): c-Jun N-terminal kinase (JNK), p38 MAPK and 
Erk1/2 (Goedert et al., 1997; Hyman et al., 1994; Mandelkow et al., 1993; Reynolds et 
al., 1997b). These have been identified in NFTs in post-mortem AD brain tissue and 
related pathologies and have also demonstrated the ability to phosphorylate tau in vitro 
(Mandelkow et al., 1993). Non-PDPK target serine or threonine residues not preceded 
by a proline and these include casein kinase 1 (CK1), protein kinase A (PKA), 
Ca2+/Calmodulin-dependent protein kinase II (CaMKII) and dual-specificity tyrosine 
phosphorylation regulated kinase 1A (DYRK1A) (Lee, 2005; Sergeant et al., 2008). 
Tyrosine kinases include the Src family kinases, Src (Lee, 2005), Lck (Williamson et 
al., 2002), Syk (Lebouvier et al., 2008), Fyn (Lee et al., 2004) and c-Abl (Derkinderen 
et al., 2005). 
GSK-3 and Cdk5 are highly expressed in the brain (Anderton et al., 2001; Liu et 
al., 2006; Wang et al., 1998). Both can target a large combination of common 
phosphorylation sites (Lew et al., 1994; Tsai et al., 1993; Woodgett, 1990) and have 
been shown to be associated with all stages of NFT pathology in AD (Pei et al., 1999; 
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Pei et al., 1998). GSK-3 exists as two isoforms, $ and #, sharing 85% sequence 
homology at the protein level and are encoded by genes on chromosome 19 and 3, 
respectively (Woodgett, 1990). A brain enriched splice variant of the GSK-3# isoform, 
GSK-3#2, has also been identified containing an additional exon encoding 13 amino 
acid (Mukai et al., 2002). The difference between GSK-3# and GSK-3#2 reside in their 
affinity for certain targets (Saeki et al., 2011). Subtle differences in substrate 
preference between isoforms and slice variants has been reported in brain (Soutar et 
al., 2010). GSK-3# is highly expressed in the brain and by neurons (Woodgett, 1990), 
making it easily accessible to tau. In post-mortem AD brain tissue, GSK-3# levels are 
increased by approximately 50% compared to non-diseased brains (Pei et al., 1997). In 
mice overexpressing GSK-3#, tau was hyperphosphorylated in the hippocampus with 
the appearance of pretangle-like structures and neuronal cell death and this was 
accompanied with cognitive deficits (Lucas et al., 2001; Spittaels et al., 2000). In vitro, 
tau phosphorylation by GSK-3 was shown to greatly reduce the ability of tau to 
associate with microtubules (Mandelkow et al., 1992) and the treatment of cells with a 
selective GSK-3 inhibitor, lithium, significantly reduced tau phosphorylation (Hong et 
al., 1997; Lovestone et al., 1999). Furthermore, lithium treatment in transgenic mice 
overexpression GSK-3# or mutant tau, reduced tau phosphorylation, tau aggregation 
and axonal degeneration (Engel et al., 2006; Leroy et al., 2010; Noble et al., 2005). It 
has been established that GSK-3# can phosphorylate tau at primed (e.g., Thr231) as 
well as unprimed (e.g., Ser202, Thr205, Ser396 and Ser404) epitopes. Priming occurs 
4-6 residues C-terminal to the GSK-3# target site (Cole et al., 2006; Li et al., 2006)  
and can be performed by PKA, CK1 or Cdk5 (Li et al., 2006; Wang et al., 1998). 
Cdk5 is regulated by a neuron-specific activator, p35, which is cleaved under 
neurotoxic conditions by calpain to form p25. It is the association of p25 with Cdk5 that 
causes the hyperphosphorylation of tau (Lee et al., 2000). In rodent models, 
overexpression of p25 led to tau hyperphosphorylation and neurodegeneration (Cruz et 
al., 2003; Noble et al., 2003), which was ameliorated by silencing of Cdk5 (Piedrahita 
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et al., 2010). Furthermore, phosphorylation of tau by Cdk5 has also been shown to 
induce neurotoxicity in Drosophila (Steinhilb et al., 2007).  
Dephosphorylation of tau is equally as important, as the lack of phosphatase 
activity may lead to the hyperphosphorylated forms of tau found in disease. The five 
major protein phosphatases (PP), PP1, PP2A, PP2B, PP2C and PP5 are highly 
expressed in the brain. In vitro, all these protein phosphatases, with the exception of 
PP2C, can dephosphorylate tau (Buee et al., 2000) (for review). In addition, all of these 
have been shown to dephosphorylate tau in the brain to some varying degrees. 
However, PP2A has been shown to be the major tau phosphatase (Goedert et al., 
1995; Liu et al., 2005). In vitro incubation of PP2A with tau aggregates was shown to 
rescue microtubule binding (Wang et al., 2007). Furthermore, the activities and 
expression of the two phosphatases PP1 and PP2A are reduced in selective areas of 
the AD brain (Gong et al., 1993). The observation that endogenous PP2A inhibitors are 
increased, colocalising with PP2A and hyperphosphorylated tau in neurons of AD brain 
tissue suggested that a reduction in dephosphorylation of tau may be of considerable 
importance for the aberrant hyperphosphorylation of tau (Tanimukai et al., 2005).  
The overall level of tau phosphorylation is determined by the action of both 
protein kinases and phosphatases. The imbalance of these activities may thus 
contribute to the abnormal phosphorylation of tau observed in AD, and therefore be 
pathogenic. 
 
1.1.2.3 Pathological functions of tau 
NTFs are not only observed in AD but also in a family of neurodegenerative 
diseases called tauopathies such as frontotemporal dementia with parkinsonism linked 
to chromosome 17 (FTDP-17), Pick’s disease, corticobasal degeneration, dementia 
pugilistica, and progressive supranuclear palsy. Although to date no mutations have 
been found in tau that lead to AD, there are tau mutations that do lead to other 
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neurodegenerative disorders such as FTDP-17 (Hutton et al., 1998). This adds to the 
idea that dysregulation of tau and/or its normal physiology contributes to neurotoxicity 
both in AD and other tauopathies. Indeed, it has been demonstrated, initially by Terry 
et al, that tau pathology correlates better with cognitive decline than amyloid pathology. 
Although, in fact, the best correlate with cognitive decline is neither tau nor amyloid 
pathology but loss of synapses (Terry et al., 1991). How tau exerts its neurotoxic 
properties has still not been fully established. Some tau becomes hyperphosphorylated 
and aggregates but tau aggregates are now not thought to be the toxic species as 
demonstrated by in vivo and in vitro experiments.  
The isolation of abnormally hyperphosphorylated tau from cytosolic fractions of 
the AD brain and hyperphosphorylated recombinant tau, both self aggregate into PHFs 
in vitro and this process was reversed upon dephosphorylation (Alonso et al., 2001a). 
Other in vitro models that used pseudophosphorylated tau, induced a cytotoxic effect in 
PC12 cells compared to wild type cells, thereby mimicking the functional and structural 
aspects of AD (Fath et al., 2002). Additionally, the Drosophila GSK-3# homologue 
shaggy, requires the overexpression of human tau for its ability to exacerbate 
neurodegeneration due to neurofibrillary pathology (Jackson et al., 2002). This is 
further supported by the use of phosphatase inhibitors which induce tau to 
hyperphosphorylate and consequently induced tau fibrillisation (Perez et al., 2002). It 
has also been postulated that tau phosphorylation may inhibit its turnover rate, giving 
rise to intracellular levels of tau (Litersky and Johnson, 1992). Furthermore, 
hyperphosphorylated tau is also known to sequester normal tau and other MAPs, 
which can deplete microtubules from functional tau and cause the instability of 
microtubules (Alonso et al., 1996; Alonso et al., 1997). Leading on from this, an in vivo 
model of mice expressing human tau treated with the microtubule stabilising drug, 
(Paxceed), stabilised microtubules which consequently restored axonal transport 
defects and improved motor impairments (Zhang et al., 2005).    
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Taken together these in vivo studies along with the in vitro data demonstrate a 
causal relationship between hyperphosphorylation of tau and the formation of NFTs 
and that hyperphosphorylation of tau can cause its loss of biological function and a 
gain of toxicity. This is thought to influence the aggregation of tau into NFT.  
As a matter of fact, tau phosphorylation occurs before the formation of NTFs 
(Braak and Braak, 1995; Iqbal and Grundke-Iqbal, 1991) and the survival of neurons 
bearing NTFs many years after tangle formation is thought to be a self-defense 
mechanism. In mouse and Drosophila models, soluble, non-aggregated, 
hyperphosphorylated tau induces a toxic effect. Furthermore, in a transgenic mouse 
model with the P301L human tau mutation, suppression of tau expression caused 
cognitive improvements and stabilised the neuron number, whilst NFTs continued to 
accumulate (Santacruz et al., 2005). This study demonstrates an association between 
the levels of soluble hyperphosphorylated tau and cognitive impairments. Interestingly, 
a Drosophila model demonstrated phosphorylation of Ser262 and Ser356 was a 
prerequisite for subsequent activation of tau kinases GSK-3 and Cdk5 (Nishimura et 
al., 2004). Likewise, staining of AD brains, revealed phosphorylation of Thr231, Ser262 
and Thr153 sites associated with the neuronal pretangle state (Augustinack et al., 
2002). Conversely, other groups found phosphorylation at the Ser262 and Ser214 
epitopes protected against tau assembly into filaments (Schneider et al., 1999) and 
was shown to be anti-apoptotic (Kyoung Pyo et al., 2004). Together, these findings 
indicate that certain tau phosphorylation sites may be associated with the toxic or 
protective functions of soluble forms of tau.  
Despite all the above the precise role of phosphorylated and aggregated tau 
remains unclear. A better understanding of the functional effect of tau phosphorylation 
at specific epitopes will greatly further our understanding of tau biology and how it then 
becomes dysregulated in disease.  
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1.1.3 Calcium and AD 
Alterations in calcium (Ca2+) homeostasis as the common cause for 
neurodegenerative diseases was first described by Khachaturian in 1989 
(Khachaturian, 1989). Experimental studies supporting this theory in AD soon followed 
as fibroblasts from asymptomatic AD patients (Etcheberrigaray et al., 1998; Ito et al., 
1994) and gene expression analysis of post-mortem AD brain tissue (Emilsson et al., 
2006) indicated enhanced inositol-1,4,5-triphosphate (IP3) receptor-mediated Ca2+ 
signalling. Recently, the drug, memantine, was approved as treatment for moderate to 
severe AD.  Memantine targets the NMDA receptors of the glutamatergic system and 
blocks the permeability of NMDA receptors to Ca2+ thereby further confirming a role for 
Ca2+ signalling in AD.   
Ca2+ signalling is central to a variety of neuronal functions, such as 
neurotransmitter release, signal transduction, gene expression, formation of radical 
species and cell death (Berridge, 1998). It is therefore important that Ca2+ signals are 
regulated.  The Ca2+ concentration within the cytosol of a cell is low under minimal 
activity (50-300 nM). This is achieved by Ca2+ influx from the extracellular environment 
and Ca2+ release from intracellular stores; the endoplasmic reticulum (ER) (LaFerla, 
2002). In contrast, the Ca2+ concentration is 1000 times higher within the ER. This 
concentration gradient within the cell is maintained by the presence of plasma 
membrane Ca2+-ATPases and sodium/Ca2+ exchangers that pumps Ca2+ into the 
extracellular space whilst the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) on 
the ER membrane actively transports Ca2+ from the cytosol into the intracellular stores.  
Upon cellular activation, extracellular Ca2+ is influxed into the cytosol either via voltage-
gated and/or ligand-gated channels (e.g. NMDA receptors), store-operated channels 
(eg. Transient receptor potential channels TRPC) or G-protein coupled receptors 
(GPCRs, e.g. metabotrophic glutamate receptors, mGluR). ER stores of Ca2+ are 
released via channels localised on the ER membrane; the IP3 receptors (IP3R) and 
ryanodine receptors (RyR). The activation of IP3R requires IP3 which is generated by 
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inositol-4, 5-biphosphate via GPCR-activated phospholipase C at the plasma 
membrane. The RyR are activated by small increases in cytosolic Ca2+ levels, a 
process known as Ca2+ induced Ca2+ release (Berridge, 1998).  
There is evidence showing Ca2+ modulates the processing of APP. Treatment 
of human embryonic kidney 293 cells (HEK-293 cells) expressing APP with a Ca2+ 
ionophore (A23187) consistently increased the production of A# by approximately 3-
fold (Querfurth and Selkoe, 1994). The same group also treated HEK-293 cells with 
caffeine, a RyR stimulator, that also increased the production of A# (Querfurth et al., 
1997). Interestingly, another group reported that high levels of Ca2+ in the cytosol, 
generated from extracellular Ca2+ influx, impairs the non-amyloidogenic pathway and 
increases the production of intraneuronal A#42 (Pierrot et al., 2004). Additionally it was 
shown that Ca2+ release from the ER alone is insufficient to induce the production of 
intracellular A#; A# production is only observed on sustaining a high cytosolic Ca2+ 
concentration by extracellular influx (Pierrot et al., 2004). Recently, a polymorphism in 
the CALHM1 gene was identified and proposed as a risk factor for LOAD (Dreses-
Werringloer et al., 2008). CALHM1 encodes transmembrane glycoprotein that controls 
cytosolic Ca2+ and A# levels. In contrast to the study by Pierrot et al, the mutation in 
CALHM1 impairs plasma membrane Ca2+ permeability and reduces the cytosolic Ca2+ 
levels thereby increasing A#42 production and A#42/A#40 ratio (Dreses-Werringloer et 
al., 2008). Conversely, other studies have, in turn, demonstrated the effects of APP 
and its metabolites on Ca2+ signalling. In vitro, the addition of A# to the media of 
hippocampal neurons increases Ca2+ concentration in the cytosol (Goodman and 
Mattson, 1994; Mattson et al., 1993). This may be mediated by the insertion of A#42 and 
A#40 oligomers into the plasma membrane via an interaction with phosphatidylserine, to 
form Ca2+ permeable pores (Arispe et al., 1993). A# oligomers can also modulate the 
activation of Ca2+ channels at the plasma membrane (De Felice et al., 2007; Nimmrich 
et al., 2008; Shankar et al., 2007) or ER-specific IP3Rs and RyRs and initiate a rise in 
cytosolic Ca2+ concentration (Ferreiro et al., 2004). Disturbances in cytosolic Ca2+ 
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levels can trigger neurotoxic mechanisms such as free radical formation (Brustovetsky 
et al., 2003), lipid peroxidation (Lovell et al., 2001) and apoptosis (Bernardi et al., 
2006). Interestingly, secreted APP may therefore have neuroprotective properties since 
they attenuate the elevation of intracellular Ca2+ caused by A# (Goodman and Mattson, 
1994). 
Ca2+ dysregulation can also affect the tight regulation of tau phosphorylation, 
leading to abnormally hyperphosphorylated tau and NFT formation. Transient 
increases in intracellular Ca2+ levels in the SHSY5Y neuronal cell line has been shown 
to activate the tau kinase, GSK-3# (Hartigan and Johnson, 1999). The activation of 
another tau kinase, Cdk5, is induced by the Ca2+-dependent protease, calpain. Calpain 
generates p25 from the p35 precursor; p25 is a strong activator of Cdk5 (Maccioni et 
al., 2001). In cultured neurons, membrane depolarisation induced a transient Ca2+-
mediated tau phosphorylation by both of these tau kinases GSK-3 and Cdk5. Tau 
phosphorylation was followed by Ca2+-dependent dephosphorylation (Pierrot et al., 
2006). These studies demonstrate the effect of increases in cytosolic Ca2+ 
concentrations on the modification of tau phosphorylation. Many other Ca2+-dependent 
proteins have been indicated to have an influence on tau pathology such as CaMK 
(Yoshimura et al., 2003) and the phosphatase calcineurin (Fleming and Johnson, 
1995). CaMK can phosphorylate purified tau in solution (Baudier and Cole, 1987). 
Specifically, CaMKII immunoreactivity is enhanced in the hippocampal neurons of the 
CA1 and subiculum regions of post-mortem AD brain tissue, these regions are 
predisposed to NFT formation (McKee et al., 1990). CaMKII is thought to 
phosphorylate tau (Ser262 and Ser356 epitopes) at the site of its interaction with 
microtubules (Litersky et al., 1996). Calcineurin can also act directly to 
dephosphorylate recombinant tau or brain extracts (Drewes et al., 1993) and was 
found to dephosphorylate GSK-3# and Cdk5 in neuronal cells, demonstrating a role in 
the regulation of tau phosphorylation (Kim et al., 2009c; Pierrot et al., 2006). 
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Ca2+ plays a key role in cell signalling processes crucial to the normal 
functioning of neuronal cells. Although research is much more focused on the 
mechanism of A# and tau neurotoxicity in AD, accumulating evidence highlights the 
importance of disturbances in Ca2+ homeostasis and its contribution to AD 
pathogenesis.  
 
1.2 Apolipoprotein E (ApoE) and AD 
A genetic contribution to the development of AD is not limited to FAD but also to 
LOAD. In 1993 Allen Rose’s group identified that the !4 allele of the gene encoding 
apolipoprotein E (APOE) was strongly linked with AD (Saunders et al., 1993). Since 
then many susceptibility genes have been identified, although replications have been 
inconsistent and most were likely to be false positives (see Alzgene website for 
candidate gene study details www.alzgene.org) (Bertram et al., 2007). Recently, the 
completion of several very large scale genome-wide association studies has finally 
identified new susceptibility genes, including CLU, PICALM and CR1, ABCA7, MS4A, 
EPHA1, CD33 and CD2AP (Harold et al., 2009; Hollingworth et al., 2011; Lambert et 
al., 2009).  
In humans, the APOE gene is polymorphic, being represented by three major 
alleles: !2, !3 and !4. This gives rise to three homozygous (APOE!2/2, !3/3 and !4/4) 
and three heterozygous (APOE!3/2, !4/3 and !4/2) genotypes. Within Caucasian 
populations, the !3 allele is the most common representing 77% of the population, 
followed by the !4 allele accounting for 15% and the !2 allele accounting for 2% (Farrer 
et al., 1997). Genetic studies have provided evidence that the !4 allele confers the 
greatest risk of developing AD, whilst the !3 allele confers intermediate risk and the !2 
allele may be a protective factor for AD (Corder et al., 1994). Relative to !3, the risk of 
AD is increase by ~3 fold with one copy of the !4 allele and by ~12 fold with two copies 
(www.alzgene.org), relative to !2, !4 increases the risk by over 500 fold. The 
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importance of APOE!4 in AD pathogenesis is highlighted by representing for 65-80% 
of all AD cases. Furthermore, the APOE!4 allele is present in ~50% of LOAD patients, 
compared to ~16% of age- and sex-matched controls (Saunders et al., 1993). In 
contrast to the autosomal inheritance of FAD genes, the APOE!4 allele itself does not 
cause disease but rather, evidence suggests it alters the risk of AD in a dose-
dependent manner by lowering the mean age of onset from 85 to 68 years (Corder et 
al., 1993). Carriers of the APOE!4 gene do not necessary develop AD and therefore 
diagnosis of AD cannot rely on the presence of !4, although the presence of !2 is a 
likely exclusion criteria (Corder et al., 1995; Tiraboschi et al., 2004).  
The mechanism by which APOE!4 confers greater susceptibility for AD remains 
unclear. There are conflicting reports about whether APOE!4 influences a rapid rate of 
cognitive and functional decline after the onset of AD. MRI studies have shown greater 
decreases in entorhinal cortex and hippocampus volume in APOE!4 positive AD 
patients (Bookheimer and Burggren, 2009). Similarly, cognitively normal children and 
adults carrying the APOE!4 allele also have a decrease in entorhinal cortex volume 
(Shaw et al., 2007). Additionally, cognitively normal APOE!4 carriers also have greater 
cognitive decline (Blair et al., 2005), and positron emission tomography studies have 
found that these individuals show cerebral glucose hypometabolism (Reiman et al., 
2001) suggesting this may be an advance measure, predictive of dementia in their later 
lives. Neuropathologically, apoE has been immunohistochemically identified in A# 
plaques and NFTs of AD post-mortem brain tissue (Namba et al., 1991) which raises 
the idea that apoE may be directly involved in the pathological mechanisms leading to 
neurodegeneration. This is supported by the observation that mice expressing FAD 





1.2.1 ApoE structure, isoforms and function 
Apolipoprotein E (apoE) is a key component of lipid transport and cholesterol 
metabolism not only within the periphery but also within the brain. The differences 
between the three isoforms of human APOE (!2, !3 and !4) reside in single base 
differences giving rise to amino acid substitutions at residues 112 and 158 (Figure 1.4). 
APOE!2 has two cysteines (Cys) at these positions, APOE!3 has a Cys at 112 and an 
arginine (Arg) at 158 whilst APOE!4 has Arg residues at both positions (Weisgraber et 
al., 1981). ApoE is synthesised as a 34 kDa protein containing 299 amino acids and 
consists of two domains connected by a flexible hinge region; the N-terminal domain 
and C-terminal domain containing the receptor binding site and lipoprotein binding site, 
respectively (Weisgraber, 1994). An interaction between these two domains is stronger 
in the apoE4 isoform than the apoE2 or apoE3 isoforms. This domain interaction 
occurs when the Arg112 residue displaces the side chain of Arg61 in the amino-
terminal that allows it to form a salt bridge with glutamic acid at position 255 at the C-
terminal (Figure 1.5) (Dong and Weisgraber, 1996; Dong et al., 1994). Interestingly, 
Arg61 is unique to humans as all other 17 species in which the apoE gene has been 
sequenced have a threonine at the same position (Weisgraber, 1994). The differences 
in amino acids that alter the charge and structural properties of apoE, ultimately 









Figure 1.4 Schematic representation of the APOE isoforms in human and mouse 
 
Human APOE is expressed as three isoforms; !2, !3 and !4. These are distinguished 
by single amino substitutions at residues 112 and 158; APOE!2 has two cysteines 
(Cys), APOE!3 has a Cys at 112 and an arginine (Arg) at 158 whilst APOE!4 has two 
Arg. Domain interaction is a unique property of the APOE!4 isoform which occurs 
between Arg61 and Glu225 and is influenced by Arg112. Mouse APOE is similar to 
APOE!4 in that it contains an Arg112 however lacks domain interaction due to a 
threonine (Thr) at position 61. Human apoE is O-glycosylated at residue Thr194 (red), 












Figure 1.5 Structure of lipid-free apoE 
 
A ribbon diagram of lipid-free apoE. The C- and N-terminal domains are connected by 
a hinge region. The N-terminal domain consists of a four-helix bundle (helix 1-4 in red, 
blue, green and yellow, respectively). The receptor binding site is situated in helix 4 of 
the N-terminal, whilst the C-terminal domain (grey) contains the lipoprotein binding site. 
Highlighted are positions 112 and 158 that contain either arginine (Arg) or cysteine 
(Cys) residues in apoE2, apoE3 and apoE4 isoforms. Also highlighted is glutamic acid 
(Glu) 225 and Arg61 that forms a salt bridge in the apoE4 isoform, allowing domain 
interaction to occur. This figure is adapted from (Hatters et al., 2006). 
 
 
In the periphery, most apoE originates from the liver as constituents of 
lipoprotein complexes, though it is also produced by several other cell types including 
macrophages, adrenal gland cells, and others. Lipoproteins consist of esterified and 
unesterified cholesterol, triglycerides and phospholipids which are delivered to cells for 
use as a source of energy, as building blocks for membrane synthesis and modulation 
of membrane fluidity. In addition, cholesterol is used as a substrate for the synthesis of 
a variety of sterols including vitamins, bile acids and steroid hormones. The continuous 
supply of cholesterol required by the body is acquired by in vivo cholesterol 
biosynthesis via the HMG-CoA pathway, which involves a series of 20 sequential 
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reactions regulated by the rate limiting enzyme, 3-hydroxy-3-methylglutaryl coenzyme 
A reductase (HMGCR), and also through diet. ApoE is found to be associated with four 
main classes of lipoproteins; chylomicrons, very low-density lipoprotein (VLDL), low-
density lipoprotein (LDL) and high-density lipoprotein (HDL). The preferences for these 
lipoproteins lies in the structural difference of the APOE isoforms; apoE2 and apoE3 
have preferential binding to small cholesterol-rich high-density lipoproteins such as 
HDLs whilst apoE4 preferably binds to lower-density lipoproteins such as VLDLs and 
LDLs (Weisgraber, 1990). ApoE serves as a ligand to the LDL receptor family on cell 
membranes, for the receptor mediated endocytosis of lipoprotein complexes. The 
apoE2 isoform has the lowest receptor binding affinity and has important implications in 
disease, such that elevated circulating levels of apoE2 protein is responsible for type III 
hyperlipoproteinemia (Weisgraber et al., 1982). 
The brain has the second highest concentration of apoE after the liver 
(Elshourbagy et al., 1985), produced locally by astrocytes (Boyles et al., 1985), 
although microglia and neurons also synthesise apoE under certain normal 
physiological and pathological conditions (Bao et al., 1996; Han et al., 1994; Xu et al., 
1999; Xu et al., 1996). Newly synthesised apoE assembles with phospholipids and 
cholesterol to form HDL-like particles. Unlike in plasma, cerebrospinal fluid (CSF) does 
not contain LDL or VLDL complexes and the assembly of apoE into HDL-like particles 
occurs without any known apoE isoform specificity (Bandaru et al., 2009; Pitas et al., 
1987). Apart from apoE, the predominant lipoprotein within the CNS, other lipoproteins 
are also present including; apoAI, apoJ (also known as clusterin and also associated 
with AD) and apoD (Fagan et al., 1999; Pitas et al., 1987). Cholesterol in the brain is 
acquired by de novo synthesis as dietary cholesterol, carried on apoB-containing 
lipoproteins, is separated from CNS cholesterol by the blood brain barrier (BBB). De 
novo cholesterol synthesis mainly occurs in astrocytes and oligodendrocytes through 
the HMG-CoA pathway. In neurons, cholesterol synthesis is high in the developing 
CNS but rapidly declines to low levels in the mature brain (Bjorkhem and Meaney, 
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2004). Therefore, neurons depend on a supply of cholesterol secreted from astrocytes 
and glia in the form of HDL-like particles (Funfschilling et al., 2007). Lipidation of the 
HDL-like particle is assisted by the cholesterol transporter, ATP-binding cassette A1 
(ABCA1) which transports cellular cholesterol and phospholipids to lipid-poor 
apolipoproteins. ApoE on HDL-like particles serves as a ligand for LRP1 and the LDLR, 
both present on neurons (Narita et al., 1997). Upon binding, the lipoprotein/receptor 
complex is internalised into endosomes and fuses with lysosomes containing hydrolytic 
enzymes which release lipids and cholesterol for use in axonal growth, neuronal repair 
and synapse formation and remodeling (Mauch et al., 2001). The resulting increase in 
intracellular cholesterol also provides a negative feedback mechanism to HMGCR, 
reducing endogenous cholesterol synthesis. Cholesterol homeostasis is maintained by 
converting excess cholesterol into a more hydrophilic oxysterol metabolite, 24S-
hydroxycholesterol (24S-OHC) by the neuron specific enzyme 24S-hydroxylase 
(CYP27A1). 24S-OHC can pass the BBB and directly enters the blood stream for 
elimination by the liver (Lutjohann et al., 1996).  In vitro, 24S-OHC released by neurons 
was shown to upregulate the transcription of APOE, ABCA1 and ABCG1 via a liver X-
receptor mechanism to induce apoE-mediated cholesterol efflux (Abildayeva et al., 
2006). This reduces cholesterol synthesis, increases cholesterol transport and storage 
thereby regulating cholesterol homeostasis. 
In response to neuronal cell damage or traumatic brain injury, large amounts of 
apoE are synthesised presumably to clear and redistribute lipid and cholesterol debris 
to cells requiring membrane repair (Boyles et al., 1989; Ignatius et al., 1987). In vitro 
studies investigating the interaction between lipid and apoE isoforms have shown that 
apoE3 containing lipoproteins are more efficient at supplying cholesterol to neurons 
and enhances neurite outgrowth compared to apoE4 containing lipoproteins 
(Michikawa et al., 2000; Minagawa et al., 2009; Nathan et al., 2002). Furthermore, 
mice expressing human APOE!3, but not APOE!4, under the neuron-specific enolase 
(NSE) promoter are protected against excitotoxin-induced neuronal damage and age-
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dependent neurodegeneration observed in the APOE knockout mice (Buttini et al., 
1999). A number of other studies have focused on apoE isoforms and synaptic 
plasticity and synaptogenesis. Infusion of recombinant apoE3 and apoE4 into the brain 
were equally able to rescue presynaptic deficits and cognitive impairment in APOE 
knockout mice (Masliah et al., 1997). However, other studies found that the apoE4 
isoform is less efficient at maintaining normal brain function and as such, APOE!4 mice 
display synaptic deficits and reduced excitatory synaptic transmission in the absence of 
A# deposition, NFTs or gliosis (Wang et al., 2005). These mice furthermore have 
impaired LTP and reduced dendritic spine formation (Ji et al., 2003). In support of this, 
examination of APOE!4 AD post-mortem brain tissue revealed significantly less plastic 
dendritic changes compared to AD post-mortem brain tissue without an APOE!4 allele 
(Arendt et al., 1997) thus suggesting poor synaptic remodeling capacity of the apoE4 
isoform may contribute to the development of AD. 
Attempts to understand the association of apoE isoforms with AD risk have thus 
focused on the role of lipid metabolism in AD. Disturbances in cholesterol homeostasis 
can alter the production of A# although reports have been controversial. One of the first 
reports showing a connection cholesterol and amyloid was by Sparks et al; rabbits fed 
a high cholesterol diet increased the accumulation of intracellular A# (Sparks et al., 
1994). This finding was later replicated in an APPSwe transgenic mouse model (Levin-
Allerhand et al., 2002). In cultured cells, proteolysis of APP occurs in cholesterol rich 
membrane microdomains and in vitro studies demonstrated that increasing the 
cholesterol content in lipid rafts induces #- and "-secretase activities which led to the 
elevation of A#40 and A#42 species (Frears et al., 1999; Wahrle et al., 2002). Thus apoE 
might affect AD through a lipid-dependent effect on A# production. AD is also 
characterised by accumulation of tau-containing NFTs, however, a role for cholesterol 
in tau pathology is not clearly defined. Nevertheless, a recent study reported that 
increasing cholesterol levels in hippocampal neurons induces A#-dependent calpain 
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activation which generates the neurotoxic 17 kDa tau fragment that becomes 
hyperphosphorylated, aggregates and forms NFTs (Nicholson and Ferreira, 2009). 
Taken together, apoE isoforms seem to have differential effects on the delivery 
of lipid and cholesterol to neurons and disturbances in this can lead to the formation of 
plaques and tangles. 
 
1.2.2 ApoE and A#  pathology 
The overproduction of A#, leading to excesses of insoluble A# peptides, is 
considered to be one of the primary events leading to disease. Under normal 
conditions, A# is produced at the synapse and intracellularly, and can be found at high 
levels in CSF or plasma, therefore the balance between A# production and clearance 
may be a possible cause of AD pathology (Hardy and Selkoe, 2002). The discovery 
that apoE and A# form a complex in CSF prompted investigations into the direct 
involvement of apoE in disease mechanisms (Namba et al., 1991; Wisniewski and 
Frangione, 1992; Wisniewski et al., 1993). Although the role of apoE remains unclear, 
there is some evidence suggesting apoE isoform specific effects on A# is associated 
with disease progression.  
The interaction between apoE and A# may play an important role in AD 
pathogenesis; it was initially demonstrated in vitro that delipidated apoE and lipidated 
apoE have different binding affinities for A# (LaDu et al., 1995). The incubation of 
delipidated apoE4 with A# allowed the rapid formation of A# fibrils and A# aggregation 
relative to the other apoE isoforms, in the order of !4>!3>!2 (Sanan et al., 1994; 
Strittmatter et al., 1993; Wisniewski et al., 1993). In contrast, for lipidated apoE and A# 
fibril formation, the reverse is true, with apoE2 and apoE3 forming complexes with A# 
more rapidly than does apoE4 isoform (in the order of !2>!3>!4) (LaDu et al., 1994; 
Tokuda et al., 2000). Since the order of binding between apoE and A# is inverse to the 
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risk of developing AD, it has been hypothesised the rate of A# clearance is enhanced 
by apoE2 and apoE3 compared to apoE4 (further discussed below). Neuropathological 
examination of AD post-mortem brain tissue revealed increased plaque load was 
associated with APOE!4 (Bales et al., 2009; Fagan et al., 2002; Fryer et al., 2005; 
Manelli et al., 2007; Manelli et al., 2004). This correlates with both pathological and 
neuroimaging studies showing APOE!4 carriers have earlier A# deposition and greater 
neuritic plaques (Tiraboschi et al., 2004). Moreover, identification of fibrillar A# 
aggregates using positron emission tomography radioligands (i.e. C11-labelled 
Pittsburgh compound C) found the highest amounts in cognitively normal APOE!4 
carriers in a gene dose dependent manner (Reiman et al., 2009). This occurs with the 
simultaneous reduction in CSF A#42 levels, which correlates with the observations from 
in vitro studies and indicates that APOE!4 promotes A# deposition in the brain (Fagan 
et al., 2006; Prince et al., 2004). Due to the rarity of APOE!2 carriers, the effect of 
APOE!2 isoform on A# pathology remains unclear (Berlau et al., 2009). However, in 
accordance with the above experiments, increased plaque deposition has been 
observed in APOE!4 transgenic mice expressing APP (Holtzman et al., 2000a). Indeed 
it has been shown that apoE is required for the formation and deposition of A# plaques 
(Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000b) and these can occur in 
an apoE isoform-dependent manner; in the order !4>!3>!2 (Bales et al., 2009; Fagan 
et al., 2002; Fryer et al., 2005; Manelli et al., 2007; Manelli et al., 2004).   
Studies investigating apoE isoforms on A# aggregation in vitro demonstrated 
that all three isoforms induced A#42 fibrillisation or A#40 aggregation which was 
enhanced in apoE4 relative to apoE3 or apoE2 (Castano et al., 1995; Ma et al., 1994; 
Wisniewski et al., 1994). These findings recapitulate those reporting increased amyloid 
load in APOE!4 subjects.  On the other hand, some in vitro studies have reported 
opposite effects, with human isoforms decreasing A# fibrillisation (Beffert and Poirier, 
1998; Evans et al., 1995; Webster and Rogers, 1996; Wood et al., 1996). These 
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conflicting findings are most likely due to differences in the apoE and A# preparations 
used. 
In addition to their role in fibril formation, accumulating evidence also proposes 
apoE as an A# binding protein that facilitates it’s clearance and degradation. Two 
pathways important for A# clearance are receptor mediated uptake by microglia and 
astrocytes, and receptor mediated transport across the BBB.  
In vitro, several studies using various neuronal cell types demonstrated human 
apoE bind and facilitate the internalisation of soluble A# (Beffert et al., 1998, 1999; 
Cole and Ard, 2000; Yamauchi et al., 2002a; Yamauchi et al., 2000; Yang et al., 1999) 
and that apoE can faciliate cellular A# degradation (Jiang et al., 2008; Koistinaho et al., 
2004). However, it is unclear whether these observations are apoE isoform dependent. 
Consistent with this, APP(V717F) mice lacking apoE have increased soluble A# levels 
prior to A# deposition (Dodart et al., 2002; Fagan et al., 2002). These findings 
apparently contradict in vivo studies showing that apoE deficiency reduces A# 
deposition. Nevertheless, A# can also be cleared from the brain to the periphery, 
mediated by the transport of apoE-A# complexes across the BBB, involving LRP1 
(Deane et al., 2004; Shibata et al., 2000). This occurs in an apoE isoform-dependent 
manner (Castellano et al., 2011; Deane et al., 2008). Further experiments by Bell et al 
using real-time in situ microdialysis demonstrated that A#40 is cleared more rapidly 
across the BBB via LRP1 than is A#42 (Bell et al., 2007). In a similar experiment, Deane 
et al demonstrated that the binding of A# to apoE4 reduced the rate of clearance 
compared to apoE2 and apoE3 through a redirection of clearance from LRP1 to the 
VLDL receptor (Deane et al., 2008). These authors suggested the reduction in A# 
deposition observed in the apoE null APP mice is likely due to loss of apoE-mediated 
A# retention. 
Finally, in other studies, apoE4 can enhance lysosomal leakage and ultimately 
apoptotic cell death. Treatment of apoE3 or apoE4 Neuro-2a cells treated with A#42  
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demonstrate greater lysosomal leakage in apoE4 compared to apoE3 or control. It is 
hypothesised that the low pH of the lysosome work in concert with the structural 
interaction between the N- and C-terminal domains of apoE (see above) and A#42 to 
cause membrane instability and lysosomal leakage (Ji et al., 2002). 
Thus, it is clear that apoE isoforms can have differential effects on A# 
production, aggregation and clearance, which may account for the role of APOE in AD. 
However, apoE isoforms also play a role in tau pathology. 
 
1.2.3 ApoE and tau pathology 
The association between apoE and tau is much less clear. Studies in humans 
have produced inconsistent findings, whilst some reported a positive relationship 
between the APOE!4 genotype and NFTs (Ghebremedhin et al., 1998; Nagy et al., 
1995; Ohm et al., 1995; Polvikoski et al., 1995), others found no clear association (Itoh 
et al., 1996; Landen et al., 1996; Morris et al., 1995; Olichney et al., 1996; Oyama et 
al., 1995). However, evidence from in vitro and in vivo experiments suggests binding 
differences between apoE isoforms and tau, independent of A#. In vitro experiments 
showed that recombinant tau bound to apoE3 more avidly than to apoE4 isoform 
(Strittmatter et al., 1994). Furthermore, the interaction between tau and apoE3 was 
prevented in a crude brain extract of phospho-tau, suggesting apoE3 binds to non-
phosphorylated tau. This binding was mediated by interaction between the LDL 
receptor binding domain on apoE3 and MTB domain of tau and was thought to prevent 
self-aggregation of tau and therefore the formation of NFTs (Strittmatter et al., 1994).  
There is evidence showing apoE is subjected to proteolysis in neurons and the 
apoE4 isoform appears to be more susceptible to proteolysis than the apoE3 isoform. 
The cleavage of apoE4 at residues methionine (Met) 272 by a neuron-specific 
chymotrysin-like serine protease and/or at leucine (Leu) 268 by thrombin cleavage 
generates neurotoxic C-terminal truncated fragments of 29 kDa and 10-20 kDa, 
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respectively (Harris et al., 2003). These fragments are toxic both in vivo and in vitro 
and weaken the neuronal response to injury (Harris et al., 2003; Huang et al., 2001; 
Ljungberg et al., 2002). Of the two truncated fragments, the 29 kDa fragment has been 
the most intensively studied. It can translocate into the cytosol and cause cytoskeletal 
changes such as formation of NFTs and disruption of mitochondrial processes (Chang 
et al., 2005). Examination of AD post-mortem brain tissue and the brains of mice 
expressing apoE in CNS neurons, revealed similar staining of C-terminal truncated 
fragments, which were furthermore associated with NFTs (Brecht et al., 2004; Harris et 
al., 2003; Huang et al., 2001). The accumulation of fragments from apoE4 is greater 
than from apoE3. Interestingly, accumulation of fragments coincides with the 
appearance of behavioural deficits and neurodegenerative changes in the APOE!4 
transgenic mice (Brecht et al., 2004). It is believed that the lipid binding region within 
the 29 kDa fragment causes neurodegeneration, as neurodegeneration is absent in 
mice expressing apoE without this region (Harris et al., 2003). These fragments are 
increased in the post-mortem brain tissue of AD relative to control individuals, however, 
there are currently no reports showing an increase of these fragments in APOE!4 
positive AD patients. 
In transgenic mice specifically expressing APOE!3 or APOE!4 in neurons using 
the NSE promotor, age-dependent impairment in hippocampal dependent learning and 
memory was found in NSE-APOE!4 mice, but not NSE-APOE!3 mice (Raber et al., 
1998). Similarly, APOE!4 knock in (KI) mice developed learning and memory deficits 
not observed in the APOE!3 KI mice (Bour et al., 2008), whilst APOE!3 mice were 
protected against excitotoxin-induced neurodegeneration compared to the APOE!4 
mice (Buttini et al., 2000). Recently, the cellular origin of apoE in the brain of mice has 
been shown to effect its action-no effect of genotype on apoE excitoprotection was 
observed when expressed in astrocytes, whereas apoE4 but not apoE3 was excitotoxic 
when expressed in neurons (Buttini et al., 2010). Additionally, in vivo, mice expression 
of human APOE!4 in astrocytes did not increase tau phosphorylation whereas 
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expression of apoE in neurons did, showing a neuron-specific effect (Brecht et al., 
2004). Other studies have shown higher levels of tau phosphorylation in APOE!4 KI 
mice compared to APOE!3 KI mice (Inbar et al., 2010; Kobayashi et al., 2003). Taken 
together, these studies show apoE isoform specific effects on AD pathology and 
experimentally confirm epidemiological studies that show that APOE!4 is detrimental in 
LOAD. 
 
1.3 The metabolic syndrome, type 2 diabetes and AD 
As well as the genetic influence on disease risk, such as APOE isoform, 
environmental factors also alter risk. A growing body of data indicates that the 
metabolic syndrome, a cluster of risk factors, characterised by impaired glucose 
tolerance, visceral obesity, hypertension, dyslipidemia, elevated triglycerides, elevated 
LDL cholesterol and low HDL cholesterol, contributes to the development of AD. The 
metabolic syndrome not only increases the risk for AD but also the risk of developing 
diabetes and cardiovascular disease. 
Diabetes mellitus (DM) is a chronic metabolic disorder associated with cognitive 
impairments and damage to the CNS. The two major types of DM are defined as type 1 
DM (T1DM) and type 2 DM (T2DM). T1DM (previously known as insulin-dependent 
diabetes), common in children and young adults, is due to an autoimmune destruction 
of pancreatic beta cells (#-cells), leading to a deficiency in insulin production. On the 
other hand, type 2 diabetes Mellitus (T2DM) (previously known as non-insulin-
dependent diabetes), which is more prevalent in the elderly, is characterised by 
hyperinsulinemia and insulin resistance during the early stages of the disorder whilst in 
the later stages insulin resistance is maintained, glucose intolerance also develops 
(Gispen and Biessels, 2000; Ramlo-Halsted and Edelman, 1999). Insulin resistance is 
caused by a reduced response of insulin-responsive tissues to insulin. As a result the 
reduced glucose lowering effects of insulin lead to an elevation of blood glucose.  
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Diabetes is a multisystemic disorder associated with pathogenic changes in 
both large and small vessels, peripheral nerves, skin and eyes. These lead to renal 
failure, visual loss, autonomic and peripheral neuropathy, peripheral vascular disease, 
myocardial infarction, as well as cerebrovascular disease (Zhao et al., 2010). Thus, it is 
not surprising that T2DM also causes vascular dementia. However the connection 
between diabetes and AD is still not clear. 
 
1.3.1 Type 2 diabetes and AD 
The association between T2DM and AD is supported by several 
epidemiological studies (Biessels et al., 2006) (for systematic review). In 1997, Leibson 
et al reported the risk of AD in type 2 diabetics was elevated (Leibson et al., 1997). 
Later findings from other longitudinal studies have also confirmed this association of 
T2DM and AD (Arvanitakis et al., 2004; Cheng et al., 2011; Irie et al., 2008; Leibson et 
al., 1997; Luchsinger et al., 2004; Ott et al., 1999). On the other hand, there are some 
large population studies indicating no association between T2DM and AD (Akomolafe 
et al., 2006; Luchsinger et al., 2001; MacKnight et al., 2002; Xu et al., 2004). 
Additionally, in an early report of the Honolulu-Asia study, no association of mid-life 
diabetes and AD were found (Curb et al., 1999). However a follow up study with the 
same samples showed a high risk of AD in patients diagnosed with T2DM (Peila et al., 
2002). This underlines the importance of examining the lifespan of T2DM as this 
disorder is more prevalent in the elderly and may not be diagnosed in the same patient 
at a young age. In some of these studies T2DM was associated with an increased risk 
of vascular dementia (Xu et al., 2004) as well as of AD (Ott et al., 1999; Peila et al., 
2002), suggesting these are independent events. In addition, the co-occurrence of 
T2DM and APOE!4 was found to synergistically increase the risk of AD (Irie et al., 
2008; Peila et al., 2002). Neuropathological studies within the same study reported the 
highest number of neuritic plaques and NFTs in the cortex and hippocampus of 
APOE!4 type 2 diabetic post-mortem brain tissue (Peila et al., 2002). Another group 
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also reported greater density of diffuse and neuritic plaques in T2DM post-mortem 
brain tissue (Janson et al., 2004). However other studies have produced conflicting 
findings and did not show an increase in AD-related pathology in post-mortem brain 
tissue of diabetics (Alafuzoff et al., 2009; Arvanitakis et al., 2006a; Heitner and 
Dickson, 1997). 
In T2DM, an elevation in the levels of fasting plasma insulin precede many 
years before the development of hyperglycaemia. The underlying factor seems to be 
due to peripheral insulin resistance, which is associated with an increased risk of 
dementia. Studies have reported that insulin resistance alone, independent of diabetes, 
increases disease risk as fasting plasma insulin levels were shown to be increased in 
people with and without diabetes (Kuusisto et al., 1997). Similar results were found in a 
larger study (Luchsinger et al., 2004). Clinical studies further support these findings in 
that AD patients have elevations in fasting plasma insulin and reduced CSF insulin 
levels (Craft et al., 1998) and lower insulin-mediated glucose disposal rates (Craft et 
al., 1999b) compared to age-matched controls. Furthermore, the aforementioned 
studies suggest that the risk of insulin resistance in LOAD is independent of APOE!4 
genotype.  
The reduced levels of CSF insulin may be due to a reduced transport of 
peripheral insulin into the brain due to chronic hyperinsulinemia (Wallum et al., 1987), 
which strongly suggests defects of insulin action in the brain. At autopsy, post-mortem 
brain tissue from AD patients have reduced expression of insulin and insulin receptors 
(Steen et al., 2005). Additionally, downstream insulin signalling is reduced in AD 
brains. The ineffective insulin signalling within the brain might therefore initiate 
neurodegenerative processes leading to cognition dysfunction. The realisation that low 
insulin, insulin receptor levels and reduced glucose homeostasis confined to the AD 
brain has led this insulin resistant brain state to be classified as ‘Type 3 diabetes’.  
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1.3.2 Insulin and memory 
It was once thought that the brain was insulin insensitive. However this theory 
was challenged by the identification of insulin and insulin receptors in the brain. Insulin 
mRNA has been detected in neurons (Devaskar et al., 1994; Schechter et al., 1988) 
and also in the rat hippocampus (Singh et al., 1997). In addition, insulin receptors are 
widely distributed in the CNS with the highest concentrations in olfactory bulb, 
hippocampus, amygdala, hypothalamus, cortex and cerebellum (Havrankova et al., 
1978; Marks et al., 1990; Werther et al., 1987). At the cellular level, insulin receptors 
are enriched in neurons compared to glia and are concentrated at synapses (Abbott et 
al., 1999). This indicates that insulin plays a important role in enhancement of memory 
functions (for review see) (Park, 2001). However, it has now been shown that little or 
no insulin synthesis occurs in the brain (Woods et al., 2003) and the major source of 
brain insulin is believed to originate from the pancreas. Insulin from the periphery 
enters the brain via a receptor-mediated saturable transport mechanism across the 
BBB (Banks et al., 1997) to increase CSF insulin levels (Baura et al., 1993). The 
binding of insulin to insulin receptors mediates diverse functions such as energy and 
glucose homeostasis (Air et al., 2002; Pocai et al., 2005), growth (Rulifson et al., 2002) 
and neuronal plasticity (Chiu and Cline, 2010). The role of insulin in memory has been 
highlighted by the following studies.  
Peripheral administration of insulin in patients with AD in euglycaemic 
conditions increased CNS insulin levels and led to the improvement in memory and 
performance (Craft et al., 1996; Kern et al., 2001). Moreover, intranasal administration 
of insulin, which results in the direct transport of insulin from the nasal cavity to the 
CNS, induces facilitation of working memory in humans (Benedict et al., 2004). 
Similarly, intranasal insulin treatment improved cognitive performance in rodents 
(Francis et al., 2008). Additionally, intracerebroventricular insulin administration in 
rodents raises CNS insulin levels (Bernstein et al., 1986), upregulates insulin receptors 
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on hippocampal neurons (Zhao et al., 1999) and acutely improves memory 
performance on a passive avoidance task (Park et al., 2000).  
Insulin may affect memory through several mechanisms. Although insulin does 
not seem to play a role in the transport of glucose into the brain or participate in basal 
cerebral glucose metabolism, evidence indicates insulin may mediate glucose uptake 
in selective regions of the brain such as the hippocampus and hypothalamus. This may 
be due to the overlapping distributions of insulin, insulin receptors with insulin sensitive 
glucose transporters; GLUT4 (cerebellum, hippocampus, pituitary and hypothalamus) 
and GLUT8 (hippocampus and hypothalamus). By contrast, glucose independent 
mechanisms also exist, for example, Craft et al demonstrated that memory in AD 
patients did not improve when plasma glucose levels were increased whilst insulin 
secretion was suppressed using somatostatin (Craft et al., 1999a). Furthermore, 
intravenous insulin infusion in patients with AD under euglycaemic conditions led to 
improvement in memory and performance (Craft et al., 1996).  
Insulin also modulates the release and re-uptake of presynaptic 
neurotransmitters such as acetylcholine and norepinephrine, which influence cognitive 
function (Figlewicz et al., 1993; Kopf and Baratti, 1999). Insulin can also modulate 
synaptic plasticity, the formation of synaptic connections underlying learning and 
memory. Insulin has been shown to increase the expression of GABA (gamma 
aminobutyric acid) receptors on postsynaptic membranes and dendrites to modulate 
synaptic plasticity (Wan et al., 1997). Similarly, insulin promotes the internalisation of 
AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate) receptors from the 
postsynaptic membrane to cause depression of excitatory synaptic transmission in the 
hippocampus (Man et al., 2000) and cerebellum (Huang et al., 2003). Additionally, 
insulin can enhance NMDA (N-Methyl-D-aspartate) receptor mediated synaptic 
transmission in hippocampal slices (Liu et al., 1995) by transiently modulating the 
phosphorylation of NR2A and NR2B subunits (Christie et al., 1999). Activation of the 
NMDA receptor increases Ca2+ influx, which is presumed to activate CAMKII and other 
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Ca2+-dependent enzymes leading to greater synaptic strength between neurons. These 
alterations in the expression and function of NMDA receptors has been implicated in 
the behavioural and electrophysiological abnormalities observed in insulin-deficient rats 
(Di Luca et al., 1999). Whilst in rat hippocampal slices insulin signalling was shown to 
mediate the induction of long-term depression (LTD) at the CA1 synapses in an 
activity, frequency, PI3K/Akt and NMDA receptor-dependent manner (van der Heide et 
al., 2005). Insulin appears to shift the NMDA receptor-dependent frequency response 
curve of activity-dependent synaptic plasticity, enabling the induction of both LTD and 
LTP at lower frequencies.  Van der Heide et al suggested insulin may function as a 
neuromodulator of activity-dependent synaptic plasticity, setting the threshold for 
NMDA receptor-dependent LTD and LTP induction.!
 
1.3.3 Insulin signalling and AD pathology 
1.3.3.1 The insulin signalling pathway 
The insulin receptor is a homodimer, composed of four subunits, two 
extracellular $ subunits and two transmembrane # subunits held together by disulphide 
bonds. Each insulin receptor monomer originates from a single precursor protein which 
is cleaved to generate an extracellular $ subunit and an intracellular # subunit linked 
together by intrinsic disulphide bonds. A insulin receptor monomer dimerises with 
another monomer to generate a functional receptor. The insulin signalling pathway is 
shown in Figure 1.6. Upon binding of insulin to the $ subunits, the # subunits undergo 
conformational change resulting in autophosphorylation on a number of tyrosine 
residues (Van Obberghen et al., 2001). Insulin receptors then phosphorylate adaptor 
proteins containing phosphotyrosine-binding domains such as the insulin receptor 
substrate (IRS) family members, IRS1 and IRS2. Following this, the p85 regulatory 
subunit of phosphoinositide 3-kinase (PI3K) containing the Src homology 2 domain 
binds to tyrosine residues on IRS1 and leads to activation of the p110 catalytic subunit 
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of PI3K. Subsequently, p110 converts membrane lipids phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 in turn 
activates phosphate dependent kinase-1 (PDK-1), which in combination with an as yet 
unidentified kinase, upregulates Akt (also known as PKB). Akt then phosphorylates 
Ser9 and Ser21 on the GSK-3$ and # isoforms respectively, leading to their 
inactivation (Lizcano and Alessi, 2002; Saltiel and Kahn, 2001) (for review). Since 
GSK-3 is implicated in APP metabolism and tau phosphorylation, defects within the 
insulin signalling pathway are widely thought to impact upon AD pathology. GSK-3 also 
regulates the activity of glycogen synthase, an enzyme that catalyses the conversion of 
glucose into glycogen. The activity of glycogen synthase is inhibited when 
phosphorylated therefore activation of the PI3K pathway leading to the inactivation of 
GSK-3 promotes the storage of glucose as glycogen. In addition, insulin has a key role 
stimulating glucose uptake into cells to maintain peripheral blood glucose levels. On 
binding to insulin receptors, vesicles containing glucose transporters, GLUT4, 
translocate from the cytosol and fuses with the plasma membrane. GLUT4 are 
subsequently inserted into the membrane which permits the diffusion of glucose into 















The insulin receptor is composed of two $ and two # subunits tethered together by 
disulphide bonds. Binding of insulin induces autophosphorylation of the insulin receptor 
at a number of tyrosine residues which are recognised by the insulin receptor substrate  
(IRS) adaptor proteins. Phosphorylation of IRS leads to the binding of the p85 subunit 
of phosphoinositide 3-kinase (PI3K) which activates the p110 catalytic subunit of PI3K. 
p110 then converts membrane lipids phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3). The subsequent activation of phosphate 
dependent kinase-1 (PDK-1) and Akt leads to the phosphorylation of GSK-3 which 
becomes inactive. GSK-3 is involved in glycogen synthesis and can influence 
pathological processes related to AD. Activation of the insulin signalling pathway also 
stimulates glucose uptake in the cell by promoting GLUT4 translocation. This figure is 





1.3.3.2 Insulin and A#  pathology 
APP metabolism is regulated by a variety of mechanisms, one of these is by 
insulin. Insulin has been shown to accelerate the trafficking of A#40 and A#42 peptides 
from the trans golgi network to the plasma membrane in neuronal cultures thereby 
increasing its secretion (Gasparini et al., 2001). This process was mediated by the 
Erk1/2 signalling pathway, suggesting reduced insulin levels can interfere with the 
trafficking of A# peptides and possibly leading to A# accumulation. In the SHSY-5Y cell 
line, insulin enhanced and shifted APP metabolism towards the non-amyloidogenic 
pathway, promoting $-secretase cleavage of APP (Solano et al., 2000). Conversely, 
GSK-3$ has been shown to influence the production of A# peptides by regulating "-
secretase activity, with the inhibition of GSK-3$ by lithium blocking the generation of 
A#40 and A#42 peptides (Phiel et al., 2003). A# has also been shown to act as a 
competitive inhibitor of insulin, competing with insulin for binding to the insulin receptor. 
This can reduce insulin receptor phosphorylation and thereby antagonise the 
downstream insulin signalling effects (Xie et al., 2002). Furthermore, A# can be 
degraded by two major proteases, neprilysin (NEP) and insulin degrading enzyme 
(IDE) (Ling et al., 2003). Both are metalloproteases involved in the degradation of 
proteins that form #-pleated sheet-rich amyloid fibrils. In APP transgenic mice, the 
overexpression of NEP or IDE reduced A# levels and prevented the formation of A# 
plaques (Iwata et al., 2000; Leissring et al., 2003; Poirier et al., 2006). It was also 
demonstrated that gene transfer of NEP by viral vector delivery could lower A# levels in 
the brain of NEP deficient and APP transgenic mice (Iwata et al., 2004). Similarly, this 
was shown to reduce A# deposition in APP transgenic mice (Marr et al., 2003). 
Conversely, the disruption or knockout of NEP (Farris et al., 2007; Huang et al., 2006; 
Iwata et al., 2001) or IDE (Farris et al., 2003; Miller et al., 2003) genes induces the 
accumulation of A# in the brain. The distinct subcellular distribution of NEP and IDE 
allows the degradation of A# at different subcellular compartments. NEP is a plasma 
membrane bound enzyme that is able to degrade monomeric and oligomeric forms of 
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A#40 and A#42 (Kanemitsu et al., 2003), both intracellullarly and extracellularly (Hama et 
al., 2004). In contrast, IDE is a cytosolic enzyme, exists as a mixture of dimers and 
tetramers (Authier et al., 1996; Duckworth et al., 1998) and degrades intracellular as 
well as extracellular A# (Sudoh et al., 2002). IDE is found in endosomes, at the cell 
surface and in the extracellular milieu (Qiu et al., 1998; Seta and Roth, 1997; Vekrellis 
et al., 2000). The secreted or cell surface associated form of CNS IDE is the 
dependent on cell type. In primary mouse microglia and the BV2 cell line, IDE was 
found to be secreted whilst in primary hippocampal neurons and differentiated PC12 
cells, IDE was found to be membrane associated only (Mentlein et al., 1998; Qiu et al., 
1998; Vekrellis et al., 2000). Insulin and A# are amongst the main substrates of IDE 
that compete for degradation (Qiu et al., 1998). In vitro, IDE degrades and clears 
soluble monomeric A# secreted by microglial and neurons (Qiu et al., 1998; Sudoh et 
al., 2002; Vekrellis et al., 2000). IDE also degrades intracellular A# and facilitates the 
degradation of AICD (Edbauer et al., 2002). In mice, insulin resistance induced by diet 
(Ho et al., 2004) or sweetened water (Luo et al., 2011) reduced the levels of IDE, and 
promoted the generation of A#, consistent with an increase in "-secretase activity. 
In AD, the activity of IDE is reduced and histopathological examination of the 
hippocampus in post-mortem AD brains revealed reduction in IDE expression 
compared to age-matched controls. Interestingly, this observation was detected in 
APOE!4 carriers only and patients homozygous for APOE!4 allele had the highest IDE 
reductions (Cook et al., 2003).  Consistent with this, the apoE4 isoform reduced 
expression of IDE by activating NMDR receptors in hippocampal neurons (Du et al., 
2009). At present the cause of this is unknown. However, studies using IDE knockout 
mice found increased accumulation of cerebral A# levels and a decrease in clearance 
of A# was observed in primary cortical neuronal cultures from the same mice (Farris et 
al., 2003). Taken together, these findings suggest IDE has a critical in vivo role in 
determining the amount of A# in the brain. Genetic studies support this association 
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between IDE and AD, as IDE is located on chromosome 10, close to the AD locus 
(Bertram et al., 2000).   
 
1.3.3.3 Insulin and tau pathology 
The insulin signalling pathway regulates the downstream activity of GSK-3, a 
major tau kinase, important in the formation of NFTs. A limited number of studies have 
shown direct effects of insulin on specific epitopes of tau phosphorylation. In vitro, 
insulin and insulin-like growth factor 1 (IGF1) treatment can downregulate GSK-3# 
activity, thereby reducing tau phosphorylation (Ser202/Thr205) and promoting the 
binding of tau to microtubules in human neuroblastoma cells (Hong and Lee, 1997). 
Following this, another study by Lesort et al demonstrated that insulin can transiently 
increase, then decrease tau phosphorylation at a range of epitopes including Ser202, 
Thr205, Ser396 and Ser404 in a neuronal cell line. This also corresponded to the 
sequential activation and deactivation of GSK-3# which was itself associated with the 
activity of Fyn kinase (Lesort et al., 1999), that was able to regulate GSK-3 activity by 
targeting the Tyr216 and Tyr279 site in GSK-3# and GSK-3$, respectively. A 
subsequent study confirmed these observations by showing the inhibition of GSK-3 
activity by lithium treatment in primary cortical neurons prevented changes in tau 
phosphorylation (Ser202/Thr205) (Lesort and Johnson, 2000). It was also shown that 
transient changes in tau phosphorylation correlated with the transient interaction of tau 
with microtubules in these neuronal cultures (Lesort and Johnson, 2000). In vivo, 
peripheral injection of insulin induced hyperphosphorylation of various tau epitopes 
including Ser199, Ser202, Thr205, Thr212, Thr214, Thr231, Ser262, Ser396, Ser404 
and Ser422 (Planel et al., 2004). The activity of GSK-3# was inhibited in this study 
however, JNK activity was increased whilst the activity of PP2A decreased (Planel et 
al., 2004). Similarly, another in vivo study demonstrated that peripheral insulin injection 
led to an increase in tau phosphorylation at the Ser202 epitope with inhibition of GSK-
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3# activity however, the activity of Erk1/2 was increased (Freude et al., 2005). 
Collectively, these studies suggest insulin can promote changes in the phosphorylation 
of specific tau epitopes. However, it remains unclear exactly which kinases or 
phosphatases are specifically linked to the regulation of each phospho-epitope in tau.  
In vivo studies have also demonstrated disruption in the insulin signalling 
pathway contributes to the hyperphosphorylation of tau. Thus, IGF1 knockout (Cheng 
et al., 2005), neuronal insulin receptor knockout (NIRKO) (Schubert et al., 2004) and 
IRS2 knockout (Killick et al., 2009; Schubert et al., 2003) mice all promote 
hyperphosphorylation of tau.  Further studies using streptozotocin, a chemical toxic to 
pancreatic #-cells, to deplete peripheral circulating insulin levels in mice also caused 
increased tau phosphorylation in the brain (Clodfelder-Miller et al., 2006; Grunblatt et 
al., 2007; Planel et al., 2007; Qu et al., 2011). Interestingly, insulin (Jolivalt et al., 2008) 
or lithium (Qu et al., 2011) treatment in insulin deficient mouse models reversed tau 
pathology. 
 
1.3.3.4 Regulation of tau kinases 
GSK-3 
As GSK-3 is central to numerous cell signalling processes and cellular 
functions, it is important that its activity is tightly regulated. One mechanism of 
regulation is by phospho-modifications at specific residues, which act to either inhibit or 
activate GSK-3. The effect of the insulin signalling pathway (described above) upon 
GSK-3 has been one of the most extensively studied. Within this pathway the 
phosphorylation of Ser21 and Ser9 for GSK-3$ and GSK-3# respectively by Akt inhibits 
GSK-3 activity (Cross et al., 1995). This induces the formation of pseudo-substrate-like 
structures within the GSK-3 proteins which occupy its kinase domain and block their 
activities towards true substrates (Doble and Woodgett, 2003; Frame and Cohen, 
2001). On the other hand, GSK-3 is a constitutively active kinase which is dependent 
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upon the phosphorylation of Tyr279 and Try216 in GSK-3$ and GSK-3# respectively 
(Hughes et al., 1993). The basal activity has been shown to increase following nerve 
growth factor withdrawal (Bhat et al., 2000), whilst insulin treatment led to a transient 
increase in Tyr216 phosphorylation by the Src tyrosine kinase, Fyn (Lesort et al., 
1999). Phosphorylation of Tyr279 and Try216 residues has also been proposed as an 
autophosphorylation event (Cole et al., 2004). 
GSK-3 is also regulated by the wnt signalling pathway, in this instance by 
altering its cellular localisation. In the absence of a wnt signal, GSK-3 exists in a 
multiprotein complex consisting of #-catenin, axin, adenomatous polyposis coli (APC) 
and casein kinase 1 (CK1). In this complex, GSK-3 constitutively phosphorylates #-
catenin, promoting its ubiquitination and proteosomal degradation. On binding of wnt to 
the frizzled (FZD) receptors, LRP5/6 is phosphorylated and activates dishevelled (Dvl). 
Dvl separates GSK-3 and #-catenin, thereby inhibits the proteolytic degradation of #-
catenin and allows the entry of #-catenin into the nucleus to interact with members of 
the Tcf/Lef family of transcription factors (Chien et al., 2009). The mechanism by which 
wnt inhibits GSK-3 has not yet been fully resolved, two models have been proposed; a) 
axin may associate with GSK-3 and are then recruited together to the plasma 
membrane by the interaction between FZD, Dvl and axin. The phosphorylation motif on 
the cytoplasmic tail of LRP6, which binds to FZD, then acts as a pseudo-substrate for 
GSK-3, thus preventing GSK-3 targeting #-catenin (Cselenyi et al., 2008; Mi et al., 
2006; Piao et al., 2008; Wu et al., 2009; Zeng et al., 2008), b) a more recent view is 
that wnt proteins induce compartmentalisation of GSK-3 into multivesicular bodies, 
further increasing the separation of GSK-3 from #-catenin (Taelman et al., 2010). 
In addition to physical separation, negative regulation by phosphorylation also 
plays a role in wnt signalling. PKC directly inhibits GSK-3 activity and activates wnt 
signalling (Chen et al., 2000; Cook et al., 1996). P38 MAPK also participates in wnt 
signalling (Bikkavilli and Malbon, 2009). The PI3K/Akt pathway has been implicated in 
wnt signalling or stabilisation of #-catenin (Ponce et al., 2011; Voskas et al., 2010) 
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however, whether crosstalk exist between the two pathways again has not been fully 
resolved (Ng et al., 2009). 
 
Cdk5 
The activity of Cdk5 is regulated by p25, a truncated form of the neuron-specific 
activator, p35. The association of p25 with Cdk5 induces the hyperphosphorylation of 
tau (Lee et al., 2000). In rodent models, the overexpression of p25 leads to tau 
hyperphosphorylation and neurodegeneration (Cruz et al., 2003; Noble et al., 2003), 
which was also observed in Drosophila (Steinhilb et al., 2007). In vitro, the 
overexpression of p25/Cdk5 complex causes tau phosphorylation and impaired axonal 
transport of neurofilaments as shown by time-lapse imaging technology. The treatment 
of Neuro-2a cells with a Cdk5 inhibitor, roscovitine, reversed this defect in axonal 
transport (Zhou et al., 2010). In cells expressing p35, treatment with (Town et al., 2002) 
or without (Hashiguchi et al., 2002) A#42 also increased phosphorylation of tau. 
Specifically, A#25-35 treatment of SHSY-5Y cells caused tau phosphorylation at lipid 
rafts (Hernandez et al., 2009). Recently, Zheng et al identified a 24 residue peptide, p5, 
derived from p35 (Zheng et al., 2010). P5 inhibited p25/Cdk5 activity and reduced A#42-
induced tau phosphorylation and apoptosis in cortical neuronal cultures, therefore 
suggesting a possible therapeutic for AD. In HFD-induced obese mice, Cdk5 activation 
in adipose tissues induced the phosphorylation of PPAR", a nuclear receptor involved 
in the regulation of adipogenesis fat cell gene expression. Phosphorylation of PPAR" 
led to the dysregulation of obesity-related genes which was reversed by the action of 
anti-diabetic ligands (rosiglitazone and MRL24). This evidence suggests that post-
translational modification of PPAR" by Cdk5 may contribute to insulin resistance (Choi 




PP2A is a major tau phosphatase (Goedert et al., 1995). It is a holoenzyme 
composed of a structural A subunit, catalytic C subunit, forming the core enzyme, and 
a regulatory B subunit that determines substrate specificity (Janssens and Goris, 2001; 
Lechward et al., 2001). The association of A and C subunits with one of a series of B 
subunits produces several species of holoenzymes with distinct functions. The activity 
of PP2A is regulated by post-translational modifications of the C subunit. The C-
terminal sequence of the C subunit is highly conserved between species, containing 
two phosphorylation sites at Thr304 and Tyr307 and a methylation site at Leu309. 
Thr304 is subjected to phosphorylation by an autophosphorylation-activated protein 
kinase (Guo and Damuni, 1993), whilst Tyr307 is phosphorylated by p60v-src, p56lck, 
epidermal growth factor receptors, and insulin receptors (Chen et al., 1992). 
Phosphorylation at both sites consequently results in the inhibition of PP2A. Leu309 
can be reversibly methylated by the PP2A methyltransferase and PP2A 
methlyesterase (Lee and Stock, 1993).  Methylation promotes the assembly of the 
PP2A holoenzyme and facilitates the association of B subunits (Tolstykh et al., 2000; 
Wu et al., 2000). The C subunit of PP2A also interacts with endogenous inhibitor 
proteins, I1PP2A and I2PP2A, both of which have been found in human post-mortem brain 
tissue and were shown to specifically block phosphatase activity of PP2A towards tau 
phosphorylation (Tanimukai et al., 2005; Tsujio et al., 2005). In rat brain slices, 
inhibition of PP2A activity by okadaic acid increased phosphorylation and the 
accumulation of neurofilaments, as shown by western blotting and 
immunohistochemistry techniques (Gong et al., 2003). Additionally, inhibition of PP2A 
activity in vivo by the injection of calyculin A into the rat hippocampus also increased 
tau phosphorylation and caused spatial memory retention in the Morris water maze test 
(Sun et al., 2003). More recently, in an AD mouse model (Tg2576) crossed with IRS2 
knockout mice, an increase in tau phosphorylation was shown to correlate with 
reduced PP2A activity (Killick et al., 2009).  
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1.4 The peroxisome proliferator-activated receptors (PPARs) 
The peroxisome proliferator-activated receptors (PPARs) belong to the NR1C 
class of the nuclear hormone receptor superfamily of ligand-activated transcription 
factors and are expressed in a wide variety of cell types. The three PPAR isoforms; 
PPAR$, PPAR#/% and PPAR" participate in the regulation of metabolism, proliferation, 
differentiation, apoptosis and the immune response specific to the tissues in which they 
are expressed. The PPARs are organised into four functional domains (Figure 1.7); the 
N-terminal A/B domain has a ligand-independent transcriptional activating function; the 
DNA binding domain is responsible for attaching specific peroxisome proliferator 
response elements (PPREs) on the promoter of PPAR target genes; the hinge region 
interacts with co-repressors and co-activators; the C-terminal ligand binding region is 
involved in the dimerisation of PPAR" and retinoid X receptors (RXR) or other ligands 
and provides ligand-dependent transactivation function (AF-2) to the receptor (Luconi 
et al., 2010). PPAR" was originally identified in Xenopus by homology cloning (Dreyer 
et al., 1992) and then subsequently in mice (Zhu et al., 1993). The PPAR" gene 
produces two splice variants that generates two proteins, PPAR"1, and PPAR"2 which 
has an additional 28 amino acids within the A/B domain at the N-terminus. PPAR"1 is 
ubiquitously expressed, whilst PPAR"2 is adipose-specific (Berger and Moller, 2002). 
The post-translational modification of PPAR" can modulate its transcriptional activity, 
for example the phosphorylation site Ser82 in PPAR"1 or Ser112 in PPAR"2 (in 
mouse) have been described as targets of members of the MAPK family (Erk1/2, JNK, 
p38 MAPK). In mice, phosphorylation of Ser112 by Erk1/2 decreases the biological 





Figure 1.7 Schematic representation of the domain structures in human PPAR 
isoforms  
 
The PPARs are formed of four functional domains; A/B, C, D and E/F. The N-terminal 
A/B domain contains a ligand-independent transactivation function known as AF-1 and 
also contains a site for mitogen-activated protein kinase phosphorylation (Adams et al., 
1997). The central region consists of a highly conserved DNA binding domain (C) that 
contains two zinc fingers responsible for binding of PPREs within the promoter region 
of specific target genes and a hinge region (D) that interacts with co-repressors and co-
activators to modulate DNA binding affinity. The C-terminal ligand binding domain (E/F) 
dimerises with ligands such as the retinoid X receptors (RXR) and provides ligand-
dependent transactivation function (AF-2) to the receptor. This figure is adapted from 
(Rosen and Spiegelman, 2001). 
 
 
To date, a specific natural ligand for PPAR" has not been reported. Some of 
their endogenous ligands include various unsaturated fatty acids, prostaglandins 
(15!PGJ2), eicosanoids and oxidized low-density lipoprotein species, (Straus and 
Glass, 2007) (for review).   
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The action of PPAR" effects adipose differentiation, lipid storage and 
inflammation. Their mechanism of action can be divided into two parts; genomic effects 
and non-genomic effects. The genomic effects involve lipid regulation, glucose 
homeostasis, anti-inflammation and anti-cancer actions whilst non-genomic effects 
modulate intracellular second messengers. In the genomic effects, ligand bound 
PPAR" forms heterodimers with RXR, allowing high affinity binding to DNA (Kliewer et 
al., 1992). This displaces co-repressors and recruits transcriptional co-activators which 
together bind to sequence-specific PPRE present in the promoter region of target 
genes to initiate transcription (Tugwood et al., 1992). Non-genomic effects involve the 
extranuclear interaction of PPAR" with second messengers leading to rapid changes in 
signalling, such as Erk1/2 (Hu et al., 1996a) and MEK-1 (Burgermeister et al., 2007). 
This mechanism excludes the PPAR" interaction with DNA and offers a regulatory role 
for PPAR" activity. However, since PPAR" has no nuclear export signal sequence, 
trafficking from the nucleus to the cytosol must involve shuttle proteins, MEK-1 has 
been demonstrated to be one of these (Burgermeister et al., 2007).  
The thiazolidinediones (TZDs), PPAR" agonists were initially discovered 
because of their insulin sensitising action in rodents which was consequently confirmed 
in humans and were identified as potential treatments for T2DM patients (Nolan et al., 
1994). An interaction between TZD and PPAR" was first discovered by Harris and 
Kletzien reporting that pioglitazone increased transcriptional activation of ARF6DNA-
binding complex on the fat selective adipocyte P2 (aP2) promoter (Harris and Kletzien, 
1994). ARF6 was subsequently identified as the PPAR"/RXR heterdimer (Tontonoz et 
al., 1994) and it was later shown that TZDs are direct agonists for PPAR" (Lehmann et 
al., 1995). In humans, mutations in PPAR" are associated with insulin resistance 
(Agostini et al., 2006; Barroso et al., 1999), further supporting the evidence that TZDs 
act through binding to PPAR" to improve insulin sensitivity.  
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1.4.1 PPAR"  and insulin resistance 
PPAR" agonists such as the TZDs, are insulin sensitisers that improve the 
action of insulin and reduce blood glucose levels. Their site of therapeutic action was 
proven to be adipose tissue as mice with the deletion of adipose tissue specific PPAR" 
are deficient in their response to TZD treatment (He et al., 2003). The action of PPAR" 
agonists was shown to cause de novo differentiation of large adipocytes into smaller 
insulin-sensitive adipocytes (Okuno et al., 1998) and it is thought that PPAR activation 
in adipose tissue alters the secretion of adipokines, bioactive molecules that enters the 
circulation and affects whole-body insulin sensitivity. Adiponectin is a adipokine present 
in plasma which is inversely correlated to adipose tissue mass and directly correlated 
to insulin sensitivity (Hu et al., 1996b). In support of this, the administration of TZDs in 
rodents and humans was found to increase adiponectin expression and consequently 
plasma adiponectin levels were increased (Pajvani et al., 2004; Yu et al., 2002). 
Furthermore, mice lacking adiponectin have impaired response to TZDs (Nawrocki et 
al., 2006). PPAR" activation of adipocytes also decreases the production of tumor 
necrosis factor (TNF)$ and resistin. Both TNF$ and resistin are postulated to cause 
insulin resistance (Hotamisligil et al., 1993; Steppan et al., 2001), as knockout mouse 
models of TNF$ or resistin improves insulin sensitivity (Banerjee et al., 2004; Uysal et 
al., 1997). 
The insulin sensitising actions of TZDs, discussed above, was the basis that led 
to investigating their potential use as treatments for AD.  
 
1.4.2 PPAR"  agonists and AD 
The TZD rosiglitazone was the first PPAR" agonist to be used in clinical trials 
with AD patients. Watson and colleagues performed a 6 month preliminary clinical trial 
using rosiglitazone in a subset of patients suffering from early stage AD which 
demonstrated to improve cognitive function (Watson et al., 2005). Following this, 
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Risner and colleagues conducted a larger rosiglitazone trial showing improvements in 
response to drug treatment in APOE!2/!3 carriers whilst no improvement was found in 
APOE!4 carriers (Risner et al., 2006). In vivo, the administration of rosiglitazone in 
animal models of AD also attenuated learning and memory deficits (Pedersen et al., 
2006). The APOE genotype specific effect may be due to the fact that APOE!4 
negative patients are more likely to be insulin resistant (Craft et al., 1999b) and 
improving insulin sensitivity may result in an increased insulin uptake into the brain 
(Craft et al., 2003). However, it is also thought that rosiglitazone may have direct 
effects in the CNS by stimulating neuronal mitochondrial biogenesis thus enhancing 
glucose utilisation (Strum et al., 2007). Furthermore, as greater mitochondrial 
dysfunction has been detected in AD APOE!4 carriers (Gibson et al., 2000), it has 
been proposed that excessive mitochondrial damage may mean that APOE!4 AD 
patients could not obtain maximum benefit from the rosiglitazone drug treatment. 
Despite the above, a recent phase III clinical trial of rosiglitazone treatment in patients 
with early stage AD, did not support these findings and reported no beneficial effect of 
rosiglitazone treatment on cognitive function (Gold et al., 2010). 
A potential explanation for the limited efficiency of rosiglitazone is the poor 
permeability through the BBB. It was initially thought that rosiglitazone was BBB 
impermeable (Pedersen et al., 2006; Watson et al., 2005), but a recent study by Strum 
et al has shown its presence in the brain after oral administration (Strum et al., 2007). 
An alternative TZD, pioglitazone, is thought to have higher permeability through the 
BBB compared to rosiglitazone. Although rosiglitazone is more potent in activity 
compared to pioglitazone; rosiglitazone has EC50 values of 0.043 µM and 0.076 µM, for 
the human and murine PPAR" receptors respectively, whilst pioglitazone has EC50 
values of 0.58 µM and 0.55 µM,  for the human and murine PPAR" receptors 
respectively (Willson et al., 2000). Recently, Geldmacher et al performed a pilot study 
on the safety of pioglitazone treatment in patients with mild to moderate AD and 
reported the drug was well tolerated and awaiting future clinical trials (Geldmacher et 
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al., 2011). Additionally, a 6 month clinical trial was conducted in a group of mild AD 
patients accompanied by T2DM. Pioglitazone treatment demonstrated improved 
cognitive function and enhanced insulin sensitivity in the diabetic AD patients, 
suggesting pioglitazone may offer a novel strategy for the treatment of AD (Sato et al., 
2011). In vivo, the use of pioglitazone by two independent studies produced conflicting 
results; Yan et al found treatment in Tg2576 mice reduced soluble A# levels but had no 
effects on the accumulation of A# or inflammatory markers (Yan et al., 2003). A 
following study by Heneka et al using a larger dose of the drug in APP(V717I) mice 
found a reduction in accumulation of A#, reduction in A#42 levels and reduced levels of 
inflammatory markers (Heneka et al., 2005). The authors of the first study claim their 
results were due to poor penetration of pioglitazone through the BBB. PPAR" activation 
has also been shown to reduce the phosphorylation of tau in neurons in vitro 
(d'Abramo et al., 2006).   
All of the above suggests PPAR" agonists may offer therapeutic benefit for the 
treatment of AD. However, the mechanism(s) by which thiazolidinediones act upon 
PPAR" still remains unclear. A better understanding of their action upon pathways and 
proteins implicated in AD pathology would help determine how they affect AD-like 
pathological symptoms and help vindicate their use for the amelioration of AD. 
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1.5 Animal models of AD and impaired insulin signalling 
That there may be a relationship between insulin resistance, as a consequence 
of T2DM, and AD is further supported by evidence from animal models. Insulin 
resistance occurs by a reduced reponse of insulin-responsive tissues to circulating 
insulin. Diabetes-like symptoms can be induced experimentally by a range of 
techniques and provide insights to the underlying mechanisms which may contribute to 
pathology. This approach may help identify targets for the development of future 
therapeutic intervention.  
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1.5.1 Streptozotocin models 
The streptozotocin (STZ) approach is the most commonly used technique to 
model insulin deficiency in AD. STZ is a nitrosurea derivative isolated from 
Streptomyces achromogenes, an alkaylating substance, which is toxic to pancreatic #-
cells; STZ enters #-cells via GLUT2 and alkaylates DNA, inducing DNA damage 
(Szkudelski, 2001). Systemic STZ injection therefore results in the development of 
insulin deficiency and glucose intolerance by the destruction of #-cells as the 
production of insulin is halted. The reduced levels of circulating insulin have an impact 
on brain insulin signalling since the major source of brain insulin is from the periphery. 
STZ administration has been shown to cause an increase in tau phosphorylation at a 
number of epitopes in the cortex and hippocampus of C57BL/6 mice (Clodfelder-Miller 
et al., 2006; Kim et al., 2009a; Planel et al., 2007). Whilst tau phosphorylation changes 
did not correlate with change in kinase activities such as GSK-3#, Cdk5, Erk1/2, JNK 
and CAMKII, a decrease in PP2A levels has been reported (Clodfelder-Miller et al., 
2006; Planel et al., 2007), suggesting the hyperphosphorylation of tau was due to a 
decrease in phosphatase activity. STZ has also been administered in Swiss Webster 
mice which reduced expression of IDE, reduced activation of the insulin receptor and 
Akt thereby increased GSK-3 activity leading to increased tau phosphorylation at the 
Thr231 epitope, elevated A# levels and induced learning deficits (Jolivalt et al., 2008). 
Interestingly, in the studies by Coldfelder-Miller et al and Jolivalt et al, 15 minutes 
insulin treatment in animals reversed tau phosphorylation at some epitopes (Thr231, 
Ser396/404) but did not restore PP2A activity (Clodfelder-Miller et al., 2006), whilst 8 
weeks of insulin treatment partially reversed phosphorylation of the insulin receptor, 
GSK-3# activity and tau phosphorylation in addition to improving the learning 
performance in animals (Jolivalt et al., 2008). The difference between these two 
studies may be attributed to the length of STZ treatment (3 days in Coldfelder-Miller et 
al and 9 weeks in Jolivalt et al), demonstrating the reversibility of tau phosphorylation 
at selective sites after short term insulin deficiency. In rats administered with STZ, 
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increased tau phosphorylation also correlated with the reduction in phosphorylation of 
Akt, GSK-3 and PP2A. However, insulin treatment did not change tau phosphorylation 
but lithium treatment reversed all tau phosphorylation sites by 30 days (Qu et al., 
2011).  Additionally, STZ treatment in the pR5 tau mouse model with the P301L human 
tau mutation, the deposition of hyperphosphorylated insoluble tau was evident along 
with the formation of NFTs (Ke et al., 2009).  
In two APP transgenic models; APP double transgenic (London V717I and 
Swedish K670M/N671L) mice and the APP/PS1 double transgenic line, STZ treatment 
increased GSK-3 activity leading to an increase in A# production and a concomitant 
increase in A# plaques (Jolivalt et al., 2010), which associated with impaired memory 
performance (Wang et al., 2010). Additionally, tau phosphorylation was increased in 
the APP double transgenic mice (Jolivalt et al., 2010). Furthermore, direct 
intracerebroventricular (ICV) injection of STZ target GLUT2 in the brain and mimics the 
insulin resistant brain state. This approach selectively decreases brain insulin without 
disturbing systemic insulin and glucose levels. STZ was found to impair glucose and 
energy metabolism and also impaired learning and memory in rats (Lannert and Hoyer, 
1998). ICV STZ injected brains also exhibit neurodegenerative features in that they 
appear reduced in size, likely due to cell loss and gliosis as evidenced by increased 
p53 immunoreactivity (Lester-Coll et al., 2006). The activation of GSK-3# increased 
phosphorylation of tau and elevated A# levels (Lester-Coll et al., 2006). In the APP 
transgenic model Tg2576 (overexpressing the APPswe mutation), ICV STZ treatment 
increased GSK-3 activity leading to an increase in A# production and a concomitant 
increase in A# plaques, which coincided with impaired memory performance (Plaschke 
et al., 2010). Interestingly, a recent study demonstrated ICV STZ injection resulted in 
deficits in hippocampal LTP and indicated synaptic dysfunction was due to reduced 
expression of NMDA receptor subunits, NR2A and NR2B (Shonesy et al., 2011).  
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1.5.2 Spontaneous diabetes models 
Spontaneous diabetes models are genetically predisposed to developing T1DM 
or T2DM. In rats, both Bio-Breeding/Worcester (BB/Wor) (T1DM) and Bio-Breeding 
Zucker diabetic rat (BBZDR)/Wor (T2DM) models develop diabetes around 2 months of 
age and by 10.5 months of age neuronal loss in the frontal cortex was visible, noticably 
higher in the BBZDR/Wor rats which was accompanied by a nine-fold increase in 
dystrophic neurites. In both models, the expression of the IGF1-receptor was reduced 
and phosphorylation of Akt and GSK-3# were reduced. In the type 2 diabetic 
BBZDR/Wor rats, this led to more than two-fold increase in the levels of APP, BACE 
and A# as well as a significant increase in tau phosphorylation (Ser396) (Li et al., 
2007). These findings indicate T2DM more likely influences the development of AD 
pathology. In another study using db/db (homozygous for diabetic gene (db) that 
encodes a point mutation for the leptin receptor) mice, which develop T2DM by 5 
weeks of age, tau phosphorylation and tau cleavage was increased in the cortex and 
hippocampus by 8 weeks of age (Kim et al., 2009a). In contrast, another study found 
no change in tau phosphorylation at 8 weeks of age in the same mice (Jolivalt et al., 
2008). Recently, Takeda et al generated mouse models that genetically develop T2DM 
and AD by crossing APP23 mice with ob/ob (leptin deficient) or Nagoya-Shibata-
Yasuda (NSY) type 2 diabetic mice (Takeda et al., 2010). Both APP+-ob/ob and APP+-
NSY mice showed features of diabetic phenotype but exhibit different pathogenic 
mechanisms. APP+-ob/ob mice exhibited early onset of diabetes and early onset of 
learning deficit in the Morris water maze test. A# deposition was not detected but 
cerebrovascular A# deposition was prominent and associated with increased RAGE 
immunoreactivity, increase reactive astrogliosis and reduced cholinergic fibres in the 
hippocampus. Insulin signalling was disturbed as levels of insulin, PIP3 and Akt 
phosphorylation were suppressed. Similar observations were observed in APP+-NSY 
mice when fed a high fat diet (HFD) for 5 months. The authors suggested that 
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cerebrovascular dysfunction and altered brain insulin signalling may play a mechanistic 
role between T2DM and AD. 
 
1.5.3 Diet-induced models of insulin resistance and diabetes  
Diet-induced insulin resistance is more reflective of modern lifestyles in man 
and the development of T2DM. In Tg2576 mice, feeding HFD for 5 months induced 
obesity, impaired glucose tolerance and resulted in high fasting plasma insulin levels. 
Impairments in the insulin signalling pathway were shown in reduce insulin receptor 
activation, phosphorylation of Akt and phosphorylation of GSK-3. A#40 and A#42 levels 
were elevated accompanied by the generation of A# plaques which corresponded to an 
increase "-secretase and a reduction in IDE activities (Ho et al., 2004). Furthermore, 
impairment in performance of the Morris water maze task was observed (Ho et al., 
2004). Feeding HFD to the same mice for 3 months by another group also induced 
insulin resistance and A#40 and A#42 levels increased however, authors did not 
examine components of the insulin signalling pathway (Kohjima et al., 2010). These 
observations were strengthened by a group using the triple transgenic AD mouse 
(APP[APPswe], PS1 [PS1M146V], and tau [P301L]), which after being fed a HFD 
showed increased levels of A#40 and A#42, as well as soluble tau. Instead of memory 
tests, decreased levels of the synaptic marker, drebrin, were found (Julien et al., 2010). 
On the contrary, Moroz et al found no AD pathology in C57BL/6 mice fed HFD for 16 
weeks, despite developing glucose intolerance and hyperinsulinemia (Moroz et al., 
2008). Although changes in brain expression levels of tau, insulin, IGF1 receptor, IRS1, 
IRS4, ubiquitin, GFAP and #-actin were detected and insulin receptor binding was 
reduced. The authors concluded that T2DM contributes to the development of AD but 
is not sufficient to cause AD. Two other papers have reported the intake of 10% 
sweetened sucrose water for 25 or 16 weeks in APP/PS1 double transgenic mice (Cao 
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et al., 2007) or rats (Luo et al., 2011) respectively, exacerbates memory impairment 
and A# deposition.  
 
1.5.4 Models with genetic manipulations 
Studies have targeted components of the insulin signalling pathway in an 
attempt to identify the level of signalling which would have the greatest impact on AD 
pathology. In NIRKO mice, the PI3K signalling pathway is reduced and thus Akt activity 
was reduced. This led to an increase of GSK-3# activity that corresponded to the 
hyperphosphorylation of tau. However, the absence of neuronal damage, impaired 
cognition or basal brain glucose metabolism suggests other factors must interact for 
the development of AD (Schubert et al., 2004). Similarly, IRS2 knockout mice 
displayed hippocampal NFTs containing hyperphosphorylated tau, corresponding to a 
reduction of the PP2A catalytic subunit (Schubert et al., 2003). A further study queried 
the effect of IRS2 knockout on amyloid pathology by crossing the IRS2 knockout mice 
with Tg2576 mice. As previous studies, tau phosphorylation was increased due to a 
reduction in the tau phosphatase PP2A, however the A# burden was significantly 
reduced, accompanied by an improvement in cognitive function of mice (Killick et al., 
2009). The reduction in A# plaques correlated with an increase in the A# binding 
protein, transthyretin, indicating increased A# clearance in the brain. Interestingly, 
another study using the same mice, Tg2576 crossed with IRS2 knockout mice, 
reported a delay in A# accumulation which rescued the premature mortality of Tg2576 
mice (Freude et al., 2009). Furthermore, the IDE knockout mice displayed increased 
cerebral A# accumulation, elevation of AICD and peripheral hyperinsulinemia and 
glucose intolerance, features of both AD and T2DM respectively (Farris et al., 2003). 
These results show IDE hypofunction might be related to the connection between AD 
and T2DM.  
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Taken together, although the mechanisms underlying the increased risk of AD 
in diabetics are not yet clear, evidence from animal models has provided some clues 
towards the underlying cause. However, as in man, these in vivo models are complex 
with some apparently contradictory evidence coming from type 1 versus type 2 and 
from genetic versus dietary models. Future studies are essential to confirm these 


















1.6 Aims and objectives of the current study 
The overall aim of this thesis was to investigate the effects of PPAR" agonism 
on insulin signalling processes relevant to AD pathogenesis and to determine if any 
such effects are APOE genotype dependent. This could give insight with regard to the 
possible use of TZDs as treatments for AD.   
 
The principle objectives were: 
 
1. To determine the effect of APOE genotype in modulating the influence of insulin 
signalling on APP metabolism and tau phosphorylation in vivo. 
 
2. To determine whether PPAR" agonists modulate the influence of insulin 
signalling on APP metabolism and tau phosphorylation in vivo and if they do, 
whether this is in an APOE-dependent manner. 
 
3. To determine the mechanism of effect of PPAR" agonists in this context - 
specifically, whether it is mediated through a direct action on neurons, via 
cholesterol related mechanisms.  
 
4. To investigate the effects of diet-induced insulin resistance on the brain 

























All reagents were obtained from Sigma Aldrich (UK) or Roche (UK) unless 
stated otherwise. Solutions were prepared using ultra-pure water from an Elga Maxima 
water purification system. 
 
2.1.1 Commonly used reagents 
Sigma 
Ammonium persulphate (APS) 
Beta-Mercaptoethanol (#-mercaptoethanol) 
Boric acid 
Ethylenediaminetetraacetic acid (EDTA) 
Ethylene glycol tetraacetic acid (EGTA) 
Glycine for electrophoresis 
Glycerol 2-phosphate disodium salt hydrate  
Phenylmethanesulphonyl fluoride (PMSF) 





TEMED (N,N,N',N'- Tetramethylethylenediamine) 
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Trichloroacetic acid 






Mini complete protease inhibitor tablets 
Mini complete phosphatase inhibitor tablets 
Tris 
 
2.1.2 General solutions 
Ammonium persulphate 
10% APS  
 
Azide 
1% Sodium azide  
 
Ponceau S 
0.2% Ponceau S 
5% Trichloroacetic acid  
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2.1.3 Solutions for electrophoresis 
Tris-Borate-EDTA (TBE) buffer for agarose electrophoresis: 
89 mM Tris 
89 mM Boric acid 
2 mM EDTA 
 
Running buffers for western blotting: 
8% Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS PAGE Tank Buffer (10x) Tris-Glycine SDS (Geneflow) 
10x buffer was diluted to 1x in ddH2O before use 
 
16% Tricine gels 
Novex Tricine SDS Running Buffer (10x) (Invitrogen) 
10x buffer was diluted to 1x in ddH2O before use 
 
Transfer buffer: 
1.88 M Glycine  
20% Methanol (VWR) 







0.1% Tween  
 
Blocking buffer: 
5% Dried skimmed milk (Marvel) in PBST  
 
2.1.4 Transgenic mice 
All transgenic mice; APOE KO, APOE!3 and APOE!4, were purchased from 
Taconic and together with the same background strain C57BL/6 mice (Charles River) 
were bred in-house at The Frythe, GlaxoSmithKline. Judy Latcham, Michael Fulleylove, 
Jason Smith and Sylvia Fung from GlaxoSmithKline were involved with the animal 
husbandry. 
Mice with human APOE genes replacing murine APOE genes (henceforth 
described as ‘APOE mice’) were generated as published (Knouff et al., 1999; 
Piedrahita et al., 1992; Sullivan et al., 1997). In brief, the mice were created by gene 
targeting of the endogenous murine APOE gene locus with the human APOE alleles; 
APOE!3 or APOE!4. Consequently, mice expressed human apoE isoforms under the 
control of murine APOE regulatory sequences and have similar apoE expression levels 





2.1.4.1 Assessment of metabolic changes 
Oral glucose tolerance test 
+D-Glucose (Sigma) 
 
Plasma insulin levels 
Mouse insulin ultrasensitive enzyme-linked immunosorbent assay (ELISA) (DRG, 
Germany. EIA 3440) 
 
Plasma adiponectin levels  
Mouse adiponectin immunoassay (R&D Systems, Minneapolis USA. MRP300) 
 
2.1.5 Protein extraction and sample preparation 
2.1.5.1 Sucrose homogenisation buffer 
250 mM sucrose 
20 mM Tris-HCl (pH 7.4) 
1 mM EDTA 
1 mM EGTA 
100 mM PMSF 
1 mini complete phosphatase inhibitor cocktail tablet  
1 mini complete protease inhibitor cocktail tablet  
1% Triton X-100  
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2.1.5.2 Protein sample buffer 
8% SDS-PAGE 
2x Laemmli Sample Buffer (BioRad) 
#-mercaptoethanol  
 
16% Tricine gels 
2x Tris-glycine SDS sample buffer containing NuPage sample reducing agent 
(Invitrogen) 
 
2.1.6 Western blotting 
2.1.6.1 Protein molecular weight markers 
8% SDS-PAGE gels 
Precision Plus Protein Kaleidoscope Standards (Bio Rad) 
 
16% Tricine gels 




4x ProtoGel Resolving Buffer (1.5 M Tris-HCl, 0.4% SDS, PH 8.8) (Geneflow) 




99% TEMED (N,N,N',N'- Tetramethylethylenediamine)  
 
Stacking gel 
ProtoGel Stacking Buffer (0.5 M Tris-HCl, 0.4% SDS, PH 6.8) (Geneflow) 




99% TEMED (N,N,N',N'- Tetramethylethylenediamine)  
 
Pre-cast gels 




All antibody sources, specificity and dilutions used are summarised in table 2.1. 
These were diluted in blocking solution PBST containing 5% milk and used for western 






Goat anti-rabbit, goat anti-mouse or donkey anti-goat secondary antibodies 
conjugated to fluorophors (Molecular Probes, Invitrogen) emitting at wavelengths of 
either 700 or 800 nm were used. Donkey anti-rabbit and donkey anti-mouse HRP-
conjugated secondary antibodies (GE Healthcare, UK) were used for the detection of 
APP processing and #-actin. 
!
Table 2.1 List of antibodies used for western blotting 
Dilution 






Apolipoprotein E Goat polyclonal Millipore 1:5000 - - 
AT8 (Ser202/Thr205) Mouse monoclonal Pierce - 1:1000 - 
AT180 (Thr231) Mouse monoclonal Pierce - 1:1000 - 
Phospho-tau 
(Ser396) Mouse monoclonal 
Cell signalling 
Technology - 1:1000 - 
PHF1 Mouse monoclonal Peter Davies - - 1:2000 
Total Tau Rabbit polyclonal Dakocytomation - 1:50,000 1:50,000 
Phospho-GSK-3 
(Ser21/9) Rabbit polyclonal 
Cell signalling 
Technology - 1:1000 1:2000 
Total GSK-3 Mouse monoclonal Stressgen - 1:1000 1:2000 
Phospho-Akt 
(Ser473) Rabbit polyclonal 
Cell signalling 
Technology - 1:1000 1:2000 
Total Akt Rabbit polyclonal 
Cell signalling 
Technology - 1:1000 1:2000 
Phospho-PP2A 
(Tyr307) Rabbit polyclonal 
Cell signalling 
Technology - 1:1000 - 
Total PP2A Goat polyclonal Santa Cruz - 1:1000 - 
p35/25 Rabbit polyclonal 
Cell signalling 
Technology - 1:1000 - 
Anti-APP 369 Rabbit polyclonal 
(Buxbaum et al., 
1990) - 1:1000 - 
#-Actin Mouse monoclonal Abcam - 1:5000 1:5000 
#-Tubulin III Rabbit polyclonal Sigma  - 1:5000 1:5000 
          
Secondary antibodies 
Goat anti-rabbit 800 
(flurophore) Rabbit polyclonal 
Molecular Probes, 
Invitrogen - 1:6000 1:6000 
Goat anti-mouse 680 
(flurophore) Mouse polyclonal 
Molecular Probes, 
Invitrogen - 1:6000 1:6000 
Donkey anti-goat 680 
(flurophore) Donkey polyclonal 
Molecular Probes, 
Invitrogen 1:6000 1:6000 - 
Donkey anti-rabbit 
(HRP) Rabbit polyclonal GE Healthcare - 1:5000 - 
Donkey anti-mouse 
(HRP) Mouse polyclonal GE Healthcare - 1:5000 - 
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2.1.8 Abeta (A#) enzyme-linked immunosorbent assays (ELISAs) 
Mouse soluble A# 1-40 and A# 1-42 were measured using the BetaMark Beta Amyloid 
x-40 (SIG-38950) and x-42 (SIG-38952) chemiluminescent ELISA kits (Covance). Both 
ELISA kits detect human and rodent A# 1-40 and A# 1-42. 
 
2.1.9 Cell culture reagents 
Poly-D-Lysine Hydrobromide (Sigma), 1 mg/ml 
Insulin (Sigma) 
Trypsin (PAA Laboratories) 
PBS tablets (Sigma) 
Pioglitazone (ChemPacific) 
 
2.1.9.1 Culture Media 
CHO cell culture media 
F12/DMEM (PAA Laboratories) supplemented with: 
10% Fetal bovine serum (Sera Labs International) 
Penicillin/Streptomycin (PAA Laboratories) 
 
Neuronal cell culture media 
Neuralbasal media (Gibco, Invitrogen) supplemented with: 
B27 supplement with insulin (Invitrogen) or B27 supplement without insulin (Invitrogen) 
200 mM L-Glutamine (PAA Laboratories) 
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Penicillin/Streptomycin 
G418 disulfate salt solution (Sigma) 
 
2.1.10 Affymetrix microarray  
All Affymetrix GeneChip Mouse Genome 430 v2.0 arrays, GeneChip 
Hybridisation Wash and Stain kits and GeneChip IVT Express kits were purchased 
from Affymetrix, UK. Agilent RNA 6000 Pico chips to assess the quality of RNA, were 
purchased from Agilent Technologies, UK. Tissues were lysed in Matrix lysing D tubes 
from Qbiogene and RNA extracted using the RNase-Free DNase Set from Qiagen, UK, 
which incorporates a DNase step to remove any genomic DNA contamination. 
 
2.2 Methods 
2.2.1 Transgenic mice 
2.2.1.1 Dietary conditions 
APOE KO, APOE!3 and APOE!4-transgenic mice together with background 
strain C57BL/6 mice, at 3 months of age, were kept on a low fat diet (LFD) (10% fat, 
Research Diets, D12450B) (n = 12 per genotype) or a high fat diet (HFD) (60% fat, 
Research Diets, D12492) (n = 12 per genotype) for 32 weeks. Details of diets are 
shown in Table 2.2 and 2.3, respectively. Mice were housed individually under 
controlled conditions of temperature and lighting and given free access to food and 





Table 2.2 Formula of low fat diet with 10% kcal fat 
Table is adapted from the Research Diets, D12450B datasheet.  
Product   D12450B (LFD) 
   gm %  kcal % 
Protein  19.2 20 
Carbohydrate  67.3 70 
Fat  4.3 10 
Total   100 
kcal/gm  3.85   
Ingredient  gm  kcal 
Casein, 80 Mesh  200 800 
L-Cystine  3 12 
Corn Starch  315 1260 
Maltodextrin 10 35 140 
Sucrose  350 1400 
Cellulose, BW200  50 0 
Soybean Oil  25 225 
Lard*  20 180 
Mineral Mix S10026  10 0 
DiCalcium Phosphate  13 0 
Calcium Carbonate  5.5 0 
Potassium Citrate, 1 H2O  16.5 0 
Vitamin Mix V10001  10 40 
Choline Bitartrate 2 0 
FD&C Yellow Dye #5  0.05 0 
Total  1055.05 4057 
 
*Typical analysis of cholesterol in lard = 0.95 mg/gram 
Cholesterol (mg)/4057 kcal = 19 










Table 2.3 Formula of high fat diet with 60% kcal fat 
Table is adapted from the Research Diets, D12492 datasheet.  
Product   D12492 (HFD) 
  gm %  kcal % 
Protein  26.2 20 
Carbohydrate  26.3 20 
Fat  34.9 60 
Total   100 
kcal/gm  5.24   
Ingredient  gm  kcal 
Casein, 80 Mesh 200 800 
L-Cystine  3 12 
Corn Starch 0 0 
Maltodextrin 10  125 500 
Sucrose  68.8 275.2 
Cellulose, BW200  50 0 
Soybean Oil  25 225 
Lard*  245 2205 
Mineral Mix, S10026  10 0 
DiCalcium Phosphate  13 0 
Calcium Carbonate  5.5 0 
Potassium Citrate, 1 H2O  16.5 0 
Vitamin Mix, V10001  10 40 
Choline Bitartrate  2 0 
FD&C Blue Dye #1  0.05 0 
Total  773.85 4057 
 
*Typical analysis of cholesterol in lard = 0.95 mg/gram 
Cholesterol (mg)/4057 kcal = 232.8 
Cholesterol (mg)/kg = 300.8 
 
 
2.2.1.2 Drug treatment 
APOE KO, APOE!3 and APOE!4-transgenic mice together with background 
strain C57BL/6 mice, at 3 months of age, were kept on a 60% HFD for 30 weeks. 
During the last 3 weeks of diet, mice were divided into vehicle and pioglitazone 
treatment groups. The pioglitazone treatment group (n = 12 per genotype) were orally 
dosed with pioglitazone (20 mg/kg) (ChemPacific) whilst the vehicle group (n = 12 per 
genotype) received 1% methylcellulose. Mice were dosed twice daily (8am and 8pm). 
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Mice were housed individually at 3 months of age under controlled conditions of 
temperature and lighting and given free access to food and water.  
 
2.2.1.3 Oral glucose tolerance test 
Glucose tolerance tests were conducted to assess the level of circulating 
glucose prior to commencing each study and then at 6 or 12 weekly intervals following 
the initiation of study. Mice were fasted overnight. The next morning, mice were placed 
in a warming chamber prior to blood sampling and blood was taken by direct 
venopuncture. Mice were then given a single oral dose of glucose (3 g/kg dose volume 
10 ml/kg) and serial blood samples collected from the tail tip post-dose at 30, 60, 90, 
120 and 180 min. Glucose levels were accessed using the Ascensia blood glucose 
meter (Bayer Diabetes Care, UK).  
 
2.2.1.4 Collection of plasma 
Blood samples collected from the tail vein at baseline into anti-coagulation 
tubes were centrifuged at 3000 x g for 5 min. Plasma was aliquoted into separate tubes 
and then stored at -80°C until analysis.  
 
2.2.1.5 Measurement of plasma insulin levels and homeostatic model 
assessment of insulin resistance (HOMA-IR) 
ELISAs used to measure insulin were ran according to the manufacturer’s 
instructions. 
All reagents and samples were brought to room temperature before use. The 
ELISA is based on the direct sandwich ELISA technique (Figure 2.1) in which 5 µl 
plasma sample plus 50 µl secondary peroxidase conjugate were loaded into a insulin 
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antibody coated 96-well plate. During the 2 h incubation, shaking at room temperature, 
insulin within the sample binds with the secondary and anti-insulin antibodies in the 
microtitration well. The unbound enzyme labelled antibodies were removed by washing 
the plate six times with 350 µl of wash buffer. Peroxidase substrate (200 µl of 3,3’,5,5’-
tetramethylbenzidine (TMB)) was then added and incubated for a further 30 min before 
the addition of stop solution (1 M sulphuric acid, H2SO4). The plate was placed onto a 
shaker for 5 sec to ensure mixing of the substrate and stop solution before measuring 
on the SpectraMax M2 microplate reader (Molecular Devices, UK) at 450 nm 
absorbance. The SoftMax Pro v5 software to was used to analyse the data. Animals 
with a lack of effect of high fat feeding on insulin sensitivity were removed from the 
corresponding data analyses. 
The HOMA-IR (Matthews et al., 1985) was calculated using the following 
formula: (fasting blood glucose (mg/dL) * fasting insulin (µU/ml))/405. 
 
Figure 2.1 Diagram of the direct sandwich ELISA technique 
 
Each well of a 96-well plate is coated with capture antibodies for the protein of interest 
(A). During the assay, the sample is loaded into the well. The target proteins are 
recognised by the capture antibodies and are immobilised onto the plate surface (B). 
Following incubation, the well is subjected to washes that remove unbound samples. 
The addition of an enzyme conjugated secondary antibody allows the detection of the 
target protein when a substrate is added (C). 
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2.2.1.6 Measurement of plasma adiponectin levels 
Adiponectin levels were measured using a commercial ELISA kit according to 
the manufacturer’s instructions. 
All reagents and plasma samples were brought to room temperature before 
use. The ELISA is based on a direct sandwich technique. Samples were diluted 2000-
fold with the calibrator diluent provided in the kit. Diluted samples (50 µl) along with 50 
µl assay diluent were loaded into an anti-adiponectin monoclonal antibody coated 96-
well plate and allowed to bind during incubation for 3 h at room temperature. Unbound 
substances were removed by washing the plate with 400 µl of wash buffer five times. 
An HRP enzyme-linked polyclonal antibody specific for mouse adiponectin (100 µl) was 
then added into the well for 1 h at room temperature. Following five 400 µl plate 
washes to remove any unbound enzyme, 200 µl of substrate solution containing 
hydrogen peroxide and TMB was added to each well and incubated for 30 min, 
protected from light. The reaction was ended by the addition of stop solution (100 µl of 
hydrochloric acid, (HCl)) and mixed gently before reading the absorbance at 450 nm on 
the SpectraMax M2 microplate reader (Molecular Devices, UK). The SoftMax Pro v5 
software to was used to analyse the data.     
 
2.2.1.7 Tissue preparation 
At termination of each study, mice were sacrificed by a lethal overdose of 
anesthetic, pentobarbitone sodium. Brains were removed, and each hemisphere was 
subdissected into the following regions: cortex, hippocampus, cerebellum and rest of 
brain. One hemisphere was fresh frozen in liquid nitrogen and subsequently stored at -
80˚C until use. The other hemisphere was preserved immediately in 10 volumes (~10µl 
per mg tissue) of RNAlater (Qiagen, UK) per 1g of tissue for 2 days at 4°C before 
removing the reagent and storing at -80°C until use. RNAlater is a tissue permeant 
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stabiliser and protectant of RNA. Samples of the liver were also collected, fresh frozen 
in liquid nitrogen and subsequently stored at -80˚C. 
 
2.2.2 Genotyping of transgenic mice 
2.2.2.1 Extraction of DNA 
The DNeasy Blood and Tissue kit (Qiagen) was used to extract DNA from livers 
of transgenic mice according to the manufacturer’s instructions. 
Livers from transgenic mice were weighed and placed in microcentrifuge tubes 
with Buffer ATL (180 µl). Proteinase K was added to each tube, mixed thoroughly by 
vortex and allowed to incubate at 56°C in a thermomixer to lyse the tissue. Following 
lysis, tubes were vortexed for 15 sec before the addition of Buffer AL (200 µl) and 
mixed thoroughly.  Ethanol (200 µl, 100%) was added to each sample and mixed 
thoroughly. The mixture from each tube was transferred into a DNeasy Mini spin 
column and centrifuged at 8000 rpm for 1 min. The flow-through was discarded. Buffer 
AW1 (500 µl) was added to each DNeasy spin column and centrifuged at 8000 rpm for 
1 min before discarding the flow-through. Buffer AW2 (500 µl) was added to each 
DNeasy spin column and centrifuged at 14,000 rpm for 3 min. Finally to elute the DNA, 
DNeasy spin columns were placed into a fresh microcentrifuge tube and the Buffer AE 
(100 µl) was added directly onto the DNeasy membrane, incubated at room 
temperature for 1 min and centrifuged at 8000 rpm for 1 min. In order to obtain 
maximum yield, the elution step was repeated once more. Eluted DNA samples were 
stored at -20°C until use. 
 
2.2.2.2 Polymerase chain reaction (PCR) 
PCR amplification was carried out in a master mix shown in table 2.4 containing 
AmpliTaq Gold DNA Polymerase (Applied Biosystems), Gold buffer (Applied 
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Biosystems), MgCl2 (Applied Biosystems), dNTPs (Roche), forward and reverse 
primers (Eurofins MWG, table 2.5) and 10 ng of genomic DNA as a template. DNA (2 
µl) was added into a PCR Thermal-Fast 96-well microplate (ThermalScientific) before 
the addition of the master mix (18 µl per reaction). The plate was subjected to a brief 
spin to collect the mixture at the bottom of the plate before placing in the BioRad 
DyadDisciple thermal cycler controlled by the Opticon Monitor 3 software. The 
following thermal cycling conditions were used: 
1. Tmelting 95°C 1 min 
2. 95°C 10 sec 
3. Tannealing 63°C 10 sec 
4. Textension 72°C 30 sec 
5. Repeat steps 2-4, 30 times 
6. End, hold at 4°C !!
Table 2.4 Reagents within the master mix prepared for one PCR reaction  
Reagent Volume (µ l) 
10 x buffer 2 
Primer 1 (10µM) 2 
Primer 2 (10µM) 2 
dNTP (2 mM) 2 
Taq polymerase 0.1 
DNA (5 ng/µl) 2 
MgCl2 (25 mM) 1.6 





Table 2.5 Primers for PCR APOE genotyping 
Gene  Primer sequence 






2.2.2.3 Agarose gel electrophoresis of PCR products 
PCR products were analysed on 1.5% agarose gels. Ultrapure agarose was 
dissolved in boiling 1x TBE buffer, cooled and ethidium bromide was added into the 
mixture before cast onto a tray with a suitable comb. Gels were placed in the 
electrophoresis tank containing 1x TBE buffer to cover the surface of the gel. PCR 
products were diluted in gel loading buffer prior to loading into the gel with a 100 bp 
DNA ladder (TrackIt, Invitrogen) and run at 115 V for 50 min. Gels were visualised 
using the AlphaImager Mini (Alpha Innotech) emitting ultraviolet light. 
 
2.2.2.4 TaqMan genotyping 
TaqMan small nucleotide polymorphism (SNP) Genotyping Assays are 
performed using a 5’ nuclease chemistry for the amplification and detection of specific 
polymorphisms in genomic DNA samples. The assay used was pre-designed and 
validated by Applied Biosystems. The assay was performed together with Dr. Michelle 
Lupton, King’s College London. 
DNA was extracted from the livers of mice by using the Qiagen DNeasy blood 
and tissue kit as described in section 2.2.2.1. The concentration of each sample was 
measured using the NanoDrop 1000 (ThermoScientific) and prepared to a 
concentration of 5 ng/µl in working plates. DNA from each sample (1 µl) was 
transferred to an optically clear 384 well plate (Thermo-fast diamond, ABgene) and left 
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to dry by evaporation. A reaction mixture containing 1x ABsolute QPCR ROX Mix 
(ABgene) and 1x genotyping assay (Applied biosystems) was then added to each well, 
to disperse the DNA before sealed with an optically clear “absolute QPCR” adhesive 
cover (ABgene). The PCR reaction was carried out using the following parameters: 
 
1. 95°C for 15 min 
2. 92°C for 15 sec 
3. 60°C for 1min 30 sec 
4. Repeat steps 2-3, 49 times 
5. End, hold at 4°C 
 
On completion of the PCR amplification, an endpoint plate read was performed 
using the Applied Biosystems 7900HT Fast Real-Time PCR System according to 
manufacturer’s instructions. Fluorescent measurements (FAM and VIC) obtained from 
each well were plotted by the Sequence Detection System (SDS) software. The plotted 
fluorescence signals indicate which alleles are in each sample by use of a clustering 
algorithm. The plate was analysed with a quality value of 95% and an automatic allele 
call. The allele calls were converted to genotype as the two different report dyes FAM 
and VIC show the presence of each allele (APOE!3 or APOE!4). The calls are 
positioned on the plot due to the level of fluorescence for each allele (Figure 3.4). 
 
APOE genotypes 
The APOE gene consists of three main alleles; !2, !3 and !4. The difference 
between these alleles are due to 2 residues therefore the APOE allele is a haplotype 
consisting of two SNPs. Between the !3 and !4 alleles there is one differing SNP, !3 
was detected as rs429348T and !4 detected as rs429348C.  
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2.2.3 Analysis of brain samples 
2.2.3.1 Protein extraction 
Individual regions of interest were weighed whilst frozen and then homogenised 
rapidly in 10-fold volume of a detergent free tissue homogenisation buffer on ice. A 
sample of total brain homogenate was collected and stored at -80°C until use for the 
A# ELISAs. Homogenates were then centrifuged at 47,000 rpm for 20 min at 4°C in a 
Beckman TLA 55 rotor (Beckman, Palo Alto, CA, USA). The soluble supernatant (S1 
fraction) was collected and the pellet resuspended in a same volume of the above 
buffer with the addition of 1% Triton X-100, then subjected to centrifugation again. The 
resultant supernatant (S2 fraction) was collected and stored at -80°C with the S1 
fraction and the pellet, P2, until use. 
 
2.2.3.2 Bradford assay 
The concentration of protein in brain lysates were determined by using the 
Bradford Protein assay from BioRad, according to the manufacturer’s instructions. The 
assay is based on the dye-binding method described by Bradford (Bradford, 1976). It 
utilises an acidic solution of Coomassie Brilliant Blue G-250 which shifts from 465 nm 
to 595 nm on binding of a protein. Samples were diluted 1:10 dilution with ddH2O and 
then 10 µl diluted sample was incubated with 190 µl Bradford reagent for 30 min in the 
dark, at room temperature. Absorbance was recorded at 595 nm using the Wallac 
spectrophotometer (Perkin Elmer) and measurements were compared to a standard 





2.2.3.3 Western blotting 
2.2.3.3.1 8% and 12% SDS-PAGE 
S1 and S2 samples were diluted in an equal volume of 2x reducing laemmli 
sample buffer and boiled at 100°C for 5 min. Denatured samples were separated on 
8% and 12% SDS-PAGE gels at 150 V for 1 h at room temperature. Proteins were then 
transferred onto nitrocellulose membranes (Whatman, UK) at 80 V for 1 h. Membranes 
were incubated in a blocking solution PBST for 1 h and then probed with primary 
antibody overnight at 4°C. The membranes were washed three times with PBST then 
incubated with either goat anti-rabbit, goat anti-mouse or donkey anti-goat secondary 
antibodies conjugated to fluorophors emitting at wavelengths of either 700 or 800 nm 
for 1 h at room temperature. Membranes were washed three times again with PBST. 
Proteins were detected using an Odyssey infrared imager (Licor, UK) and densitometry 
performed using ImageJ. 
 
2.2.3.3.2 16% Tricine gels 
S2 samples were diluted in an equal volume of 2x Tris-glycine SDS sample 
buffer containing NuPage sample reducing agent and heated for 3 min at 85°C. 
Samples were spun briefly then separated on 16% Tricine gels at 130 V for 2 h. 
Proteins were then transferred onto 0.2 µm pore size nitrocellulose membranes 
(Invitrogen, UK) at 200 mA for 2 h at room temperature. Membranes were boiled by 
microwave for 5 min in 1x PBS then incubated in a blocking solution for 1 h then 
probed with primary antibody overnight at 4°C. The membranes were washed three 
times with PBST incubated with either goat anti-rabbit or goat anti-mouse HRP-
conjugated secondary antibodies for 1 h at room temperature. Membranes were 
washed three times with PBST. Immunoreactivity was visualised using enhanced 
chemiluminescence reagents (GE Healthcare, UK), x-ray film (Fuji, UK) and developer. 
ImageJ was used for quantification. 
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2.2.3.4 A#  ELISAs 
The levels of mouse soluble A#40 and A#42 were measured according to the 
manufacturer’s instructions. The ELISAs are based on a sandwich ELISA technique 
and 50 µl total brain homogenates from the cortex were diluted with 50 µl working 
incubation buffer containing the HRP detection antibody before adding in duplicate (2x 
100 µl) into the antibody coated plate. The ELISA plate was incubated overnight at 4°C 
to allow binding of sample and antibody. Subsequently, the plate was washed with 300 
µl of wash buffer 5 times before the addition of chemiluminescent substrate and 
measured using a Wallac luminometer (Perkin Elmer). The resultant A# ELISA data 
was normalised to the total protein levels within each brain sample, as determined by 
the Bradford assay. 
 
2.2.4 Cell Culture 
2.2.4.1 Chinese hamster ovary (CHO) cells 
ApoE3 and apoE4 stable CHO cells were generated in house (unpublished 
studies). In brief, cDNAs encoding the human !3 and !4 alleles of APOE were cloned 
into pEGFP-C1 to add C-terminal tags. These constructs were transfected into CHO 
cells and stable clones established using G418 selection. 
 
2.2.4.2 Rat cortical neuronal cultures 
Sprague-dawley rats (Charles River Laboratories) at gestational day 18 were 
culled by cervical dislocation in accordance with Schedule 1 of the Animals (Scientific 
Procedures) Act 1986. Embryos were decapitated and whole brains removed into ice-
cold Hanks buffered saline solution (HBSS). Cortices were dissected, meninges 
removed and the whole cortex was incubated in papain solution at 37°C for 30 min and 
then triturated using a sterile Pasteur pipette to dissociate the tissue. The mixture was 
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filtered through a 70 µm nylon strainer (BD Biosciences) then centrifuged at 1200 rpm 
for 5 min at room temperature. The supernatant was discarded and cell pellet 
resuspended in HBSS containing albumin-ovomucoid inhibitor and DNase. The cell 
suspension was carefully overlayed on top of 5 ml ovomucoid solution, then 
centrifuged at 600 rpm for 5 min at room temperature. The supernatant containing 
membrane fragments was discarded whilst the pellet containing the dissociated cells 
was resuspended in neural basal media supplemented with B27 containing insulin. 
Viable cell numbers were estimated using trypan blue (Sigma) and a haemocytometer. 
Cells were plated on poly-D-Lysine coated 6-well or 12-well plates at a density of 
750,000 and 500,000 per well respectively. Cells were maintained in a humidified 
incubator (5% CO2 atmosphere at 37°C). 
 
2.2.4.3 Treatment of cortical neurons with CHO-apoE conditioned media 
Media was removed from the cortical neuronal cultures 24 h post seeding and 
replaced with neurobasal media supplemented with B27 without insulin. Neurons were 
maintained in culture for a further 6 days. On day 6, 600 µl of the media from these 
cultures were transferred into confluent 6-well plates containing wild type (WT) CHO, 
CHO-apoE3 and CHO-apoE4 cells for 24 h to make “conditioned” media (CM). On day 
7, neurobasal media was removed from the neurons and replaced with CM from WT 
CHO, CHO-apoE3 and CHO-apoE4 cells. Neurons were incubated in CM for 24 h with 
or without 10 µM pioglitazone. 
Neurons were lysed in 150 µl of 2x reducing Laemmli sample buffer containing 
0.5 M #-glycerolphosphate and heated to 100°C for 5 min. Samples were 
immunoblotted using 8% SDS-PAGE gels as described in section 2.2.3.3.1. For qRT-
PCR, neurons were collected in 500 ml Trizol/well (of a 12-well plate) and stored at -
80°C for subsequent total RNA extraction. 
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2.2.4.4 Non-radiolabelled “pulse-chase like” experiment  
WT CHO and CHO-apoE CM was applied onto 6-well plates of 1 week old 
cortical neurons as described above and incubated for 24 h at 4°C or 37°C. At the end 
of the experiments, neurons were washed twice with cold 1x PBS. Lysates were 
collected in 150 µl 2x reducing Laemmli sample buffer for immunoblotting on 12% 
SDS-PAGE gels. Blots were probed for apoE using an apoE antibody (Calbiochem) as 
described in section 2.2.3.3.1. 
 
2.2.4.5 Insulin time-response experiment  
Neurons (12-well plates) treated with WT CHO or CHO-apoE CM were also 
treated with 50 nM insulin for 15 min, 30 min, 1 h, 3 h and 24 h at 37°C. Lysates were 
collected in 150 µl of 2x reducing Laemmli sample buffer for immunoblotting on 8% 
SDS-PAGE gels as described in section 2.2.3.3.1. Blots were probed with PHF1, total 
tau, phospho-GSK-3 and total GSK-3 antibodies.  
 
2.2.4.6 Insulin dose-response experiment 
Neurons treated with WT CHO and CHO-apoE CM were treated with 10, 50, 
100, 500 or 1000 nM for 15 min at 37°C. Lysates were collected in 150 µl 2x reducing 
Laemmli buffer for western blotting on 8% SDS-PAGE gels as described in section 
2.2.3.3.1. Blots were probed with PHF1, total tau, phospho-GSK-3 and total GSK-3 
antibodies. 
 
2.2.4.7 Live dead assay  
Neurons were assessed for cytotoxicity using a dual staining kit from 
Promokine, UK. This assay is based on the differential uptake of 2 compounds which 
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stain healthy cells (green) and dead cells (red) using calcein AM and ethidium 
homodimer III (EthD-III) respectively. Calcein AM penetrates through the plasma 
membrane of living cells and is hydrolysed by intracellular esterases, enabling calcein 
to release green fluorescence at 515 nm whilst ethidium homodimer III can only 
intercalate with DNA through damaged membranes of dying cells, and emits in the 
spectrum of red at 635 nm. Neurons on coverslips were treated with WT  CHO, CHO-
apoE3 or CHO-apoE4 CM with or without pioglitazone for 24 h. Cells were labeled 
according to manufacturer’s instructions as follows: to remove serum esterase activity 
neurons grown on coverslips were washed gently three times with  1x PBS. Neurons 
were then fixed with 4% paraformaldehyde for 10 min, washed and stained with a 
solution consisting of 2 µM calcein AM and 4 µM EthD-III at 37°C. After 45 min, the 
Calcein AM/EthD-III solution was aspirated and coverslips were mounted onto slides 
then sealed with nail polish to prevent evaporation. Labeled cells were visualised using 
a fluorescence microscope (Zeiss Axiovert). 
 
2.2.4.8 RNA extraction  
Lysates were collected in 500 µl Trizol, in RNase-free Eppendorf tubes. 
Chloroform (100 µl) was then added, vortexed and subjected to centrifugation at 
13,000 rpm for 5 min. The supernatant was transferred into fresh RNase-free 
Eppendorf tubes and 200 µl isopropanol was added to precipitate the RNA. The tubes 
were vortexed briefly before centrifuged again at 13,000 rpm for 5 min. The 
supernatant was removed without disturbing the pellet and washed with 200 µl 70% 
ethanol to clean the pellet. Tubes were centrifuged at 13,000 rpm for 5 min. The 
supernatant was discarded and the pellet was resuspended in 15 µl of RNase-free 
H2O, concentrations and quality measured using a NanoDrop 1000 (ThermoScientific) 
and stored at -20°C until use. 
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2.2.4.9 Reverse transcription of RNA into cDNA 
The extracted total RNA was reversed transcribed using a TaqMan reverse 
transcription kit (Promega). The content of the kit was prepared as a master mix (MM) 
shown in Table 2.6. The MM (6.15 µl) was added to 1 µg total RNA in a final volume of 
3.85 µl per reaction, in 0.2 ml PCR tubes and kept on ice. The reaction was performed 
on a G-Storm thermal cycler using the following parameters: 25°C for 10 min, 48°C for 
30 min and 95°C for 5 min. The cDNA was diluted at 1:10 ready for use. 
 
Table 2.6 Reagents within the master mix prepared for the reverse transcription of 
RNA to cDNA for one reaction 
Reagent Volume (µ l) 




RNase inhibitor 0.2 
Reverse transcriptase enzyme 0.25 
 
 
2.2.4.10 Quantitative real time polymerase chain reaction (qRT-PCR) 
Primer sets were designed using the Universal Probe Library package (Roche, 
UK) as shown in Table 2.7, which were diluted at 1:10 in RNase-free H2O prior to use. 
A master mix (MM) shown in table 2.8 was prepared and targets were amplified using 
8 µl MM with 2 µl of 1:10 diluted cDNA on 96-well plates on ice. The 96-well plates 
were subjected to a brief spin to collect mixtures at the bottom of the plate and cycling 
was performed using the BioRad DyadDisciple thermal cycler controlled by the Opticon 
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Monitor 3 software under the following thermal cycling conditions: 3 min at 95°C 
followed by 40 cycles of 95°C for 20 sec and 60°C for 30 sec. Mean values for the 
genes of interest were normalised to the mean value obtained for #-actin. The absolute 
threshold cycle values (Ct values)! for each gene was then converted to relative 
quantities using the comparative Ct method. 
 
Table 2.7 Primers used for qRT-PCR 
Gene  Primer sequence 
HMGCR Forward GACCTTTCTAGAGCGAGTGCAT 
 Reverse GCTATATTCTCCCTTACTTCATCCTG 
MVD Forward TGGCGTCAGTGAACAACTTC 
 Reverse ACCCGGGCCAAGGTATAG 
LSS Forward GAACAGACGGGGCTAGAGG 
 Reverse TGTTTGAGCTTTAGGTAAGTTCTTGA 
DHCR7 Forward CACCGCCTGTGACAGCTA  
 Reverse AGCCAGGAGTAAAGCAGCAC  
ABCA1 Forward CAGACGATATCTCGATTCATGG 
 Reverse GAGCGTGACTTCGGTTGG 
ABCG1 Forward GGACCTTTCTTACTCCGTACCC 
 Reverse CCTTTCAAAAGGGTCTTGTATCC 
 
Table 2.8 Reagents within the master mix prepared for one qRT-PCR reaction 
Reagent Volume (µ l) 
SYBR green polymerase 5 
Primer 1 0.5 
Primer 2 0.5 
RNase-free H2O 2 
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2.2.5 Affymetrix microarray 
Gene expression was performed on the cortical region using 3-4 microarray 
chips for each condition as follows: WT LFD (n = 4), APOE!3 LFD (n = 4), APOE!4 
LFD (n = 4), APOE KO LFD (n = 3), WT HFD (n = 3), APOE!3 HFD (n = 4), APOE!4 
HFD (n = 4) and APOE KO HFD (n = 4).  
 
2.2.5.1 RNA extraction 
The Qiagen RNeasy Lipid Tissue Mini Kit was used according to manufacturer’s 
instructions as follows.  
RNAlater stabilised brain tissue from 30 samples in the LFD vs HFD study were 
homogenised in matrix lysing D tubes, in QIAzol (1 ml) in a FastPrep Automated 
Homogeniser (MP, UK). The lysates were left at room temperature for 5 min before 
being transferred into RNase-free tubes. Chloroform (200 µl) was added to each tube, 
vortexed, and left at room temperature for 3 min and then centrifuged at 13,000 rpm for 
15 min at 4°C. The upper aqueous phase of the supernatant, which contains the RNA, 
was transferred into a new RNase-free tube, and an equal volume of 70% ethanol was 
added and then mixed thoroughly by vortexing. Samples were transferred into RNeasy 
mini spin columns placed in collection tubes and centrifuged at 10,000 rpm for 15 sec 
at room temperature, with the flow-through discarded.  The spin column membranes 
were washed by the addition of 700 µl Buffer RW1 and then centrifuged at 10,000 rpm 
for 15 sec before discarding the flow-through. Columns were then washed two more 
times with 500 µl Buffer RPE and centrifuged at 10,000 rpm for 15 sec and 2 min 
respectively, with the flow-through was discarded. The RNeasy spin columns were 
then placed in new collection tubes before being centrifuged at maximum speed spin 
for 1 min to eliminate possible RPE buffer carry over. To elute the RNA, RNeasy 
columns were placed into Eppendorf tubes and 60 µl RNase-free water was added 
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directly onto the membranes. The column was spun at 10,000 rpm for 1 min and 
eluents stored at -80°C until use. 
 
2.2.5.1.1 RNA quantification 
RNA yields were determined using the NanoDrop 1000 (Thermal Scientific). 
Protein and solvent contamination were determined by the optical density readings 
OD260/OD280 and OD260/OD230 respectively. OD260/OD280 should fall between 1.7-2.1 as 
a measure of RNA purity. 
 
2.2.5.1.2 RNA integrity 
High quality RNA is required for microarray analysis, and thus the quality was 
assessed using the Agilent RNA 6000 Pico kit (Agilent Technologies), which provides a 
RNA integrity number (RIN). This is a measure of RNA quality on a scale of 0-10, with 
10 being maximal. In this study samples had RIN "7.30. 
 
2.2.5.2 Affymetrix Genechip process 
The process involved seven stages as illustrated in Figure 2.2. Each of these 







Figure 2.2 An illustrative overview of the microarray process 
 
1 Poly-A is added to RNA for 2 reverse transcription to synthesise the first strand of 
cDNA using the T7 oligo (dT) primer. 3 Second strand cDNA synthesis converts the 
single stranded cDNA into double stranded cDNA and is ready for in vitro transcription. 
4 In vitro transcription generates biotin-modified amplified RNA (aRNA) and is 5 purified 
to remove unincorporated NTPs, salts, enzymes and inorganic phosphate. 6 Labelled 
aRNA is fragmented for 7 hybridisation onto GeneChip 3’ expression arrays. This figure 
is adapted from the Affymetrix GeneChip 3’ IVT Express Kit manual. 
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2.2.5.2.1 Poly-A RNA control addition 
Poly-A RNA controls (lys, phe, thr and dap) are exogenous positive controls 
that monitor the whole RNA labelling process. The set of poly-A RNA controls provided 
in the GeneChip 3’ IVT Express Kit are obtained from several B.subtilis genes, absent 
in eukaryotic samples. The Poly-A Control Stock was diluted in RNase-free centrifuge 
tubes with Poly-A Dil Buffer to achieve the final concentrations required when spiked 
into the RNA samples. The control was diluted by serial dilutions based on the 
guideline of 250 ng of total RNA as starting material. 
 
2.2.5.2.2 Reverse transcription to synthesise first-strand cDNA 
The first strand synthesis reagents (First-strand buffer mix and First-strand 
enzyme mix (5x first strand reaction mix, 0.1 M DTT and 10 mM dNTP)) were 
assembled into a master mix on ice before being vortexed and then centrifuged briefly. 
The first strand master mix (5 µl) was transferred to individual tubes for each of the 30 
samples and 5 µl of the total RNA/poly-A control Mixture was aliquoted into the 
corresponding tubes. Tubes were mixed thoroughly by gently vortexing and subjected 
to a brief spin before incubated for 2 h at 42°C in a thermal cycler. After the incubation, 
tubes were centrifuged briefly and placed on ice ready for the next step. 
 
2.2.5.2.3 Second-strand cDNA synthesis 
The second-strand master mix (Nuclease-free water, second-strand buffer mix, 
second-strand enzyme mix (5x second strand reaction mix, 10 mM dNTP, E.coli DNA 
ligase, E,coli DNA polymerase I and RNase H)) was assembled on ice and mixed 
gently by vortexing before being centrifuged briefly.  The master mix (20 µl) was 
transferred to each of the cDNA samples. Tubes were vortexed before being subjected 
to a brief spin and incubated for 1 h at 16°C followed by 10 min at 65°C in a thermal 
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cycler. Tubes were centrifuged briefly to collect mixtures at the bottom of the tube and 
then place on ice immediately before proceeding to the in vitro transcription step. 
 
2.2.5.2.4 In vitro transcription (IVT) to synthesise labeled amplified RNA (aRNA) 
The IVT master mix (reaction buffer, ATP solution, CTP solution, UTP solution, 
GTP solution, enzyme mix) was prepared at room temperature in a nuclease-free tube 
and centrifuged briefly to collect the master mix at the bottom of the tube. The IVT 
master mix (30 µl) was transferred to each double-stranded cDNA sample, mixed 
thoroughly by gently vortexing and centrifuged briefly before placing in a thermal cycler 
block and incubated for 4 h (250 ng) at 40°C. The aRNA was frozen immediately at -
20°C overnight. 
 
2.2.5.2.5 aRNA purification 
The purification of aRNA is required to remove enzymes, salts and 
unincorporated nucleotides. The aRNA binding mix was prepared at room temperature, 
consisting of RNA binding beads and aRNA binding buffer concentrate. The binding 
mix (60 µl) was added to each sample and transferred into a 96-well plate and then 
mixed by pipetting.  To bind the sample to the RNA binding beads, 100% ethanol (120 
µl) was added to each sample and mixed thoroughly by pipetting and shaking gently for 
2 min on a plate shaker.  RNA binding beads were captured by placing the plate onto a 
96-well magnetic-ring stand (Ambion) for 5 min. Once the capture was complete, the 
mixture became transparent and the RNA binding beads formed pellets against the 
magnets in the magnetic field. The supernatant was removed and discarded. Beads 
were washed by the addition of 100 µl aRNA washing solution to each sample, shaken 
at moderate speed for 1 min and then placed on the magnetic stand again to capture 
the RNA binding beads. The washing step was repeated a second time. The plate was 
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moved to a plate shaker and shaken vigorously for 1 min to evaporate the residual 
ethanol from the beads. Purified aRNA from the RNA binding beads were eluted by the 
addition of 50 µl preheated (50-60°C) aRNA elution solution to each sample. The plate 
was shaken vigorously for 3 min to disperse the beads. The plate was moved onto the 
magnetic stand to capture the RNA binding beads once again. The supernatant 
containing the eluted aRNA was transferred to a nuclease-free tube and placed on ice 
for the next step. 
 
2.2.5.2.6 Fragmentation 
The concentration of the aRNA was quantified using the NanoDrop 1000 
spectrophotometer (Thermo Scientific). All samples were diluted to 15 µg with 
nuclease-free water and the aRNA fragmentation mixture was added before incubation 
at 94°C for 35 min. The reaction was then immediately placed on ice. 
 
2.2.5.2.7 Target hybridisation   
The hybridisation cocktail was mixed for a 49 standard format array consisting 
of fragmented and labelled aRNA (15 µg), control oligonucleotide B2 (50 pM), 
hybridisation controls (bioB (1.5 pM), bioC (5 pM), bioD (25 pM), cre (100 pM)) (heated 
at 65°C for 5 min), 1x hybridisation mix, 10% DMSO, nuclease-free water. The 
hybridisation cocktail was then preheated to 99°C for 5 min and then immediately 
transferred to a 45°C heat block for 3 min. Meanwhile, a volume of the pre-
hybridisation mix was pipetted through the septa of each probe arrays equilibrated to 
room temperature and incubated at 45°C for 10 min rotating. The pre-hybridisation mix 
was then removed and replaced with an appropriate volume of hybridisation cocktail. 
The arrays were incubated in the hybridisation oven at 45°C for 16 h rotating at 60 rpm.  
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2.2.5.2.8 Array washing and staining  
The hybridisation cocktail was removed from the array and was filled with a 
volume of non-stringent wash buffer A (6x SSPE (0.9 M NaCl, 0.06 M NaH2PO4, 0.006 
M EDTA), 0.01% Tween-20). The arrays were then immediately washed and stained 
using the Affymetrix GeneChip Fluidics Station 450/250, which was prepared with the 
appropriate buffers. The arrays were stained with streptavidin-phycoerythrin (2x stain 
buffer (100 nM MES, 1 M Na+, 0.05% Tween-20), 50 mg/ml BSA, 1 mg/ml streptavidin 
phycoerythrin) and the fluorescent signal was amplified with biotinylated anti-
streptavidin antibody (2x stain buffer, 50 mg/ml BSA, 10 mg/ml goat IgG, 0.5 mg/ml 
biotinylated anti-streptavidin). An automated protocol (Fluidic Script FS450-0001) was 
used on the fluidics station.  
 
2.2.5.2.9 Array scan 
Once the arrays were stained, they were scanned using an Affymetrix 
GeneChip Scanner 3000. The image from each array were saved as .DAT files.  
 
2.2.5.3 Analysis of microarray data 
Affymetrix GeneChip analysis was performed together with Dr. Caroline 
Johnston, King’s College London. All analyses were carried out in Bioconductor. The 
simpleaffy package was used to assess array quality. The arrays were then normalised 
using Robust Multichip Average (RMA), consisting of three stages; 1) background 
correction, 2) quartile normalisation and 3) summarisation. The expression data was 
then log transformed before using LIMMA, a bioconductor package for MA analysis 
and moderated t-tests. P-values were corrected for multiple testing according to the 
false discovery rate (FDR) procedure of Benjamini and Hochberg (Benjamini and 
Hochberg, 1995).  
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2.2.5.4 Bioinformatics-Functional categorisation and pathway analysis 
Genes were categorised into Gene Ontology (GO) biological processes 
according to the GO Consortium (http://www.geneontology.org/). This was performed 
using NetAffx and searches on GeneCards or NCBI Gene databases. Biological 




WebQTL is a internet based resource containing, amongst other data sets,  
biological traits and microarray-based gene expression data from more than 30 BXD 
recombinant inbred (RI) strain lines. RI lines were derived from a cross between the 
two common progenitor strains C57BL/6 (B) and DBA/2 (D) (BXD), followed by 
repeated sibling intercross of the F2 progenies. The recombination events are fixed in 
each RI line and therefore provides recombinant animals of the same genotype that 
are unlimited in number. By combining web-based analysis software with the database, 
webQTL can be used for searching for associations between a trait and genotypes at 
known marker loci for mapping quantitative trait loci (QTL) or for searching for 
correlations among traits. This web-based tool was used to identify the correlation of 
genes found in the current study with the expression of other genes across the BXD 
strains in hippocampal brain tissue. 
 
2.2.6 Statistics 
Statistical analysis was performed using either a one-way analysis of variance 
(ANOVA), two-way ANOVA, both followed by a Tukey post hoc test. The Students t-
test was used where two groups were compared. These analyses were used when 
appropriate, as indicated in the text. All analysis was performed in SPSS version 15.0 
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or in Microsoft Excel. Data are presented as mean,SEM. In all analyses, significance 









































Apolipoprotein E (apoE) is a key component of lipid transport and cholesterol 
metabolism not only within the periphery but also within the brain. The brain has the 
second highest concentration of apoE (Elshourbagy et al., 1985), produced locally by 
astrocytes (Boyles et al., 1985), although microglia and neurons also synthesise apoE 
under certain physiological and pathological conditions (Bao et al., 1996; Han et al., 
1994; Xu et al., 1999; Xu et al., 1996). In human and mouse, the APOE gene consists 
of four exons and three introns. Human APOE is located at q13.31 on chromosome 19 
(Olaisen et al., 1982; Paik et al., 1985), whilst the mouse APOE gene is located on 
band A2 of chromosome 7. In both human and mouse genes, exon 1 is non-coding 
(Horiuchi et al., 1989; Paik et al., 1985). ApoE is synthesised with a N-terminal signal 
peptide (Zannis et al., 1984) which undergoes intracellular processing before being 
secreted as a 34,200 Da (Mahley, 1988) mature glycoprotein consisting of 299 amino 
acids (Rall et al., 1982). The three isoforms of human apoE are distinguished by single 
amino acid differences that alter each isoform’s structure and consequently their 
function (Figure 1.4). 
Since the discovery of an association with the APOE!4 gene and Alzheimer’s 
disease (AD) by Strittmatter and colleagues in 1993 (Strittmatter et al., 1993), the need 
to understand the role of apoE in the central nervous system (CNS) has grown 
enormously. As such, APOE mouse models have been increasingly used to 
understand the pathogenesis of AD. 
The APOE models used in this project were originally generated by Dr Nobuyo 
Maeda and colleagues to study atherogenesis using gene targeting replacement 
technology. These mice were generated to overcome problems with earlier work where 
the creation of transgenic mice by pronuclear injection of human DNA resulted in 
expression of varying levels of the transgene, which was on a background of 
endogenous mouse apoE expression.  
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Gene targeting by homologous recombination in embryonic stem cells provides 
a means to generate animals with changes in specific genes and to more specifically 
study the effects of the transgene. In target replacement, mice retain the murine apoE 
regulatory sequences and thus produce solely human apoE proteins within the normal 
physiological range. The tissue distribution and levels are also identical to that of the 
endogenous gene.  
The APOE KO model was generated using a plasmid containing a modification 
of the murine apoE locus where a portion of the WT mouse APOE gene that had been 
replaced by the marker genes, neomycin resistance and thymidine kinase, was 
electroporated into E14TG2a cells (Figure 3.1). Sucessfully electroporated cells were 
identified by positive neomycin resistance and were injected into blastocytes of 
C57BL/6J mice to produce chimeric mice (Piedrahita et al., 1992). Similarly, APOE!3 
(Sullivan et al., 1997) and APOE!4 (Knouff et al., 1999) transgenic mice were achieved 
by electroporation of embryonic stem cells with a target construct containing the human 
coding sequence (exons 2-4) in combination with flanking sequences from mouse as 
shown in Figure 3.2. The resultant transgenic mice were homozygous for human 
APOE!3 or APOE!4. 
Here I describe the genotyping of all mice used in the main studies of this 









Figure 3.1 Homologous integration of the APOE KO replacement gene 
 
 
The structure of the WT mouse APOE locus shown in A), was targeted with the 
plasmid construct B) containing the neomycin resistance (Neo) and thymidine kinase 
(TK) genes for the selection of targeted embryonic stem cells. C) Shows the APOE 
locus after homologous recombination. Mouse exons 1-4 are indicated by solid boxes. 
Mouse regulatory and flanking sequences are indicated by solid lines. E, EcoRI; X, 













Figure 3.2 Homologous integration of the human APOE!3 and APOE!4 transgenes 
 
 
A) The structure of the WT mouse endogenous APOE locus was targeted with a 
construct containing the human APOE!3 or APOE!4 exons indicated by striped boxes 
and clear lines, and neomycin resistance (Neo) and thymidine kinase (TK) genes for 
the selection of targeted embryonic stem cells B). The structure of the genes after 
homologous recombination is shown in C). E, EcoRI; S, SacI; H, HindIII; P, PvuI; K, 












All transgenic mice; APOE!3, APOE!4, together with APOE knockout (KO) and 
background strain C57BL/6 (WT) were genotyped by GlaxoSmithKline at the beginning 
of each in vivo study, discussed in the following chapters. However, once these studies 
were completed we ensured the APOE genotypes of all mice were correctly labeled. 
The APOE genotypes of transgenic mice were determined using a range of techniques 
in order to distinguish human APOE from mouse APOE, as described below.  
 
3.2.1 Identification of APOE mice by western blotting 
Terminal bleeds from all mice were processed and the plasma was taken for 
the detection of apoE by western blotting. Protein bands were detected as a doublet 
around 34 kDa in all mice transgenic for the human APOE!3 or APOE!4 genes. In WT 
mice, a lower band at 32 kDa was observed for mouse apoE. Protein bands were 
absent for apoE in APOE KO mice (Figure 3.3).  
 
 
Figure 3.3 Western blot of apoE in mouse plasma 
 
 
APOE!3 and APOE!4 transgenic mice show a protein band as a doublet around 34 
kDa, WT mice show a band at 32 kDa, whilst in APOE KO mice no protein bands were 
detected. Samples were collected by colleagues at GlaxoSmithKline. 
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3.2.2 Genotyping of mice by the TaqMan and the polymerase chain reaction  
As the western blotting method was unable to distinguish between the human 
isoforms of APOE, the TaqMan SNP assay was used to identify mice carrying the 
APOE!3 or APOE!4 alleles. In these experiments we used liver tissue as an alternative 
source to plasma and because a greater quantity of DNA can be extracted from liver. 
Fluorescent signals from the TaqMan assay were plotted as shown in Figure 3.4; two 
different reporter dyes (FAM and VIC) at the endpoint plate read indicate the presence 
of either a APOE!3 (blue dots) or APOE!4 (red dots) allele within a sample. Samples in 
which the reaction failed during the assay are represented by the black crosses on the 
graph. Within the APOE transgenic mice, a total of 53 out of the 82 expected samples 
were called positive for either the APOE!3 or APOE!4 allele. The assay was repeated 
with the samples expected to have an APOE!3 or APOE!4 allele however, the assay  
failed repeatedly. Consequently, we had to rely on the combination of genotyping data 
provided by GlaxoSmithKline and data from western blotting.  
The remaining samples which were uncalled (black crosses) from the TaqMan 
assay consisting of APOE KO and WT mice were distinguished from each other by 
PCR. Primers were designed specifically to recognise a region of the neomycin gene. 
This gene is one of the selectable markers that replaced part of the murine APOE gene 
during the generation of APOE KO mice and were also included in the transgenic 
APOE!3 and APOE!4 plasmid constructs. Thus, when the PCR products were ran on 
an agarose gel, only APOE KO, APOE!3 and APOE!4 mice would show the presence 






Figure 3.4 TaqMan allelic discrimination plot 
 
 
There is one differing amino acid between the !3 and !4 alleles, !3 was detected as 
rs429348T (Allele Y) and !4 detected as rs429348C (Allele X). The blues dots 
represent transgenic mice with the APOE!3 allele, the red dots represent transgenic 
mice with the APOE!4 allele. The wells where the reaction failed are uncalled and are 
indicated by black crosses. 
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Figure 3.5 Electrophoresis of PCR products from using primers for the neomycin gene 
 
 
Bands visualised at 170 bp represents the neomycin gene present in the APOE KO, 
APOE!3 and APOE!4 target constructs. The normal WT mouse APOE gene does not 
















In this chapter, genotyping experiments were set up to determine the APOE 
genotype of mice used in the studies described in the following chapters. A range of 
techniques was used to distinguish human APOE from mouse APOE and both of these 
from APOE KO mice.  
The three APOE mouse models (APOE KO, APOE!3 and APOE!4) were 
generated by the Maeda group using the concept of gene targeting in embryonic stem 
cells (Knouff et al., 1999; Piedrahita et al., 1992; Sullivan et al., 1997). By replacing the 
coding sequence for mouse apoE with human apoE allows the expression of human 
apoE with identical tissue distribution and levels to that of WT mouse apoE.  
In the TaqMan assay 29 samples which we expected to be APOE!3 or APOE!4 
failed to be identified, despite repeated runs of the assay. This is likely due to poor 
DNA quality or a high level of impurities in the DNA samples. However, western 
blotting data showed these samples contain human apoE and with the information 
given by GlaxoSmithKline we were confident these samples were correctly identified. 
We also successfully identified all APOE KO from WT mice that failed to give a 
fluorescent signal in the TaqMan assay by PCR.  All APOE KO samples showed a 
band at 170 bp as a product of the PCR reaction with the neomycin primer. Both of 
these techniques (TaqMan and PCR) confirm results observed in western blotting. 
Human apoE is posttranslationally modified and was detected as two bands by 
western blotting. The lower band represents the mature apoE protein whilst the upper 
band represents the sialylated form of apoE. Contrastingly, mouse apoE is detected as 
one band only.  In humans, the apoE protein is subject to O-linked glycosylation by the 
addition of sialic acid (Jain and Quarfordt, 1979; Zannis and Breslow, 1981) to the 
threonine (Thr) 194 residue (Wernette-Hammond et al., 1989). The lack of sialylation in 
WT mouse apoE is because the Thr194 residue is not conserved (Weisgraber, 1994). 
Interestingly apoE in the brain is more sialylated (Pitas et al., 1987) and is detected as 
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multiple bands which can be removed upon neuraminidase treatment (Zannis and 
Breslow, 1981). The role of sialylation is unclear but as the addition of carbohydrate 
groups renders proteins biologically active, and in brain there is increased sialylation of 
apoE, it may be indicative of an important CNS function. It has been speculated that 
apoE sialylation is involved in neuronal growth, regeneration of the peripheral and 
central nervous systems and recently in formation of lipid particles and the deposition 
of A# in the brain (Kawasaki et al., 2009; Sugano et al., 2008). 
The function of mouse and human apoE are similar however human apoE 
exists as three isoforms, differing by arginine (Arg) or cysteine (Cys) residues at 
positions 112 and 158, whilst mice have one form only. An interaction between the N- 
and C-terminal domains is a unique property of the apoE4 isoform, mediated by a salt 
bridge between glutamine (Glu) 225 and Arg61, promoted by Arg112. Regarding 
structure, mouse apoE is similar to human apoE4 containing the equivalent Arg112 
and Glu225 but lacks Arg61, instead mouse has a threonine residue at this position 
(Figure 1.4). Thus, domain interaction by formation of a salt bridge between Arg61 and 
Glu225 is prevented making mouse apoE functionally more similar to human apoE3, 
including its preferential binding to high density lipoproteins (Weisgraber, 1994). 
Furthermore, introducing the Thr61Arg mutation in mice creates a human apoE4-like 
molecule (Raffai et al., 2001).  
Mouse models of APOE have long been used for the studies of atherosclerosis 
and cholesterol metabolism (Breslow, 1996; Meir and Leitersdorf, 2004) because there 
were no adequate in vitro systems were available. After the discovery of an association 
between apoE and AD, the APOE mouse models were made use for investigating AD 
pathogenesis. Mouse models used for research in the AD field not only include gene 
target replacement mice which replaces murine apoE with human apoE but also mice 
that express human apoE in astrocytes and neurons under the GFAP (glial fibrillary 
acidic protein) or for example the NSE (neuron-specific enolase) promoters, 
respectively (Huber et al., 2000; Lesuisse et al., 2001; Raber et al., 1998; Sun et al., 
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1998; Tesseur et al., 2000). These have proven to be particularly useful in the analysis 
of cell specific effects of apoE isoforms on A# and tau pathology.  
In summary, all transgenic mice were characterised with regard to APOE 
genotype. Tissues from these mice were then subsequently analysed as described in 

























The Effects of Diet-Induced Insulin Resistance on Tau 
Phosphorylation and A# Metabolism in Humanised APOE!3 












Type 2 diabetes mellitus (T2DM) is a risk factor of Alzheimer’s disease (AD). 
T2DM is characterised by a gradual decline in insulin action due to insulin-responsive 
tissues developing a reduced response to insulin, and is described as insulin 
resistance (Gispen and Biessels, 2000). As a consequence, the #-cells of the pancreas 
compensate by increasing the secretion of insulin to maintain the normal glucose levels 
in the blood. Of the 2.6 million individuals currently diagnosed with diabetes in the UK, 
T2DM accounts for 90% of the cases (Diabetes UK). This figure is still set to rise 
because the population is aging and obesity is increasing. 
Insulin resistance is regarded as the underlying cause of the metabolic 
syndrome (Gallagher et al., 2010). Interestingly, there is evidence of a synergistic 
interaction between T2DM and APOE, in particular, the APOE!4 isoform of APOE.  
T2DM patients carrying the APOE!4 allele have an increased risk for AD, and 
neuropathological studies have reported the highest number of AD lesions in brain 
tissue of !4 diabetic patients compared to age-matched controls (Peila et al., 2002). 
However, other studies have produced conflicting findings and have failed to show an 
increase in AD-related pathology in diabetic brain (Alafuzoff et al., 2009; Arvanitakis et 
al., 2006b; Heitner and Dickson, 1997).  
Further evidence for a link between insulin signalling and AD comes from 
rodent models. The use of rodent models has greatly increased our knowledge of 
neuropathological disease mechanisms. However, these in vivo models are complex 
with some apparently contradictory evidence coming from genetic versus dietary, and 
from type 1 versus type 2 diabetes models. For example, diet-induced insulin 
resistance accelerates A# pathology (Ho et al., 2004), whilst peripheral insulin injection 
induces tau phosphorylation in brain (Freude et al., 2005). Gene deletion experiments 
of the neuronal insulin receptor (NIRKO) and insulin receptor substrate 2 (IRS2) in 
mice, which induces insulin resistance, reduces A# deposition (Killick et al., 2009) and 
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yet, counter-intuitively, increase tau phosphorylation (Killick et al., 2009; Schubert et 
al., 2003; Schubert et al., 2004). 
Since it is unclear what role apoE may play in APP metabolism and tau 
phosphorylation when insulin signalling is impaired, we explored this by utilising an 
APOE humanised mouse model. Mice lacking the mouse APOE gene and is replaced 
with the human APOE!3 or APOE!4 gene (Knouff et al., 1999; Piedrahita et al., 1992; 
Sullivan et al., 1997). In order to model diet-induced insulin resistance, these mice 


















4.2.1 Mice fed HFD develop diet-induced insulin resistance 
APOE KO, APOE!3, APOE!4 and WT mice were fed either a high fat diet 
(HFD, 60% fat) or low fat diet (LFD, 10% fat) for 32 weeks to induce insulin resistance. 
Throughout the 32 weeks, food consumption and body weights were monitored weekly. 
Metabolic tests were carried out at 6 week intervals to monitor diet-induced insulin 
resistance in mice. 
 
4.2.1.1 High fat feeding promotes weight gain 
Throughout the 32 weeks, HFD fed mice gained significantly more weight than 
LFD fed mice. All mice displayed a similar weight prior to initiation of the study. It is 
apparent in both dietary conditions that WT mice gained the least weight; WT mice 
weighed less than the other HFD fed mice from the beginning of the study but all mice 
fed on a HFD followed a similar pattern of weight gain (Figure 4.1). Mice fed with HFD 
gained weight as early as 6 weeks: APOE KO gained 13.9±0.8 g higher than baseline 
weight, APOE!3 gained 13.2±1.2 g, APOE!4 gained 14.0±1.2 g and WT gained 
8.7±1.0 g (Figure 4.1B). On the other hand, LFD fed mice showed a slight increase in 
body weight compared to their starting weight: APOE KO 4.4±0.4 g, APOE!3 4.6±0.5 
g, APOE!4 4.4±0.6 g and WT 1.7±0.3 g (Figure 4.1A).  As the weeks progressed, the 
body weights of mice fed on a HFD increased dramatically. At the end of the study 
(week 32), HFD mice gained an average weight of APOE KO 31.5±0.8 g, APOE!3 
25.2±0.6 g, APOE!4 26.9±1.4 g and WT 25.6±1.0 g (Figure 4.1B). In contrast LFD fed 
mice showed a modest increase body weight gain: APOE KO 11.4±0.8 g, APOE!3 
12.5±1.7 g, APOE!4 11.7±1.3 g and WT 8.0±0.9 g (Figure 4.1A). APOE KO, APOE!3 
and APOE!4 mice weighed significantly more than the WT mice throughout the study 
as indicated in Figure 4.1A and B. 
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Figure 4.1 Body weight increases in HFD fed mice  
 
 
Body weight of APOE KO, APOE!3, APOE!4 and WT mice over 32 weeks of A) low fat 
diet (LFD) and B) high fat diet (HFD), starting from 3 months of age. Data were 
generated by colleagues at GlaxoSmithKine. Data are represented as mean,SEM, n = 
10-12. Body weights in A) and B) reached **p<0.01, ***p.0.001 by one-way ANOVA 
with Tukey post hoc test at all weeks indicated compared to WT mice. Significance is 




4.2.1.2 Mice fed HFD develop impaired glucose metabolism 
The oral glucose tolerance test (OGTT) was taken at baseline and at 6 weekly intervals 
following the initiation of study. This test was used to assess for impaired glucose 
metabolism in mice throughout the study. OGTT measures the ability of the body to 
metabolise glucose and to clear it from the blood stream; glucose is given orally after 
an overnight fast and blood samples are taken for glucose measurement over a time 
course of 180 minutes. In a normal OGTT curve, blood glucose at baseline fasting 
state rises steeply after the administration of a bolus of glucose, which reaches a peak 
around 30 minutes. At this time, insulin production increases within the pancreas and 
blood glucose levels begin to fall. Insulin causes the liver and muscles to remove 
glucose from the blood and to convert it into glycogen stores, thus the OGTT curve 
falls. The OGTT curve gradually tails off as blood glucose levels are bought to the 
normal fasting levels towards the end of 180 minutes. The key findings of the OGTT 
between LFD and HFD mice are as follows.  
• All mice have normal OGTT curves at week 0 baseline (before commencement 
of study) (Figure 4.2A and B). 
LFD fed mice: 
• In all LFD mice, throughout weeks 6, 12, 18, 24 and 32, the OGTT curve 
appears to be normal and similar shape to week 0 baseline; blood glucose 
peaks at 30 minutes, falls by 60 minutes and gradually tails off over time 
towards 180 minutes when blood glucose returns to fasting levels (Figures 
4.2C, E, G, I and K). 
HFD fed mice: 
• At week 6, all HFD mice begin to show signs of impaired glucose metabolism 
as glucose elimination occurred at a slower rate (Figure 4.2D).  
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• At weeks 6 and 12, APOE!3 and APOE!4 mice glucose metabolism seem to be 
more impaired compared to WT and APOE KO mice (Figures 4.2D and F). 
Glucose levels in APOE!3 and APOE!4 mice peaked at 60 minutes and 
elimination occurred at a much slower rate. 
• Throughout weeks 18, 24 and 32 glucose metabolism in all HFD mice became 
increasingly impaired (Figure 4.2H, J and L). Blood glucose was increasingly 
removed at a much slower rate compared to week 6. The peak and the tail of 
the OGTT curve are less well defined in all mice.  
 
 
Figure 4.2 Mice develop impaired glucose metabolism over 32 weeks of high fat 
feeding 
Oral glucose tolerance tests (OGTT) were conducted at baseline and then at 6 weekly 
intervals. Mice were fasted overnight. The following morning, mice were placed in a 
warming chamber prior to blood sampling and blood was taken by direct venopuncture. 
Mice were then given a single dose of glucose by oral gavage (3 g/kg, dose volume 10 
ml/kg) and serial blood samples collected from the tail tip post-dose at 30, 60, 90, 120 
and 180 min. Glucose levels were accessed using a blood glucose meter by 
colleagues at GlaxoSmithKline. Graphs show plasma glucose concentrations at weeks 
0, 6, 12, 18, 24 and 32 of APOE KO, APOE!3, APOE!4 and WT mice fed A, C, E, G, I, 
K) LFD and B, D, F, H, J, L) HFD. Data were generated by colleagues at 
GlaxoSmithKine. Data are represented as mean±SEM, n = 10-12. *p<0.05, **p<0.01, 
***p<0.001 versus WT mice by one-way ANOVA with Tukey post hoc test. Significance 








4.2.1.3 Fasting plasma insulin levels increase in HFD fed mice 
Blood samples from fasted mice were taken at 6 weekly intervals, before the 
OGTT was carried out. Blood was processed and plasma was measured for insulin 
levels by ELISA. 
At baseline, all mice had similar levels of plasma insulin. Beginning from week 6 
and as the weeks progressed plasma insulin levels elevated which accompanied 
hyperglycaemia in all groups of HFD fed mice. At the end of the 32 weeks study, all the 
HFD group of mice had statistically significantly elevated levels of plasma insulin in 
comparison to the LFD group, with the highest in APOE!4 (5.9±0.5 µg/l) followed by 
APOE!3 (5.2±0.6 µg/l), APOE KO (4.8±0.5 µg/l) and then WT (3.5±0.6 µg/l) (Figure 
4.3B). In contrast, mice fed with LFD had similar levels of insulin at the end of the 32 
weeks study compared to baseline: APOE KO 0.8±0.1 µg/l, APOE!3 0.8±0.1 µg/l, 
APOE!4 0.8±0.2 µg/l and WT 0.4±0.1 µg/l (figure 4.3A). 
The homeostatic model assessment of insulin resistance (HOMA-IR) was 
calculated as a measure of insulin sensitivity. HOMA-IR did not differ between diet 
groups prior to the initiation of study however, HOMA-IR was significantly increase 
(p<0.001) in all HFD fed mice compared to LFD fed mice within each genotype after 32 









Figure 4.3 HFD fed mice develop diet-induced insulin resistance 
 
Plasma insulin levels were measured in APOE KO, APOE!3, APOE!4 and WT mice 
over 32 weeks of feeding with A) LFD and B) HFD. Blood samples from the tail vein at 
each OGTT were collected and plasma was analysed for ifasting nsulin levels by 
ELISA. C) Homeostatic model assessment of insulin resistance (HOMA-IR) after 32 
weeks of HFD, HOMA-IR was calculated using the formula (fasting blood 
glucose*fasting insulin)/405. In A) plasma insulin levels in all LFD fed mice reached 
*p&0.05 by one-way ANOVA with Tukey post hoc test compared to WT mice. In B) 
plasma insulin levels in HFD fed mice reached *p&0.05, **p<0.01 or ***p&0.001 by one-
way ANOVA with Tukey post hoc test compared to WT mice as indicated. Significance 
is indicated by * APOE KO, + APOE!3, ^ APOE!4. In C) ***p&0.001 by Student’s t-test. 
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Samples were provided by colleagues at GlaxoSmithKline. Data are represented as 
mean'SEM, n = 10-12. 
 
 
4.2.2 Tau phosphorylation is reduced in HFD fed mice 
Three phospho-tau epitopes (Ser396, Ser202/Thr205 and Thr231) were 
examined on western blots; immunoreactivity for tau was observed around the 50 kDa 
size marker with each of these phospho-epitope specific sera and with a non-phospho 
dependent antibody, Dako A0024, raised against human tau. Phospho and non-
phospho tau immunoreactivity was detected using an near infrared scanner and 
quantitated using IMAGEJ software. Phospho-immunoreactivity was determined from 
the ratio of phospho-specific to total tau immunoreactivity on the same blots. In the 
comparison between HFD and LFD fed mice, a decrease in tau phosphorylation was 
detected in the insulin resistant mice at all three tau epitopes. This decrease was 
preserved across all genotypes with a significant decrease in tau phosphorylation in 
HFD fed WT and APOE!4 mice at the Ser202/Thr205 (p=0.01 and p=0.03, 
respectively) and Thr231 (p=0.04 and p=0.04, respectively) epitopes, and a trend 
towards reduction at Ser396 (Figure 4.4B). Analysis of all genotypes and all phospho-
tau epitopes by two-way ANOVA shows a significant interaction between diet and tau 
phosphorylation (p<0.05) but no effect of genotype. Combining all genotypes and 
comparing LFD and HFD groups shows a highly significant effect of tau 
phosphorylation at all three epitopes examined (Ser396 p=0.03, Ser202/Thr205 (AT8) 





Figure 4.4 Tau phosphorylation is reduced in HFD fed mice, independent of APOE 
genotype 
The cortical brain region from mice were homogenised in sucrose homogenisation 
buffer, lysates were then immunoblotted with the indicated antibodies. A, D, G) 
Western blot of tau antibodies in the frontal cortex of APOE KO, APOE!3, APOE!4 and 
WT mice fed LFD or HFD. B, E, H) Density of phosphorylated tau normalised against 
total tau. C, F, I) Tau phosphorylation is dependent on diet. Phosphorylated tau is 
normalised to total tau, data is grouped by diet. Analysis of all genotypes and all 
phospho-tau epitopes by ANOVA shows a significant interaction between diet and tau 
phosphorylation (p<0.05). Samples were provided by colleagues at GlaxoSmithKline. 










































4.2.3 APP metabolism is unchanged in HFD fed mice 
The levels of soluble A"40 and A"42 were measured by ELISA. A trend was 
detected whereby HFD fed WT, APOE!3 and APOE!4 mice had higher levels of A"40 
whereas in APOE KO mice fed HFD, a reduced level was observed (Figure 4.5A). 
Similarly, A"42 levels appeared higher in WT, APOE KO and APOE!4 mice fed HFD 
whereas in APOE!3 mice lower levels of A"40 were detected (Figure 4.5B). These 
alterations in both A" species did not reach statistical significance. 
For APP processing, the Triton-soluble fraction from brain samples were 
measured by western blotting (section 2.2.3.3). Figure 4.6A shows three bands around 
110 kDa representing full length APP, whilst five bands were resolved for the 
phosphorylated forms of APP C-terminal fragments (APP-CTFs); C83, C89 and C99, 
between 10 kDa-15 kDa. The non-amyloidogenic and amyloidogenic processing (#- 
and "-processing respectively) of APP was assessed by measuring the levels of APP-
CTFs C83 & C89 (non-amyloidogenic) and C99 (amyloidogenic). The levels of full 
length APP were not significantly altered when mice were grouped by genotype or diet 
(Figure 4.6B and C). No significant changes were observed in the APP-CTFs C83 & 










Figure 4.5 Levels of soluble A"40 and A"42  in mice fed LFD or HFD for 32 weeks 
 
 
Soluble levels of A" were analysed by ELISA. A) Standard curve and A"40 levels, and 
B) standard curve and A"42 levels, in the brain of mice fed LFD or HFD. Samples were 











Figure 4.6 APP processing is not altered in mice fed HFD 
 
 
A) Immunoblot of APP processing in the cortical brain region of mice fed LFD and 
HFD. Triton-soluble lysates from the cortical brain region were run on 16% Tricine gels 
! "($!
and immunoblotted with the 369 antibody for full length (FL)-APP and APP-CTFs. 
Three bands around 110 kDa were observed for FL- APP whilst five bands were 
resolved for the phosphorylated forms of APP-CTFs between 10 kDa and 15 kDa. No 
differences in the levels of B), C) FL-APP or D), E) C83 & C89 or F), G) C99 between 
APOE KO, APOE!3, APOE!4 or WT mice were observed. FL-APP was normalised to 
"-actin and APP-CTFs were normalised to FL-APP for quantification. Samples were 




4.2.4 Regulators of tau phosphorylation are not altered 
Given the changes in tau phosphorylation due to the dietary conditions, the 
insulin signalling pathway and level of active tau kinases and tau phosphatases were 
measured; Akt and GSK-3 by using antibodies to phospho-epitopes at sites reflective 
of activation state of the kinases, Cdk5 by using the p35/25 specific antibody and the 
tau phosphatase, PP2A. Surprisingly, no significant changes in the brain were found in 











Figure 4.7 Proteins of the insulin signalling pathway, tau kinases and tau 
phosphatases were not altered in HFD fed mice 
 
 
The activity of A) Akt, B) GSK-3, C) Cdk5 and D) PP2A did not change in mice fed a 
HFD. Samples were provided by colleagues at GlaxoSmithKline. Data are represented 








The aim of this set of experiments was to determine whether AD-like pathology 
in diet-induced insulin resistant mice might be modulated in an APOE-dependent 
manner.  
Diabetes can be induced experimentally by a range of techniques. The model 
used here manifests most of the features of patients with a predisposition to T2DM; 
obesity, weight gain, hyperinsulinemia, insulin resistance and glucose intolerance 
(Srinivasan and Ramarao, 2007). These are the exact features we observed in our 
HFD fed APOE transgenic mice with a C57BL/6 background, consistent with those 
initially reported in HFD fed C57BL/6 mice by Surwit et al (Surwit et al., 1988). 
Reassuringly, the metabolic tests used in our study such as the oral glucose tolerance 
test (OGTT), show similar curves to published studies using the same APOE 
transgenic mice (Arbones-Mainar et al., 2010; Karagiannides et al., 2008) as early as 6 
months of age. There is also a similar OGTT trend to that reported by Arbones-Mainer 
and colleagues where APOE!4 animals show greater glucose intolerance compared to 
APOE!3 animals (Arbones-Mainar et al., 2010). Additionally, it has been suggested 
that the APOE!4 genotype can elevate fasting plasma insulin and glucose levels in 
obese men (Elosua et al., 2003).  Fasting insulin levels are expected to rise in HFD fed 
mice over time due to the gradual decline in pancreatic "-cell function, this is also very 
similar to our observations. 
The results from this set of data show an effect of diet upon tau 
phosphorylation; HFD reduces tau phosphorylation compared to LFD fed mice, 
independent of APOE genotype. These observations are contrary to our predictions, as 
well as other published findings that have shown insulin resistance or the disruption of 
insulin signalling causes AD pathology and this may be due to the differences in animal 
models used. In particular, our results are contrary to a recent finding by Moroz et al 
where HFD had no effect on tau phosphorylation despite an increase in tau gene 
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expression (Moroz et al., 2008). Although their study uses the same strain of mice and 
the same 60% HFD as our study, it is possible that our results are different because 
their mice were examined at a considerably younger age; mice were sacrificed and 
examined at 4 months by Moroz et al., and at 11 months in this study. In addition, in 
the former study the duration of feeding was shorter, 16 weeks compared to 32 weeks 
used in this study. Therefore, our observations on tau phosphorylation are likely due to 
long-term high fat feeding. Our observation is also counter to that of Freude and 
colleagues (Freude et al., 2005), where peripheral hyperinsulinemia promoted tau 
pathology in mouse brain. In this study, peripheral hyperinsulinemia was initiated with 
an acute insulin challenge; 20 minutes after peripheral injection, tau phosphorylation 
was increased in the brain. This study by Freude and colleagues is not comparable to 
the data reported in this section where tau phosphorylation was reduced in the context 
of long-term HFD induced hyperinsulinemia; arguably a model more representative of 
diet-induced hyperinsulinemia in man. The presence of insulin and insulin receptors in 
the brain is well established. In post-mortem brain tissue of AD patients, reduced 
expression of both insulin and insulin receptors has been found (Steen et al., 2005). 
Since insulin signalling inhibits the activity of the tau kinase, GSK-3, a reduction in 
insulin signalling might be expected to reduce inhibition of GSK-3, leading to an 
increase in tau phosphorylation. This is evidenced from gene deletion models such as 
the NIRKO, IRS1 and IRS2 knockout mice, all of which exhibit increased brain tau 
phosphorylation (Killick et al., 2009; Schubert et al., 2003; Schubert et al., 2004). 
Interestingly, intravenous infusion of insulin whilst maintaining euglycaemic conditions 
in AD patients resulted in an improvement in memory and performance (Craft et al., 
1996). This indicates peripheral insulin may have a role in rescuing the impairment of 
insulin metabolism within the brain. Consequently, a further clinical study by Reger and 
colleagues found daily intranasal insulin raised the level of brain insulin and improved 
memory in AD patients (Reger et al., 2008). It is thought that by means of intranasal 
administration, insulin bypasses the blood brain barrier and reaches the CNS via the 
olfactory and trigeminal neural pathways (Hanson and Frey, 2008). Thus, any defect in 
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brain insulin signalling is corrected. Improved cognitive performance has also been 
demonstrated in animals administered with intracerebroventricular insulin (Park et al., 
2000) or intranasal insulin (Francis et al., 2008), which also improved diabetic brain 
neuropathy (Francis et al., 2009). Putting this into context with our study, it is possible 
that the peripheral hyperinsulinemia in the HFD mice may induce increased entry of 
insulin into the brain, which, in the absence of brain insulin resistance, results in a 
reduction in the levels of phosphorylated tau. 
Furthermore, in contrast to previous studies we found tau phosphorylation was 
independent of APOE genotype (Genis et al., 1995; Harris et al., 2004; Hoe et al., 
2006; Kobayashi et al., 2003; Tesseur et al., 2000). Whilst we are unable to provide a 
full explanation for this, one possible source of discrepancy is the difference between 
our study and in both papers by Tesseur (Tesseur et al., 2000) and Harris (Harris et al., 
2004) is the use of transgenic mice expressing neuronal apoE3 and apoE4. Previously, 
the cellular origin of apoE in the brain has been shown to affect its actions-astrocytic 
expression of apoE3 or apoE4 had no effect on excitoprotection whereas neuronal 
expression of apoE4 but not apoE3 was excitotoxic (Buttini et al., 2010). It is possible 
that such differences in the models used in the experiments underlie our conflicting 
observations. 
Insulin resistance has also been shown to cause A" pathology in rodents (Bales 
et al., 2009; Cao et al., 2007; Ho et al., 2004; Kohjima et al., 2010; Luo et al., 2011). In 
the current study, LFD versus HFD, trends in increased levels of soluble A"40 and A"42 
was observed in HFD fed WT and APOE!4 mice. In APOE KO mice, HFD caused a 
reduction in levels of A"40 whilst the more toxic form, A"42, was increased. In HFD 
APOE!3 mice, the reverse was observed; levels of A"40 increased whilst the more toxic 
form, A"42, reduced. However, this data, in addition to the data from APP processing, 
did not reach statistical significance when pooled regardless of APOE genotype or diet. 
This is surprising since it has been reported (Bales et al., 2009; Cao et al., 2007; Ho et 
al., 2004; Kohjima et al., 2010; Luo et al., 2011) that diet-induced insulin resistance 
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promotes the generation of A"40 and A"42. However, since these published studies 
used transgenic mice overexpressing mutant human APP (Tg2576 mice carry the 
Swedish mutations K670N/M671L, and the double transgenic APP/PS1 mice carry the 
Swedish mutations K670N/M671L with PS1 deleted in exon 9), animals are 
predisposed to the formation of toxic A" oligomers that are detected with human APP 
only, as APP in non-transgenic mice do not generate oligomeric species. Toxic A" 
oligomers are thought to induce A" aggregation leading to the formation of A" plaques 
that has the potential to cause tau phosphorylation. This may allow the detection of a 
significant effect with diet or APOE genotype, which we failed to find. In agreement with 
many studies, our data suggests the APOE!3 genotype is protective for amyloid 
pathology in HFD mice. According to the amyloid cascade hypothesis of AD, it is the 
formation or deposition of A" that initiates the formation of neurofibrillary tangles 
(Hardy and Allsop, 1991). In our mice, human A" is not expressed therefore A" 
oligomers cannot be formed and cause downstream pathological effects. Our data 
therefore suggest that in our APOE model of diet-induced T2DM, tau phosphorylation 
arises due to a process independent of A". 
Several of the published studies previously mentioned have identified upstream 
candidates responsible for tau phosphorylation and increased A" levels. In our study; 
LFD versus HFD, we did not detect any changes in activation of members of the insulin 
signalling pathway (Akt, GSK-3), tau kinases (GSK-3, Cdk5) or the tau phosphatase, 
PP2A. The lack of differences in Akt, GSK-3 or Cdk5 phosphorylation indicates the 
possibility of other proteins affecting the reduction in tau phosphorylation. However, 
this was not due to PP2A, as we detected no changes in this tau phosphatase. 
Moreover, in addition to serine phosphorylation, GSK-3 activity is regulated by tyrosine 
(Tyr) phosphorylation at residues Tyr279 and Tyr216 in GSK-3# and GSK-3" 
respectively (Hughes et al., 1993). Under physiological conditions, GSK-3 is 
constitutively active and phosphorylation at these sites is thought to augment its 
activity, thus for future experiments, these phosphorylation sites should be 
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investigated. Despite our findings, many tau phosphatases and kinases have been 
identified to date (Chung, 2009) and further examination of these may help us identify 
the possible candidates responsible for dephosphorylation of HFD-induced tau 
phosphorylation, such as PKA, JNK, MAP Kinases and PTEN. Furthermore, it is 
probable that the period required to increase sufficient levels of insulin in the brains of 
these mice by HFD feeding led to a failure in detecting changes in the insulin signalling 
cascade. This may have occurred transiently at an earlier time point.  
In summary, this chapter has found an effect of diet on tau phosphorylation, 
independent of APOE genotype. That is, a reduction of tau phosphorylation in HFD fed 






















The Effect of Pioglitazone on Tau Phosphorylation and A"  













New therapeutics are urgently needed to prevent or slow down the progression 
of cognitive decline seen in Alzheimer’s disease (AD). Current evidence points towards 
the role of a dysregulation of the insulin signalling pathway as a possible cause of 
amyloid beta (A") and tau pathology in the AD brain and in memory loss. This is 
supported by the observations that the expression of both insulin and insulin receptors 
are reduced in post-mortem AD brain tissue (Frolich et al., 1998; Steen et al., 2005). 
Based on this concept, treatments aimed at restoring the adequate levels of brain 
insulin have been proposed as a therapeutic approach for AD. As such, the 
administration of insulin via peripheral (Craft et al., 2003; Craft et al., 2000) or 
intranasal (Reger et al., 2006; Reger et al., 2008) routes has been found to facilitate 
memory in AD patients. Some of these effects were shown to be more prominent in 
non-APOE!4 carriers (Craft et al., 2000; Reger et al., 2006). Intranasal insulin 
treatment in animal models has also demonstrated to improve cognitive performance 
(Francis et al., 2008). These results have provided a strong rationale for use of the 
thiazolidinediones (TZDs) as therapeutic agents for AD. TZDs are a class of insulin 
sensitising drugs that reduce peripheral insulin resistance and blood glucose levels, by 
targeting peroxisome proliferator-activated receptor gamma (PPAR$). Since these 
drugs are prescribed to type 2 diabetes (T2DM) patients and T2DM is a risk factor for 
AD, TZDs would provide additional therapeutic benefits to these patients. In two early 
clinical trials, rosiglitazone (Avandia) improved memory and cognition in patients with 
mild to moderate AD (Watson et al., 2005) in an APOE-dependent manner (Risner et 
al., 2006). More recently, pioglitazone (Actos) also slowed cognitive decline in AD 
(Sato et al., 2011). Consistent with these observations, treatment with the same insulin 
sensitising agents in experimental models attenuated learning and memory deficits 
(Pedersen et al., 2006), reduced the accumulation of A", reduced A"42 levels and 
reduced levels of inflammatory markers (Heneka et al., 2005). PPAR$ activation has 
also been shown to reduce the phosphorylation of tau in vitro (d'Abramo et al., 2006), 
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whilst the overexpression of PPAR$ reduces the accumulation of A" (Camacho et al., 
2004; d'Abramo et al., 2005).  
The observations in man that increased risk of AD with T2DM is APOE 
dependent, that insulin affects A" pathology in an APOE-dependent manner and that in 
the early clinical trials with TZDs there was a stratification of effect by APOE led to the 
hypothesis that diet-induced insulin resistance and subsequent treatment with TZDs in 
animal models would have APOE-dependent effects on ‘downstream’ AD pathology.  
In order to explore this, the experiments in this chapter sought to determine the effects 
of the PPAR$ agonist, pioglitazone, on tau phosphorylation and A" metabolism in diet-
















5.2.1 Body weights of mice increase during high fat feeding and pioglitazone 
treatment does not alter body weight 
Feeding mice on a high fat diet (HFD) is known to be sufficient for the 
development of diet-induced insulin resistance and was observed previously in chapter 
4. Here, mice also gained weight throughout 27 weeks of high fat feeding; APOE KO 
mice gained the most weight followed by APOE!3, APOE!4 and WT mice (Figure 5.1A 
and B). Although WT mice weighed less compared to the other HFD mice at the 
beginning of the study, a similar pattern in weight gain was observed. APOE KO, 
APOE!3 and APOE!4 mice weighed significantly more than the WT mice throughout 
the study. At week 27, mice were divided into vehicle and pioglitazone treatment 
groups for the final 3 weeks of the study whilst continuing to receive HFD. In the HFD 
mice given vehicle treatment, there was no significant change in body weight in 
APOE!3 and APOE!4 mice but body weight was significantly reduced in the APOE KO 
(p=0.02) and WT (p<0.001) mice (Figure 5.1A). In all HFD mice given pioglitazone 











Figure 5.1 Body weights of mice fed HFD for 30 weeks and treated with pioglitazone in 





Body weights of APOE KO, APOE!3, APOE!4 and WT mice over 30 weeks of HFD, 
where in the final 3 weeks mice were given A) vehicle or B) pioglitazone treatment 
(indicated by the arrow). Data were generated by colleagues at GlaxoSmithKine. Data 
are represented as mean±SEM, n = 9-12. *p<0.05, **p<0.01; ***p<0.001 versus WT 
mice by one-way ANOVA with Tukey post hoc test. Significance is indicated by * APOE 
KO, + APOE!3, ^ APOE!4, & WT. !
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5.2.2 Glucose metabolism is impaired in mice fed HFD before treatment with 
pioglitazone  
All mice had normal glucose tolerance profiles at week 0, before being given a 
HFD. The oral glucose tolerance test (OGTT) curve shows plasma glucose levels rising 
rapidly and reaches a peak at 30 minutes after being given a single oral dose of 
glucose. Thereafter, glucose levels falls sharply at 60 minutes as insulin production by 
the pancreas increases and glucose is eliminated from the bloodstream. The curve 
falls gradually and forms a tail as blood glucose returns to normal levels at 180 minutes 
(Figure 5.2A and B). The key findings of the OGTT are as follows. 
• At week 12 of HFD, all mice show signs of impaired glucose metabolism (Figure 
5.2C and D). Glucose took longer to reach peak levels in APOE!3 and APOE!4 
mice and in all mice glucose elimination occurred at a much slower rate 
compared to week 0 baseline.  
• At week 24, glucose metabolism continued to be increasingly impaired in all 
mice; the peak and the tail of the OGTT curve is less well defined compared to 
the start of the study (Figure 5.2E and F). WT mice appeared to have an 
increased impairment in glucose metabolism at all time points compared to all 
other mice.   
• Mice were divided into two groups 3 weeks before the termination of the study. 
One group was given the vehicle 1% methylcellulose whilst the other group was 
given 20 mg/kg pioglitazone by oral gavage. After 3 weeks treatment of vehicle 
or pioglitazone at week 30, blood glucose levels were reduced in all animals of 
both treatment groups. The glucose peak was less pronounced and blood 




Figure 5.2 Oral glucose tolerance tests in mice fed a HFD for 30 weeks and treated 
with pioglitazone in the final 3 weeks 
Oral glucose tolerance tests (OGTT) were conducted at baseline and then at 12 weekly 
intervals thereafter. Mice were fasted overnight. The next morning, mice were placed in 
a warming chamber prior to blood sampling and blood was taken by direct 
venopuncture. Mice were then given a single oral dose of glucose (3 g/kg, dose volume 
10 ml/kg) and serial blood samples were collected from the tail tip post-dose at 30, 60, 
90, 120 and 180 minutes. Glucose levels were accessed using a blood glucose meter. 
Graphs show glucose concentrations before vehicle and pioglitazone treatment at 
week; A,B) 0, C,D) 12 and E,F) 24 of HFD. At week 30, mice fed HFD were given 3 
weeks of G) vehicle or H) pioglitazone treatment. Data were generated by colleagues 
at GlaxoSmithKine. Data are represented as mean±SEM, n = 9-12. *p<0.05, **p<0.01; 
***p<0.001 versus WT mice by one-way ANOVA with Tukey post hoc test. Significance 














5.2.3 Levels of fasting plasma insulin reduce in insulin resistant mice after 3 
weeks of pioglitazone treatment 
Fasting levels of plasma insulin increased in all mice given a HFD from week 0 
to week 24 (Figure 5.3A and B). Mice were divided into vehicle or pioglitazone 
treatment groups at week 27, the drug was administered for 3 weeks. At the end of the 
treatment period no significant changes in plasma insulin levels was observed in mice 
given vehicle treatment (Figure 5.3A). In mice given pioglitazone treatment, plasma 
insulin levels tended towards a decrease and reached significance in the APOE!4 and 
WT mice, p=0.02 and p=0.03 respectively (Figure 5.3B).  
The homeostatic model assessment of insulin resistance (HOMA-IR) was 
calculated as a measure of insulin sensitivity. HOMA-IR levels were statistically 
significantly increased (p<0.001) after 24 weeks of HF feeding in all mice, indicating all 
mice were increasingly insulin resistant (Figure 5.3.C and D). After three weeks of 
pioglitazone treatment, HOMA-IR levels decreased within each genotype in 
comparison to the HOMA-IR levels before treatment (Figure 5.3D). In contrast, in all 
mice given vehicle treatment, HOMA-IR levels were similar to before treatment (Figure 
5.3C). By comparing HOMA-IR levels at week 30, after vehicle and pioglitazone 
treatment within mice of the same genotype (Figure 5.3E), reduced levels of HOMA-IR 
in all mice given pioglitazone was detected, however this difference did not reach 
statistical significance. Significant differences were recorded for WT (p=0.004) and 







Figure 5.3 Levels of fasting plasma insulin is reduced in insulin resistant mice after 3 
weeks of pioglitazone treatment 
 
 
Levels of fasting plasma insulin were measured by ELISA in APOE KO, APOE!3, 
APOE!4 and WT mice over 24 weeks of HFD and a further 3 weeks of HFD with A) 
vehicle or B) pioglitazone treatment. The homeostatic model assessment of insulin 
resistance (HOMA-IR) was calculated at baseline (week 0), before (week 24) and after 
(week 30) treatment with either C) vehicle or D) pioglitazone. E) Comparison of HOMA-
IR in mice treated with 3 weeks of vehicle or pioglitazone. In A) and B) plasma levels 
reached *p<0.05, **p<0.01 versus WT mice by one-way ANOVA with Tukey post hoc 
test. Significance is indicated by * APOE KO, + APOE!3, ^ APOE!4, & WT. in C), D) 
and E) **p<0.01, ***p<0.001 by Student’s t-test. Samples were provided by colleagues 




5.2.4 Levels of plasma adiponectin increase on the administration of pioglitazone 
in HFD fed mice 
Adiponectin is an insulin sensitising hormone and plasma levels of adiponectin 
were measured as an indication of the effectiveness of pioglitazone treatment. In all 
HFD fed mice given vehicle treatment, there was no significant change in fasting 
plasma adiponectin levels between week 24 and week 30 (Figure 5.4A). However, in 
HFD fed pioglitazone treated mice, as expected, there was a highly significant increase 
(p<0.001 for all mice) in plasma adiponectin levels between week 24 and week 30 in 
the order of; 1.9±0.1 to 8.7±1.2 ng/ml in APOE!3, 2.1±0.1 to 8.1±0.5 ng/ml in APOE 
KO, 2.8±0.2 to 7.4±0.4 ng/ml in WT mice and 1.1±0.1 to 6.9±0.3 ng/ml in APOE!4 















Figure 5.4 Levels of plasma adiponectin increase on the administration of pioglitazone 




Levels of fasting plasma adiponectin was measured by ELISA in APOE KO, APOE!3, 
APOE!4 and WT mice over 24 weeks of HFD and a further three weeks of HFD with A) 
vehicle or B) pioglitazone treatment. Samples were provided by colleagues at 
GlaxoSmithKine. Data are represented as mean±SEM, n = 9-12. *p<0.05, **p<0.01; 
***p<0.001 versus WT mice by one-way ANOVA with Tukey post hoc test. Significance 
is indicated by * APOE KO, + APOE!3, ^ APOE!4, & WT. 
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5.2.5 Pioglitazone treatment selectively lowers the phosphorylation of tau at the 
Ser202/Thr205 epitope in APOE!3 mice 
Tau phosphorylation was not significantly altered after vehicle or pioglitazone 
treatment at any of the three tau epitopes (Ser396, Ser202/Thr205 or Thr231) (Figure 
5.5B,E and H). However, there was a genotypic effect with APOE!3 mice showing a 
decrease in tau phosphorylation at the Ser202/Thr205 epitope (p=0.01) and the 
reverse, a significant increase in tau phosphorylation in APOE!4 mice (p=0.03) with 
pioglitazone treatment (Figure 5E). This trend was also detected with the AT180 
antibody which recognises the Thr231 phospho-tau epitope (Figure 5.5H).  
 
 
Figure 5.5 Pioglitazone treatment selectively lowers tau phosphorylation at the 
Ser202/Thr205 epitope in APOE!3 mice 
Mice fed HFD for 30 weeks were treated with vehicle or pioglitazone for the final 3 
weeks. The cortical brain region from mice were homogenised in sucrose 
homogenisation buffer, lysates were then immunoblotted with the indicated antibodies 
as shown in A, D and G). The density of phosphorylated tau was normalised against 
total tau. B, C) ptau Ser396, E, F) Ser202/Thr205 (AT8), H, I) Thr231 (AT180). 
Samples were provided by colleagues at GlaxoSmithKine. Data are represented as 
































5.2.6 Pioglitazone treatment on APP processing and soluble A"  levels  
Pioglitazone treatment has been shown to lower amyloid load in animal models 
(Heneka et al., 2005; Yan et al., 2003). In our study, we measured the levels of soluble 
A"40 and A"42. On comparison of A"40 levels within each genotype, A"40 tended 
towards a decrease although these did not reached statistical significance (Figure 
5.6A). Similarly, alterations in the levels of A"42 were statistically insignificant; in WT, 
APOE KO, APOE!3 and APOE!4 mice fed HFD and treated with pioglitazone, A"42 
was reduced, albeit this change was very small in APOE!3 mice (Figure 5.6B). 
The non-amyloidogenic and amyloidogenic processing (#- and "-processing 
respectively) of the amyloid precursor protein (APP) was assessed by measuring the 
levels of C-terminal fragments C83 & C89 (non-amyloidogenic) and C99 
(amyloidogenic). The levels of full length APP were not significantly altered when mice 
were grouped by genotype or treatment groups (Figure 5.7B and C). In pioglitazone 
treated APOE!3 mice, the levels of C83 & C89 were significantly reduced compared to 
vehicle treated APOE!3 mice (p=0.001) whilst no significant changes were detected in 
the levels of C99 (Figure 5.7D and F). In the pioglitazone treated APOE KO, APOE!4 
and WT mice the levels of C83 & C89 and C99 were not significantly altered (Figure 
5.7D and F). There was no significant change in APP processing when mice were 













Soluble levels of A" were analysed in the cortical brain region of mice by using 
chemiluminescent ELISA kits. A) Standard curve and A"40 levels, and B) standard 
curve and A"42 levels, in the brain of mice fed HFD and treated with vehicle or 
pioglitazone. Samples were provided by colleagues at GlaxoSmithKine. Data are 













The dissected cortical regions from mice were homogenised in brain homogenisation 
buffer containing 1% Triton. A) Lysates were immunoblotted on 16% Tricine gels and 
probed with a C-terminal specific APP antibody for full-length (FL)-APP and C-terminal 
fragments (CTFs). CTFs were normalised against FL-APP. B) and C) FL-APP, D) and 
E)  #- (non-amyloidogenic) processing and F) and G) "- (amyloidogenic) processing. 
Samples were provided by colleagues at GlaxoSmithKine. Data are represented as 
mean±SEM, n = 9-12. **p<0.01 by Student’s t-test.  
 
 
5.2.7 Regulators of tau phosphorylation are not altered 
Given the APOE isoform specific change in tau phosphorylation at the 
Ser202/Thr205 epitope, the level of active tau kinases GSK-3 and Cdk5, the tau-
phosphatase PP2A and changes in Akt, a component of the insulin signalling pathway 
were measured. However, we found no significant changes correlating to the APOE 












Figure 5.8 Regulators of tau phosphorylation are not altered 
 
 
Lysates from the cortical brain region of mice were subjected to SDS-PAGE and were 
immunoblotted for some of the regulators of tau phosphorylation A) Akt, B) GSK-3, C) 
Cdk5 and D) PP2A. The density of phosphorylated forms of the proteins were 
normalised against the total form of the same protein. Samples were provided by 







This set of experiments was designed to examine the effect of the PPAR$ 
agonist, pioglitazone, on tau phosphorylation and APP metabolism in diet-induced 
insulin resistant APOE mice. 
The HFD fed C57BL/6 mouse has been shown to be a good model for studying 
the mechanisms and treatment of T2DM (Winzell and Ahren, 2004). As such, we used 
APOE mice on a background strain of C57BL/6 for this study. In the previous chapter 
(chapter 4), we developed a diet-induced insulin resistance mouse model. In this 
section, we used these same conditions and went on to investigate the effects of the 
PPAR! agonist, pioglitazone. 
The PPARs are members of the NR1C class of the nuclear hormone receptor 
superfamily of ligand-activated transcription factors that are expressed in a variety of 
cell types. The three PPAR isoforms; PPAR", PPAR#/$ and PPAR! are involved in 
adipocyte differentiation, lipid storage and glucose metabolism. PPARs are activated 
upon binding of a natural or synthetic ligand which causes conformational changes in 
PPAR (Berger et al., 1996). This change in conformation promotes the recruitment of 
transactivator complexes and the subsequent transcription of target genes. The TZDs; 
rosiglitazone, pioglitazone and troglitazone are all pharmacological ligands of the 
PPAR$ isoform (Lehmann et al., 1995). They control blood glucose concentration by 
binding PPAR$ with various affinities and are therefore able to exert their insulin-
sensitising and hypoglycaemic effects. PPAR$ is predominately expressed in adipose 
tissue (Chawla et al., 1994), allowing the direct actions of TZDs on adipose cells. For 
example, mice with the deletion of adipose tissue specific PPAR$ are deficient in their 
response to TZD treatment (He et al., 2003). PPAR agonists also promote the 
differentiation of preadipocytes into adipocytes (Chawla et al., 1994; Lehmann et al., 
1995; Sandouk et al., 1993; Tontonoz et al., 1994). Additionally, two recent papers 
reported that neuronal PPAR$ signalling is also required for the hepatic insulin 
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sensitising effects of TZDs. By using various techniques to inactivate PPAR$ in the 
brain, authors demonstrated rosiglitazone-induced hyperphagia and weight gain were 
abolished (Lu et al., 2011; Ryan et al., 2011). Currently, rosiglitazone and pioglitazone 
are the only Food and Drug Administration-approved TZDs clinically prescribed to 
T2DM patients. 
In this study, we chose to use pioglitazone as it has a higher permeability 
through the blood brain barrier (BBB) compared to rosiglitazone. Although it was 
initially thought that rosiglitazone was BBB impermeable (Pedersen et al., 2006; 
Watson et al., 2005), a recent study by Strum and colleagues has shown its presence 
in the brain after oral administration (Strum et al., 2007). The effectiveness of 
pioglitazone treatment in mice was assessed by measuring plasma adiponectin levels. 
Adiponectin is an insulin sensitising hormone secreted by adipocytes in adipose tissue 
and enhances insulin sensitivity in the body by carrying out three key roles: 1) 
increased uptake of glucose on tissues and accelerating fatty acid clearance 
(Yamauchi et al., 2001); 2) reduction in hepatic glucose production (Berg et al., 2001); 
and 3) reduced levels of circulating insulin (Winzell et al., 2004). As PPAR$ acts 
directly on adipocytes, circulating adiponectin levels increase upon the administration 
of these TZDs (Miyazaki et al., 2004), acting as a biomarker for the restoration of 
insulin sensitivity. As we observed an increase in plasma adiponectin levels, this 
demonstrates the effectiveness on the target of the drug used in this study, at both the 
dose and length of treatment specified. All mice given 20 mg/kg pioglitazone treatment 
for 3 weeks by oral gavage showed a concomitant increase (p<0.001) in plasma 
adiponectin. Accompanying the striking increase in levels of plasma adiponectin, was a 
decrease in fasting plasma insulin levels in mice receiving pioglitazone treatment. In 
contrast, fasting levels of plasma insulin in vehicle treated mice reached a plateau and 
remained at the same level from week 24 to week 30. This observation was expected 
because TZDs increase the levels of circulating adiponectin and the action of 
adiponectin reduces the level of plasma insulin. In the final measurement of the OGTT 
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at week 30, the expected improvement of glucose metabolism in HFD fed and 
pioglitazone treated mice was not observed. Both the vehicle and pioglitazone 
treatment groups, after 3 weeks of treatment, had a reduction in glucose levels, despite 
the fact that vehicle treated mice were expected to have a continuation in the 
impairment of glucose metabolism. It is obvious that this observation was not due to 
inadequate drug treatment as our adiponectin and insulin data indicates pioglitazone 
treatment was effective and it is highly likely that something went wrong during the 
OGTT process, for example mice were not given the correct dose of glucose. 
Despite that TZDs improve glycaemic control and insulin sensitivity in T2DM 
patients, one of the negative side-effects is the potential to cause weight gain (Mori et 
al., 1999; Patel et al., 1999). Similarly, TZD treatment in rodents has also been shown 
to cause weight gain (Eldershaw et al., 1995; Fujiwara et al., 1991; Hallakou et al., 
1997; Kaufman et al., 1995), although in one study they failed to do so (Fujiwara et al., 
1988). Several studies have attempted to elucidate the mechanisms behind improved 
tissue insulin sensitivity and simultaneous weight gain; these include adipocyte 
proliferation (Chawla et al., 1994; Kletzien et al., 1992) and reduced leptin production 
(Kallen and Lazar, 1996; Shimizu et al., 1998). In this study, pioglitazone treatment in 
HFD fed mice did not cause weight gain and it is possible that increases in body weight 
may have appeared if mice were given pioglitazone for a longer period.  
Our data from biochemical analysis of the cortical region of the brain shows that 
pioglitazone has an APOE genotype specific effect at the Ser202/Thr205 
phosphoepitope of tau; in pioglitazone treated HFD APOE!3 mice, a reduction of tau 
phosphorylation was observed in comparison to APOE!3 mice treated with vehicle. 
The reverse, an increase in tau phosphorylation was observed in pioglitazone treated 
HFD APOE!4 mice. Whilst in the APOE KO or WT mice, no significant change in tau 
phosphorylation by pioglitazone treatment was detected. This trend, although not 
reaching statistical significance, was also observed at the Thr231 phosphoepitope of 
tau. These results are consistent with the results from an early rosiglitazone clinical trial 
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in which drug treatment improved cognition in APOE!4 negative patients with mild to 
moderate AD (Risner et al., 2006), However, rosiglitazone was not shown to be 
effective in a recent phase III clinical trial (Gold et al., 2010). A recently published 
paper also observed APOE isoform dependent effects of rosiglitazone in adipose 
tissue (Arbones-Mainar et al., 2010). As mentioned earlier, there is some evidence of a 
synergistic interaction between the APOE!4 allele and T2DM and the risk of AD is 
higher amongst APOE!4 carriers with T2DM (Irie et al., 2008; Peila et al., 2002). 
Evidence on mitochondrial dysfunction as part of the pathophysiology of both AD 
(Bubber et al., 2005) and T2DM (Lowell and Shulman, 2005) is also emerging. Greater 
mitochondrial dysfunction has been detected in AD APOE!4 carriers (Gibson et al., 
2000) and significant evidence shows that this is the cause of apoE4 protein fragments 
(Nakamura et al., 2009), as apoE4 is more susceptible to degradation compared to the 
apoE2 and apoE3 isoforms (Huang et al., 2001). One hypothesis is that the formation 
of C-terminal truncated fragments by neuron-specific cleavage of the apoE4 protein 
escapes through the secretory pathway, enters the cytosol and interacts with 
mitochondria via its hydrophobic lipid-binding region (Chang et al., 2005). This leads to 
perturbation of mitochondrial function and therefore diminishes the participation of 
mitochondria in the glycolytic processes. Via the same route, apoE4 truncated 
fragments can also induce tau phosphorylation, as shown in vivo and in vitro (Brecht et 
al., 2004; Harris et al., 2003; Huang et al., 2001; Ljungberg et al., 2002; Zhou et al., 
2006). Since a direct role of PPAR! agonism is to stimulate mitochondrial biogenesis 
(Bolten et al., 2007; Miglio et al., 2009; Wang et al., 2002; Wilson-Fritch et al., 2004), 
this suggests that perhaps neurotoxic C-terminal fragments in our APOE!4 mice 
caused excessive damage to the mitochondria in neurons. Accordingly, APOE!4 mice 
did not respond to pioglitazone treatment, like that of APOE!3 mice. A higher dose of 
pioglitazone may possibly overcome the detrimental effects of the APOE!4 isoform by 
upregulating mitochondrial biosynthesis. 
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In relation to amyloid, we analysed the processing of full-length APP and 
soluble levels of A"40 and A"42 in the same brain samples from the mice. Full-length 
APP is metabolised by two competing pathways; the non-amyloidogenic pathway (#-
processing) gives rise to soluble APP# and C83 & C89 whereas the amyloidogenic 
pathway ("-processing) yields soluble APP" and C99. C99 is further cleaved by $-
secretase to produce the A"40 and A"42 species. Biochemical analyses revealed a 
significant decrease in #-processing of APP in the pioglitazone treated APOE!3 mice. 
This finding is intriguing because we also observed changes in tau phosphorylation 
with the same mice, however because there are no reported mechanisms between 
apoE isoforms, TZDs and APP, further work is required to investigate this interaction. 
In other studies, a recent in vivo study using PDAPP transgenic mice expressing 
human APOE isoforms (Castellano et al., 2011) and in an in vitro study using cell lines 
expressing human APOE (Biere et al., 1995), both studies demonstrate no significant 
alterations in APP processing. Furthermore, soluble levels of A"40 and A"42 were not 
significantly altered in this study when HFD fed mice were administered with 
pioglitazone. However, a trend was observed in all mice showing pioglitazone 
treatment reduced both A" species. In addition, higher levels of both soluble A"40 and 
A"42 were detected in APOE KO mice in comparison to mice with the APOE gene, 
which has also been demonstrated in another study (Dodart et al., 2000). The idea that 
APOE KO animals cannot clear A" from brain has been suggested (Shibata et al., 
2000), it being proposed that the clearance of A" from the brain to the periphery is 
mediated by the transport of apoE-A" complexes across the BBB via LRP1 (Deane et 
al., 2004; Shibata et al., 2000). An alternative explanation is that APOE KO mice have 
an altered plasma lipid profile due to apoE protein deficiency, which is essential for the 
transport and metabolism of lipids. APOE KO mice begin to develop atherosclerotic 
lesions rapidly at 3 months of age (Zhang et al., 1992) and the progression of 
atherosclerosis can be accelerated by HFD feeding (Plump et al., 1992). In APOE KO 
mice fed HFD, the integrity of the BBB is altered (Mulder et al., 2001), this can lead to 
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increased lipid peroxidation and subsequently an increase in the generation of A" 
(Chen et al., 2008; Pratico et al., 2001). In the current study, to test for the evidence of 
leakage at the BBB, the levels of BBB integrity markers such as the S100" protein 
(Kapural et al., 2002) could be examined in a tail tip bleed from the APOE KO mice. 
This could contribute to further work for this study. S100" is a marker of astrocytic 
damage (Griffin et al., 1989) and has been implicated as a possible mechanism 
underlying the progression of neuropathological changes in AD (Hu et al., 1997; Mrak 
et al., 1996; Sheng et al., 1997). Furthermore, our results did not replicate the finding of 
a reduction in A" levels following pioglitazone treatment, as reported in two earlier in 
vivo studies using Tg2576 mice (Yan et al., 2003) and APPV717l mice (Heneka et al., 
2005). This is most likely due to the use of different mouse models and both groups 
may have seen a more pronounced effect with A", as their models are engineered to 
develop amyloid pathology.  
In this study of HFD together with pioglitazone treatment, we did not detect any 
changes in any of the regulators of tau phosphorylation examined; components of the 
insulin signalling pathway (Akt, GSK-3), tau kinases (GSK-3, Cdk5) or the tau 
phosphatase PP2A. Further investigation using other tau kinases and phosphatases or 
a whole brain transcriptomic study (chapter 7) may help to identify possible pathways 
relating to our genotypic effect in tau phosphorylation. 
To summarise, this set of experiments found an APOE-dependent effect of 
pioglitazone on tau phosphorylation. The APOE!3 genotype responded to pioglitazone 
treatment, which is in line with an early clinical trial using rosiglitazone in AD patients. 
We found that pioglitazone treatment was effective at reducing tau phosphorylation at 
the Ser202/Thr205 epitope, with a trend also observed at the Thr231 phospho-tau site. 
Pioglitazone treatment also reduced #-processing of APP in the APOE!3 pioglitazone 
treated mice, this observation requires further investigation. Further work will also be 










The Effects of ApoE3 and ApoE4 Isoforms and Pioglitazone 













Apoliproteins are proteins that bind lipids such as cholesterol to form lipoprotein 
particles. In the periphery, lipoproteins are delivered in the plasma to cells in the body 
requiring cholesterol for the production of cell membranes, to maintain membrane 
fluidity or for the synthesis of vitamin D and hormones. ApoE is the most studied 
member of this protein family and in the brain, apoE is thought to serve similar 
functions. It is clear that the brain has its own system of cholesterol supply to meet its 
need for cholesterol in processes such as membrane remodeling during synapse 
formation and increases in dendritic arbourisation. This is acquired through de novo 
cholesterol synthesis which involves a series of sequential modifications in a 20 step 
reaction, the 5 key steps are as follows: Acetyl Co A is firstly converted to 3-hydroxy-
methylglutaryl-CoA (HMG-CoA) and then to mevalonate; mevalonate is phosphorylated 
to isopentenyl pyrophosphate (IPP) and other isoprenoid units which form squalene; 
squalene is finally converted to lanosterol which, subsequently, will finally form 
cholesterol (Leduc et al., 2010). Cholesterol synthesis is thought to mainly occur in 
astrocytes and oligodendrocytes and delivers cholesterol to neurons via high density 
lipoprotein (HDL)-like particles. The formation of HDL-like particles containing apoE is 
assisted by the cholesterol transporters, ATP-binding cassette, subfamily A, member 1 
(ABCA1), which transports cellular cholesterol and phospholipids to lipid-poor 
apolipoproteins and also ATP-binding cassette, subfamily G, member 1 (ABCG1). 
Newly synthesised HDL-like particles migrate in a gradient dependent manner towards 
the apoE receptors on the plasma membranes of neurons for uptake and subsequent 
release of cholesterol. 
Cholesterol homeostasis is maintained by synthesis, degradation and transport 
processes, and disturbances in brain cholesterol homeostasis can alter brain function. 
Rabbits fed a high cholesterol diet were found to have increased amyloid beta (A") 
accumulation in hippocampal neurons (Sparks et al., 1994). The APP processing 
enzymes, "- and $-secretase, are found in cholesterol rich membrane microdomains 
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and increasing the cholesterol content in these lipid rafts induces amyloidogenic 
processing, leading to the increased generation of A"40 and A"42 species (Frears et al., 
1999; Wahrle et al., 2002). Accordingly, the use of cholesterol lowering drugs such as 
the statins (HMG-CoA inhibitors), reduced A" production in mice (Fassbender et al., 
2001). Excess cholesterol has also been identified in tau bearing neurons from AD and 
Niemann-Pick C (NPC) post-mortem brain tissue (Distl et al., 2001). NPC is a 
hereditary cholesterol storage disorder with Alzheimer-like tau pathology appearing in 
youth or adolescence, without amyloid plaque deposition. Statins have also been 
shown to reduce tau phosphorylation in NPC mice (Ohm et al., 2003). In addition, 
some epidemiological studies suggests that statins may reduce the incidence of AD 
(Haag et al., 2009; Li et al., 2004; Simons et al., 2002; Sparks et al., 2005). 
In respect to apoE, isoform-specific effects have been observed on cholesterol 
delivery. For example, in vitro, apoE3 was shown to deliver cholesterol more efficiently 
to neurons than apoE4 (Michikawa and Yanagisawa, 1998). Since the apoE4 isoform 
is a major risk factor for AD (Strittmatter et al., 1993), this implies that altered 
cholesterol metabolism may have an impact on A" and tau pathologies. In fact, the 
interaction between A" and native apoE isoforms (associated with lipid particles) has 
different affinities, and as a consequence this may affect the trafficking and deposition 
of A" (LaDu et al., 1994). For tau, the inhibition of cholesterol biosynthesis in vitro 
increases tau hyperphosphorylation (Fan et al., 2001) and the apoE4 isoform has been 
reported to impair neurite outgrowth and be neurotoxic (Nathan et al., 1994; Nathan et 
al., 1995).  
Interestingly, in a recent publication from our group, transcriptomic analysis of 
neurons treated with the thiazolidinedione (TZD), pioglitazone, showed an upregulation 
in cholesterol biosynthetic genes at the 6 hours time point and by 24 hours these 
genes were downregulated with the subsequent upregulation of the cholesterol 
transporters ABCA1 and ABCG1 (Cocks et al., 2010). However, these observations 
were via a PPAR$ independent mechanism as co-treatment of neurons with the PPAR$ 
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antagonist, GW9662, did not reduce the effects. Other studies have shown that 
another TZD, rosiglitazone, can upregulate the transcription of ABCA1 (Chawla et al., 
2001; Chinetti et al., 2001), which can protect against diabetes as the absence of 
ABCA1 in "-cells of the pancreas was shown to increase cholesterol content and 
impair "-cell function (Brunham et al., 2007). Taken together, these findings indicate 
PPAR$ agonists have a role on the influence of cholesterol biosynthesis. 
Given there is evidence that cholesterol metabolism is differentially affected by 
the different apoE isoforms, and given the relationship with APOE genotype and both 
amyloid and tau pathologies discussed above, we hypothesised that the APOE!3 and 
!4 isoforms may differentially modulate the effects of the pioglitazone, on tau 
phosphorylation and cholesterol biosynthesis. I established an in vitro model to 
determine if this is the case. Primary neuronal cultures were incubated with native 
apoE preparations, insulin and with or without pioglitazone. Insulin was used to mimic 
the HFD-induced hyperinsulinemia observed in mice. Measures of tau phosphorylation 
and cholesterol biosynthesis were subsequently performed, using western blotting and 











6.2 Results  
6.2.1 Neuronal uptake of human apoE from the conditioned media  
To model neurons expressing human apoE in vitro, we applied conditioned 
media (CM) from Chinese hamster ovary (CHO) cells expressing EGFP-tagged human 
apoE3 or apoE4 to cortical neuronal cultures. As a control, we applied WT CHO CM 
onto the neuronal cultures. Figure 6.1 shows that lysates from untransfected, WT CHO 
cells barely express apoE, whilst very robust bands are detected in the CHO cells 
containing the human APOE constructs. This blot also shows that the expression levels 
of each APOE construct are comparable. It can also be observed that, as expected, 
apoE is secreted into the media and that there is no isoform specific effect on 
secretion. This sets the basal conditions for the subsequent experiments. Thus, a non-
radiolabelled “pulse-chase like” experiment was carried out to investigate the neuronal 
uptake of apoE from WT CHO or CHO-apoE CM. Neurons were cultured in WT CHO 
or CHO-apoE CM for 24 h at 4°C or 37°C. Incubation at these two temperatures would 
allow us to track the uptake process because cellular processes are reduced within a 
cell at 4°C compared to 37°C. Lysates were collected after 24 h to assess neuronal 
uptake of apoE from the CM by western blotting. Figure 6.2 shows an immunoblot of 
the lysates from neurons incubated at 4°C or 37°C with WT CHO, CHO-apoE3 or 
CHO-apoE4 CM. A distinct band at 60 KDa can be observed corresponding to the 
apoE protein. ApoE is normally detected at 34 kDa, however due to it being tagged 
with EGFP (27 kDa), the band detected in the presented blots ran at ~60 kDa. In 
neurons incubated overnight at 4°C, a faint band was detected in those exposed to 
CHO-apoE3 or CHO-apoE4 CM, with neuronal uptake of apoE appearing to be similar. 
However, when neurons were incubated overnight at 37°C, a more intense band 
corresponding to apoE was detected exclusively in the neurons exposed to apoE3 and 
apoE4 CM, therefore showing a greater uptake of apoE. 
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Figure 6.1 CHO cells express the apoE protein 
 
 
Western blot of apoE protein in lysates and conditioned media (CM) from WT CHO 
cells and CHO cells transfected with the human APOE!3 or APOE!4 EGFP-tagged 
constructs, indicated as CHO, CHO-apoE3 and CHO-apoE4, respectively.  
 
 
Figure 6.2 Neuronal uptake of apoE from CHO-apoE conditioned media 
 
 
Pulse chase-like experiment to show the uptake of apoE in neurons incubated with 




6.2.2 Treatment of neurons with CHO-apoE conditioned media improves cell 
viability 
Neuronal cultures were treated with WT CHO, CHO-apoE3 or CHO-apoE4 CM 
with or without 10 µM pioglitazone for 24 h. A live dead staining assay was used as a 
measure of cell viability; calcein AM stains healthy cells green whilst ethidium 
homodimer III stains dead cells in red (Figure 6.3A-F). In neurons treated with WT 
CHO CM, approximately 34% of the neurons were dead after 24 h. Surprisingly, 
incubating neurons with CHO-apoE3 or CHO-apoE4 CM for the same period (24 h) 
appeared to reduce cell death compared to neurons incubated with WT CHO CM, by 
8% and 6% respectively, although this reduction in cell death was non-significant. This 
pattern was also observed after 24 h pioglitazone treatment and there was a 
statistically significant reduction in cell death in neurons exposed to CHO-apoE3 CM 
compared to WT CHO CM (p= 0.02) (Figure 6.3G).  
 
 
Figure 6.3 Calcein AM and ethidium homodimer III dual staining for cell viability  
Immunofluorescence of healthy and dead neurons which were cultured in A) WT CHO 
CM, B) CHO-apoE3 CM, C) CHO-apoE4 CM, D) WT CHO CM with 10 µM 
pioglitazone, E) CHO-apoE3 CM with 10 µM pioglitazone and F) CHO-apoE4 CM with 
10 µM pioglitazone. G) Bar chart showing the percentage of dead neurons with the 
corresponding treatments shown in A-F. Data shown is mean±SEM, *p<0.05 by 
















6.2.3 The effect of insulin treatment on neuronal cultures 
Preliminary experiments were carried out in an attempt to determine the most 
effective dose and time course of insulin treatment. Neurons were treated with 50 nM 
insulin at 15 min, 30 min, 1 h, 3 h or 24 h. Neurons were also treated with 10, 50, 100, 
500 or 1000 nM insulin for 15 min. However despite repeated experiments, results 
were inconclusive, which may in part be due to the reported biphasic temporal effect of 
insulin on GSK-3 activity. It was therefore decided to remove insulin treatment from 
these experiments. 
 
6.2.4 Levels of tau and GSK-3 phosphorylation in neurons incubated with CHO-
apoE conditioned media and pioglitazone treatment  
Neurons treated with CHO-apoE conditioned media alone or with 10 µM 
pioglitazone for 24 h were immunoblotted for tau phosphorylation with the PHF1 
antibody recognising the Ser396/404 epitope and for the phosphorylation of GSK-3 
(Ser21/9). The dose of pioglitazone drug treatment used on neurons was determined 
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previously by this lab (Cocks et al., 2010). Although the levels of phosphorylated Akt 
were also measured, the signal was very weak, even with increased loading, and could 
not be measured reliably by densitometry. Comparison of the neurons cultured with 
WT CHO CM and CHO-apoE3 CM shows a significant reduction in tau phosphorylation 
(p=0.01) whilst no significant difference was detected between neurons treated with 
WT CHO CM and CHO-apoE4 CM (Figure 6.4A). Treatment of neurons cultured in WT 
CHO or CHO-apoE CM with 10 µM pioglitazone did not cause significant changes in 
tau phosphorylation (Figure 6.4B).  
The same samples were immunoblotted for phospho-GSK-3. No significant 
differences were observed for neurons cultured in WT CHO CM and CHO-apoE CM 
(Figure 6.4C). We therefore tried treating neurons briefly with 500 nM insulin to test if 
GSK-3 was in an inactive state. Insulin treatment for 15 min significantly increased 
GSK-3 phosphorylation (p<0.001), hence showing GSK-3 was not in an inactive state. 
Treatment of neurons with 10 µM pioglitazone for 24 h in the various CHO CM did not 











Figure 6.4 Levels of tau and GSK-3 phosphorylation in neurons cultured with CHO-
apoE conditioned media and pioglitazone treatment  
 
 
Lysates were immunoblotted for A, B) tau phosphorylation at the Ser396/404 epitope 
with the PHF1 antibody and C, D) phosphorylation of GSK-3 at Ser21/9 epitope. Data 
are represented as mean±SEM, n = 6, *p<0.05, ***p<0.001 by Student’s t-test. 
 
 
6.2.5 Effects of pioglitazone on the expression of cholesterol biosynthesis genes 
in neurons cultured with CHO-apoE conditioned media 
To investigate whether apoE isoforms have differential effects on cholesterol 
biosynthesis we treated neurons as above with WT CHO, CHO-apoE3 or CHO-apoE4 
CM with 10 µM pioglitazone for 6 h or 24 h. The following genes were investigated due 
to their critical involvement in cholesterol synthesis: HMG-CoA reductase (HMGCR), 
mevalonate decarboxylase (MVD), lanosterol synthase (LSS) and 7-
dehydrocholesterol reductase (DHCR7). We also looked at cholesterol transporters; 
ATP-binding cassette, subfamily A, member1 (ABCA1) and ATP-binding cassette, 
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subfamily G, member1 (ABCG1). These particular genes and time points were chosen 
based on a previous study from our lab. Results showed a trend towards an increase in 
cholesterol biosynthetic genes at the 6 h time point in neurons cultured with WT CHO 
CM and pioglitazone treatment (Figure 6.5A). However, only LSS reached statistical 
significance (p=0.04). At the 24 h time point, there seem to be a trend towards a 
reduction in the expression of these genes except for DHCR7. Expression levels of 
DHCR7 remained similar to the 6 h time point (Figure 6.5A). In neurons cultured in 
CHO-apoE3 and CHO-apoE4 CM, genes involved in cholesterol biosynthesis were not 
significantly altered (Figure 6.5B and C). Additionally, the levels of ABCA1 and ABCG1 
genes were not altered in neurons cultured with WT CHO or CHO-apoE3 CM (Figure 
6.5A and B). However, in neurons cultured with CHO-apoE4 CM, ABCA1 expression 
increased significantly at the 24 h timepoint compared to 6 h (p=0.02), whilst no 
changes in the level of ABCG1 expression was observed (Figure 6.5C). 
 
 
Figure 6.5 Expression of genes in the cholesterol biosynthesis pathway in neurons 
cultured with CHO-apoE conditioned media and treated with pioglitazone 
Neuronal cultures were incubated in A) WT CHO CM, B) CHO-apoE3 CM and C) CHO-
apoE4 CM. Following pioglitazone treatment for 6 h or 24 h, expression of the following 
genes were measured by qRT-PCR: HMG-CoA reductase (HMGCR), mevalonate 
decarboxylase (MVD), lanosterol synthase (LSS), 7-dehydrocholesterol reductase 
(DHCR7), ATP-binding cassette, subfamily A, member 1 (ABCA1) and ATP-binding 
cassette, subfamily G, member 1 (ABCG1). Data are represented as normalised 




































In this set of experiments, we sought to determine the effects of apoE isoforms 
and pioglitazone on tau phosphorylation and cholesterol biosynthesis in vitro.  
In this in vitro model, we were able to show in neurons cultured in CHO-apoE 
CM, the movement of apoE from CM into neurons by a pulse chase-like experiment. 
We chose to use native preparations of apoE because the biologically active form of 
apoE requires lipid association (LaDu et al., 1995). By incubating neurons with CM at 
37°C, apoE isoforms were transported into neurons and were visible in lysates after 24 
h whereas the incubation of neurons at 4°C decreased the rate of this effect. The very 
small amounts of apoE protein visible on the immunoblot at 4°C most likely represents 
the presence of apoE bound to cell surface LRP receptors, the most preferentially 
expressed apoE receptor in neurons (Rebeck et al., 1993). A similar in vitro model has 
been used previously by LaDu and colleagues using CM from HEK-293 cells 
transfected with the human APOE3 or APOE4 constructs, to look at the interaction 
between apoE and A" (LaDu et al., 1994).  
In our experiments, neurons cultured with CHO-apoE3 or CHO-apoE4 CM were 
equally protective and although insignificant, reduced the number of dead cells 
compared to neurons cultured in WT CHO CM. When neurons were treated with 
pioglitazone, cell death was again reduced in neurons cultured with CHO-apoE3 or 
CHO-apoE4 CM. ApoE isoform-specific effects on tau phosphorylation was observed 
in neurons cultured in CHO-apoE CM; apoE3 significantly reduced tau phosphorylation 
in neurons whilst apoE4 did not. This observation, that apoE3 seems to be protective is 
in agreement with other publications. Previously, in vitro experiments demonstrated 
that the apoE3 isoform has a greater avidity for tau thereby forms more stable 
complexes with tau compared to the apoE4 isoform (Strittmatter et al., 1994). It has 
been suggested that this might form the basis of the neuroprotective effects of apoE3 
compared to the apoE4 isoform in AD. In these experiments, it was shown that apoE 
binds to the microtubule domains on tau and was proposed to protect tau from 
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abnormal phosphorylation thereby reducing its propensity to undergo self-assembly 
into paired helical filaments. Other studies further supports this hypothesis showing 
that the interaction between apoE3 and tau could be abolished by the phosphorylation 
of tau within the microtubule binding domain (Huang et al., 1995). Furthermore, in vitro 
studies have shown apoE isoforms have differential effects on neuronal protection. 
Thus, apoE2 and apoE3 isoforms promote neurite outgrowth, whilst apoE4 is 
associated with the depolymerisation of microtubules (Bellosta et al., 1995; Fagan et 
al., 1996; Holtzman et al., 1995; Nathan et al., 1994; Nathan et al., 1995).  
Treatment of neurons cultured in the various CHO-apoE CM with pioglitazone 
for 24 h showed a trend towards a decreased in tau phosphorylation however, this did 
not reach statistical significance. This observation is in line with another study using a 
similar drug, rosiglitazone, which reduced tau phosphorylation in a human  SHSY-5Y 
neuron-like cells transfected with tau (Yoon et al., 2010). Furthermore, this group 
reported that GSK-3 activity was not associated with tau phosphorylation, an 
observation we have also made.  
A recently published microarray study from our lab shows cholesterol 
biosynthesis is upregulated with treatment of 10 µM pioglitazone at 6 h and 
downregulated at 24 h. At 24 h, the cholesterol efflux transporters ABCA1 and ABCG1 
were upregulated (Cocks et al., 2010). In the experiments within this chapter, we 
looked at the effects of a range of the cholesterol biosynthesis genes identified by 
Cocks and colleagues by pioglitazone treatment at 6 h and 24 h in neurons cultured 
with different CHO-apoE CMs. In line with their study, we observed a trend of 
increased cholesterol gene expression (HMGCR, MVD and LSS) in neurons treated 
with WT CHO CM at 6 h, which were subsequently reduced at 24 h. In neurons 
cultured with the CHO-apoE3 or CHO-apoE4 CM and treated with pioglitazone, 
cholesterol gene expression was not significantly altered, although there were some 
indication of increased gene expression by 24 h, for example, MVD in CHO-apoE3 and 
CHO-apoE4 CM treated neurons. The gene expression of the cholesterol transporter, 
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ABCA1, was not altered in neurons incubated with WT CHO and CHO-apoE3 CM, 
however, in neurons cultured with CHO-apoE4 CM, ABCA1 expression increased at 24 
h compared to 6 h. ABCG1 expression was not altered in neurons cultured with each of 
the three CMs. The different observations between these results and that of Cocks and 
colleagues may be because these experiments require further repeats, which may give 
more conclusive results. Our findings showing no significant apoE isoform-specific 
effects on cholesterol biosynthesis are different to those published by Michikawa and 
colleagues who have shown the neurotoxic effects of apoE4 are mediated by 
suppression of de novo cholesterol synthesis (Michikawa and Yanagisawa, 1998). 
However, they are in line with published data from Jansen and colleagues, showing 
that cholesterol biosynthesis is independent of apoE genotype (Jansen et al., 2009).  
In summary, the experiments in this chapter show an in vitro model system 
whereby neurons gain the effects of human apoE by the uptake of apoE protein from 
CHO CM. The uptake of these apoE isoforms has pro-survival effects on cell viability. 
In these neurons, tau phosphorylation is reduced with uptake of the apoE3 isoform and 
this is not correlated with GSK-3 activity. Finally in this in vitro system no significant 
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7.1 Introduction  
It is well documented that impairments in brain insulin signalling can influence 
Alzheimer’s disease (AD) pathology. This may be associated with peripheral insulin 
resistance, a feature of type 2 diabetes mellitus (T2DM), which is a risk factor for AD 
(Watson and Craft, 2003). Circulating insulin is thought to enter the brain by a receptor 
mediated transport process (Banks et al., 1997) and binds to insulin receptors that are 
highly expressed in neurons. Insulin has many roles in the brain including maintaining 
synaptic plasticity, neuronal growth, phosphoinositide 3-kinase (PI3K) signalling, and 
regulating amyloid beta (A") production and tau phosphorylation (de la Monte, 2009). 
Furthermore, A" itself can inhibit PI3K/Akt signalling (Lee et al., 2009). Disruption of 
insulin signalling can be detrimental, leading to neurotoxicity and synaptic defects. As 
the metabolic syndrome becomes more prevalent, combined with a greater incidence 
of AD, the need to develop effective treatments, which will slow down and possibly 
ameliorate pathology due to impaired insulin signalling in the brain, has never been 
more urgent. Rosiglitazone or pioglitazone, drugs currently used to treat diabetes, have 
been shown to improve cognition in AD patients, at least in early phase clinical studies 
(Risner et al., 2006; Sato et al., 2011; Watson et al., 2005). However, rosiglitazone was 
not shown to be effective in a phase III clinical trial (Gold et al., 2010). More recently, 
metformin, another anti-diabetic drug, has also been shown to ameliorate neuronal 
insulin resistance and AD-like changes in an in vitro model (Gupta et al., 2011). At 
present, it is unclear the extent to which peripheral insulin resistance accompanying 
T2DM may impact processes within the brain and exacerbate AD pathology. In 
addition, diabetics possessing the APOE!4 allele have an increased risk of developing 
AD (Irie et al., 2008; Peila et al., 2002). This suggests APOE may mediate specific 
pathological changes in the insulin resistant brain.  
One approach to understanding the molecular link between insulin signalling and 
AD pathology is to explore signalling processes in relevant models using gene 
expression. Gene expression can be measured at a whole genome level by a 
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microarray based approach. Several such studies on post-mortem AD brain tissue 
have been reported (Courtney et al., 2010; Liang et al., 2008) (for review) as well as in 
a range of AD mouse models, such as Tau23 (Woo et al., 2010), Tg2576 (George et 
al., 2010) PDAPP (APPV717F) (Selwood et al., 2009) and AD11 mice (Arisi et al., 
2011). Transcriptomics has also been used to study insulin resistance in a 
streptozotocin model (Grunblatt et al., 2004).  
In chapter 4, we developed an in vivo model of diet-induced insulin resistance. 
These mice developed hyperinsulinemia, impaired glucose metabolism and tau 
pathology in the brain. The aim of this chapter is to elucidate the molecular 
mechanisms underlying diet-induced insulin resistance in the brain of mice by using 
microarray gene expression technology. The objectives were:  
 
• To identify APOE genotypic changes in brain gene expression by comparing 
WT mice, APOE KO, APOE!3 and APOE!4 transgenic mice (fed a “normal” low 
fat diet-LFD) 
• To identify diet-responsive changes by comparing the brain transcriptome of 
mice fed a LFD with that of mice fed a high fat diet (HFD) (within each 
genotype). 
• To identify APOE genotypic changes that may interact with diet-responsive 
changes by comparing brain gene expression in WT mice, APOE!3 and 







In chapter 4, we showed that all mice used in this study develop insulin 
resistance when fed a HFD for 32 weeks. This hyperinsulinemia is accompanied by 
changes in tau phosphorylation. To gain insight into the mechanism(s) responsible for 
this and to identify key pathways, we performed microarray analyses on the 
contralateral brain region from the same mice used for protein analyses in chapter 4.  
 
7.2.1 The effect of APOE genotype on the brain transcriptome 
As we ultimately aimed to investigate the effect of HFD on brain gene 
expression, and how this may be affected by APOE genotype, we initially investigated 
the effect APOE genotype had on cortical gene expression in mice fed a LFD. There 
were 49 genes that were significantly differentially expressed in APOE knockout mice 
(KO) compared to normal wild-type (WT) mice at an FDR corrected q-value !0.05 
(Table 7.1). Reassuringly, one of the most significant changes, with the greatest fold 
change in expression was the APOE gene (~52, log2fold). To elucidate the molecular 
mechanisms by which APOE may act centrally, functional categories were assigned to 
the transcripts using NetAffx, GeneCards or NCBI Gene searches. The remaining 48 
genes that were altered encoded a diverse range of functions including apoptosis, 
metabolic processes, signal transduction, transcription and translation. We next 
compared gene expression between normal WT mice and those where murine APOE 
had been deleted, and replaced with human APOE!3 (E3) (Table 7.2) or APOE!4 (E4) 
(Table 7.3) We identified in these comparisons 51 genes and 47 genes respectively 
that reached an FDR corrected q-value !0.05. Genes that featured in all three tables 
(7.1 to 7.3) are likely to be genes affected by the deletion of murine APOE, whilst 
genes unique to table 7.2 or 7.3, are likely due to the effect of humanised APOE!3 or 
APOE!4 respectively on brain gene expression. To clarify, we built a Venn diagram  
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(Figure 7.1) to identify the number of genes, which were unique or common to the 
three comparisons.  
 
Figure 7.1 Venn diagram showing the number of common genes differentially 
expressed between APOE KO, APOE!3 or APOE!4 and WT mice fed LFD 
 
 
The up and down arrows indicate upregulation or downregulation of genes 
respectively. (L-WT = WT mice fed LFD; L-KO = APOE KO mice fed LFD; L-E3 = 
APOE!3 mice fed LFD; L-E4 = APOE!4 mice fed LFD). 
 
 
We identified 32 genes altered in all three comparisons, which are presumably 
due to the deletion of murine APOE (Table 7.4a). Classification of the 19 upregulated 
transcripts revealed genes involved in apoptosis, cell differentiation, development, 
metabolic processes, proteolysis, signal transduction, transcription, translation and 
ubiquitination. On the other hand 12 genes were downregulated that are involved in 
cytoskeletal organisation, metabolic processes, protein modification, signal 
transduction, transcription and transport. We also identified five genes altered by 
introducing human APOE genes (Figure 7.1; Table 7.4b). The only upregulated gene, 
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ZFP772, currently has no identifiable biological function. There were four 
downregulated genes; BLVRB (biliverdin reductase B) that catalyses the final step of 
heme metabolism, PSG16 (pregnancy specific glycoprotein 16), DMPK (dystrophia 
myotonica-protein kinase) and EXOC3L2 (exocyst complex component 3-like 2).  
There were 10 genes significantly altered uniquely in APOE!3 mice compared 
to WT mice (Figure 7.1; Table 7.4c). All 10 transcripts were upregulated with biological 
functions enriched in transcription, as well as sugar binding (LGALS4), transport 
(ARL5A) and a regulator of protein modification by phosphorylation (FAM129A).  
In contrast, the presence of APOE!4 altered the transcripts of 6 different genes 
(Figure 7.1; Table 7.4d). The only upregulated gene, ZFP180, is involved in gene 
transcription, whilst biological processes of the other five genes included transport 
(NAPA), signal transduction (ICOSL), development (CLPTM1) and protein 
phosphorylation (PRKD2). 
 
7.2.2 The effect of diet on the brain transcriptome 
As brain insulin signalling can influence AD pathology as in T2DM, we were 
interested to investigate the effects of diet on brain transcription. As we had identified a 
number of gene expression differences between WT and transgenic mice in section 
7.2.1, we felt it was important to compare LFD and HFD fed mice within each 
genotype. When we compared the brain transcriptomes of all mice fed LFD and HFD, 
we found no differentially expressed genes when using a FDR corrected q-value !0.05. 
Although this method was adequate for identifying differences between our WT and 
transgenic mice, we felt it may be too stringent to detect more subtle changes caused 
by dietary modifications. As such, we therefore decided to identify the top 50 genes 
when ranked by significance of change, using an uncorrected p-value, to identify 
central changes that may be associated with HFD feeding (Tables 7.5, 7.6, 7.7 and 
7.8). 
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Genes differentially expressed in WT mice fed a LFD versus HFD, are 
presented in Table 7.5. To elucidate the mechanisms and pathways involved centrally 
in diet-induced insulin resistance, we again assigned functional categories to the 
transcripts using NetAffx, GeneCards or NCBI Gene searches. 
Differentially expressed transcripts encoded proteins from many diverse 
functional categories. These included cytoskeletal organisation, development, 
phosphorylation, proteolysis, signal transduction and transport (Table 7.5).  
 
7.2.3 The effect of diet on the brain transcriptome in APOE KO transgenic mice 
As we identified both a number of genes that were altered in the brain due to 
deletion of the murine APOE gene (Table 7.1), and others altered in the brain as a 
consequence of diet in WT mice (Table 7.5), we therefore decided to investigate 
whether different genes are altered in APOE KO mice fed a HFD compared to those 
fed a LFD (Table 7.6). Differentially expressed transcripts encoded genes related to 
development, signal transduction, transcription, translation and transport. Of particular 
interest was the increased expression of the cholesterol transporter ABCA1 (ATP-
binding cassette sub-family A member 1), as ABCA1 is associated with clearance of A" 
in the brain. 
 
7.2.4 The effect of diet on the brain transcriptome in transgenic mice expressing 
human APOE transgenes. 
As we had shown that diet has a small effect on brain gene expression in 
trangenic mice with the APOE gene deleted (Table 7.6), we thus decided to investigate 
whether the introduction of human APOE!3 and !4 alleles, which increase the risk of 
developing AD in humans, could result in different genes being altered during dietary 
changes.  
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In APOE!3 transgenic mice, HFD feeding altered the expression of transcripts 
related to development, metabolic processes involving mitochondria and lipids, signal 
transduction, transcription, translation and transport (Table 7.7).  
In APOE!4 transgenic mice, differentially expressed genes in HFD fed animals 
were involved in kinase and phosphatase activities, signal transduction, transcription, 
translation and transport (Table 7.8). Also noteworthy is the increased expression of 
ADRA2A, which encodes an adrenergic, G-protein coupled receptor that is associated 
with insulin secretion (Fagerholm et al., 2004). This gene did not feature in tables 7.5, 
7.6 or 7.7, and is thus associated with the presence of the human APOE!4 transgene 
and HFD, and provides a possible interaction between diet and genotype in regulating 
insulin levels. 
 
7.2.5 The interaction between diet and APOE genotype in regulating brain 
cortical gene expression.  
Although we did not observe any APOE isoform-dependent effects on tau 
phosphorylation in these HFD fed mice, we went on to investigate the effects of APOE 
isoform on the cortical transcriptome in mice fed this HFD. It was hoped this may be 
informative as to the possible mechanisms underlying the APOE isoform-dependent 
effects on tau phosphorylation observed in pioglitazone treated HFD fed mice, as 
presented in chapter 5. 
To establish the effect of loss of APOE in mice, we looked at the effect of HFD 
feeding in APOE KO mice compared to WT mice (Table 7.9). Using an FDR corrected 
q-value !0.05, we found 55 transcripts differentially expressed. We were interested to 
compare this list to the list of genes significantly different in APOE KO mice compared 
to WT mice fed LFD, and to the list of genes significantly different when comparing 
APOE KO mice fed LFD and HFD. As such, we produced a Venn diagram (Figure 7.2) 
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of these three comparisons to help us identify which genes may be important in 
mediating the effect of diet in the absence of the APOE gene.   
 
Figure 7.2 Venn diagram showing the number of common genes differentially 
expressed between APOE KO mice fed LFD or HFD with WT mice fed LFD or HFD 
and APOE KO mice fed HFD compared to those fed LFD  
 
 
The up and down arrows indicate upregulation or downregulation of genes 
respectively. (L-WT = WT mice fed LFD; L-KO = APOE KO mice fed LFD; H-WT = WT 
mice fed HFD; H-KO = APOE!KO mice fed HFD). 
 
 
A total of 28 genes were altered in APOE KO mice, regardless of diet, of these 
genes 18 were upregulated whilst ten were downregulated (Table 7.10a). As expected, 
this list of genes was very similar to the list of genes in the centre of Venn diagram 
Figure 7.1, which were genes that are affected by deletion of murine APOE. Extra 
genes that are not common to those listed in the centre of Venn diagram in Figure 7.1 
include CCDC123 (upregulated), the biological function of which is unknown, MTHFD2 
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(upregulated) that has a role in magnesium ion binding and KPTN (downregulated), 
which is involved in actin cytoskeleton organisation.  
Unique to the loss of APOE and not related to dietary changes are 21 
transcripts, of which 15 were upregulated and 6 were downregulated (Table 7.10b). In 
contrast, unique to the loss of APOE, combined with HFD feeding is 27 transcripts; 3 
upregulated and 24 downregulated (Table 7.10c). Within this list (H-WT vs H-KO), 
upregulated include transcripts encoding a sugar binding protein, LGALS4 and 
CEACAM2, which has a role in signal transduction. The exact function of Ceacam2 is 
unclear however it has recently been reported that within the brain, Ceacam2 regulates 
feeding behaviour, energy balance and insulin sensitivity (Heinrich et al., 2010). 
Downregulated transcripts were enriched in kinases, metabolic processes, transcription 
and translation. Another interesting gene is NAPA, which is part of the SNARE 
complex that allows docking and fusing of vesicles to their target surface on the plasma 
membrane. Napa has been reported to be associated with GLUT4 vesicles that are 
insulin responsive and increases the absorption of glucose (Mastick and Falick, 1997). 
The downregulation of NAPA in our list may reduce association of GLUT4 vesicles with 
the plasma membrane and dysregulate storage of glucose in the brain of HFD fed 
APOE KO mice.     
No overlapping genes were found between APOE KO mice fed LFD and HFD 
with APOE KO mice compared to WT mice fed LFD or HFD. The genes in the APOE 
KO mice fed LFD and HFD comparison were compiled by identifying the top 50 genes 
ranked by significance of change, using an uncorrected p-value (discussed in section 
7.2.3). The fact that we have identified significant changes, which however do not pass 
FDR correction suggests HFD does cause gene expression changes in the brain, but 
we may have too few mice in our study to detect subtle changes in expression. 
After identifying genes that may be altered as a consequence of dietary 
changes, in the absence of APOE, we then went on to investigate whether human 
APOE transgenes may impact on cortical gene expression in mice fed a HFD. 
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Genotypic comparisons between WT and either APOE!3 or APOE!4 mice fed HFD 
using a FDR-corrected q-value !0.05 revealed a total of 50 transcripts (Table 7.11) and 
71 transcripts (Table 7.12) differentially expressed respectively. As we have identified a 
number of diet responsive genes, which are altered in transgenic mice expressing 
APOE!3 or APOE!4, we were interested to examine first whether the same genes or 
different genes were altered in transgenic mice expressing APOE!3 or APOE!4 fed 
HFD, as this would give us an insight into the molecular mechanisms that could be 
involved in the interaction between diet and APOE genotype in affecting brain gene 
expression. For ease of illustration this has been displayed as a Venn diagram (Figure 
7.3). Of our 50 genes that were significantly altered in transgenic mice expressing 
APOE!3 fed HFD and 71 genes altered in transgenic mice expressing APOE!4 fed 
HFD, 38 featured in both lists (Table 7.13a). GO processes in this common gene list 
included enzymes involved with metabolic processes, kinase and phosphatase 
activities, transcription and translation. Reassuringly, all 38 genes showed the same 
direction of chance in both transgenic groups. These genes could be altered due to 
either the deletion of murine APOE, the insertion of human APOE (regardless of allele), 
or an interaction of genotype with diet. To investigate this further, we searched for 
these 38 genes in both table 7.1 (genes altered in KO mice compared to WT mice) and 
tables 7.2 and 7.3 (genes altered in APOE!3 fed LFD and genes altered in APOE!4 fed 
LFD, respectively). Altogether, 37 genes were also identified in tables 7.1, 7.2 and 7.3. 
The transcript for DEDD2 (death effector domain containing DNA binding protein 2) 
was the only gene not identified in these lists and therefore could be due to an 
interaction between genotype and diet (highlighted in Table 7.13a).   
Genes unique to APOE!3 were also compared to tables 7.7 (genes altered in 
APOE!3 mice fed HFD compared to LFD) and 7.2 (genes altered in APOE!3 mice 
compared to WT mice fed LFD). A total of 8 genes were identified as not featuring in 
neither tables 7.7 or 7.2. These genes are likely due to an interaction between APOE!3 
and diet (highlighted in Table 7.13b).  
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Finally, we compared genes unique to APOE!4 to tables 7.8 (genes altered in 
APOE!4 mice fed HFD compared to LFD) and 7.3 (genes altered in APOE!4 mice 
compared to WT mice fed LFD). In comparison to tables 7.8 and 7.3, 21 transcripts 
were different and could therefore be due to interaction between APOE!4 allele and 
diet (highlighted in Table 7.13c).  
We found 12 genes (6 upregulated, 6 downregulated) that were uniquely 
differentially expressed in APOE!3 mice compared to WT mice fed HFD but not in 
APOE!4 mice. These genes encode proteins involved in processes such as 
development, phosphatase activity, signal transduction, synaptic vesicle recycling, 
transcription and translation (Table 7.13b). The genes unique to the HFD APOE!4 vs 
HFD WT comparison consisted of 9 upregulated genes, which were mostly involved in 
calcium or magnesium binding, development, signal transduction, transcription and 
translation, and 14 downregulated genes representing the following processes; iron 
homeostasis (TRFR2 (transferrin receptor 2)), proteolysis and vesicle transport (STX17 
(syntaxin 17) and AP1G2 (adaptor-related protein complex 1, $2 subunit)), signal 












Figure 7.3 Venn diagram showing the number of common genes differentially 
expressed between WT mice fed HFD and APOE!3 or APOE!4 mice fed HFD 
 
 
The corresponding gene lists are presented in tables 7.13a (overlapping genes), 7.13b 
(genes unique to WT vs APOE!3 comparison) and 7.13c (genes unique to WT vs 
APOE!4 comparison). The up and down arrows indicate upregulation or 
downregulation of genes respectively. (H-WT = WT mice fed HFD; H-E3 = APOE!3 





7.2.6 Pathway analysis and webQTL 
In this chapter we have identified 71 genes that are significantly altered in the 
brains of transgenic mice expressing human APOE!4 when fed HFD. Of these, 21 
were believed to be due to a combination of the presence of the !4 allele and a HFD, 
as they were not observed in other comparisons. These genes are particularly 
interesting as they may be important molecular mechanisms by which diet-induced 
diabetes may increase the risk of AD in at risk individuals. In chapter 5, we 
demonstrated that pioglitazone reduced tau phosphorylation in APOE!3 mice fed HFD 
but not in APOE!4 mice fed HFD. As we did not find components of the insulin 
signalling pathway (Akt, GSK-3), tau kinases (GSK-3, Cdk5) or the tau phosphatase 
PP2A altered in our protein studies, network analysis using ingenuity pathway analysis 
(IPA) may indicate pathways associated with changes in tau phosphorylation at a 
transcriptional level. We therefore compared gene expression levels between APOE!3 
mice fed HFD and APOE!4 mice fed HFD (Table 7.14), IPA revealed one of the top-
scoring canonical pathways was axonal guidance signalling (Figure 7.4). In this 
network, tubulin is directly related to some of the genes from our list (TUBB4, CNP, 
MAG) and together suggests cytoskeletal changes related to the microtubular network 
is fundamental to the remodelling of dendrites and axons. Tubulin is also indirectly 
related to Erk1/2 and Igf1 signalling via Akt or Cnpase. Furthermore, Akt is associated 
with p38 MAPK, JNK and the calcineurin protein. This network suggests that the 
altered tau phosphorylation by APOE genotype observed in chapter 5 may be 






Figure 7.4 Network for APOE!3 mice fed HFD vs APOE!4 mice fed HFD 
 
 
IPA revealed axonal guidance signalling as one of the top-scoring canonical pathways. 
The intensity of the node colour indicates upregulated (red) or downregulated (green) 







Many transcripts were altered when murine APOE was absent or when human 
APOE was introduced, regardless of diet. Two genes of interest, WDFY1 and NUDT19, 
were differentially expressed in these lists. To identify genes that are co-ordinately 
expressed with WDFY1 and NUDT19, and thus could also be involved in susceptibility 
to tau phosphorylation, these genes were entered individually into the webQTL 
database. Searches were run on the BXD Hippocampal Consortium M430v2 database. 
Among the brain regions for which data is available, hippocampus was chosen 
because it is one of the most affected brain regions in AD. The top 15 Pearson 
correlations for WDFY1 and NUDT19 are shown in tables 7.15 and 7.16. Of particular 
interest for this study was the neuropeptide Y receptor Y2 (NPY2R) gene, which 
showed the 6th highest correlation with WDFY1 (Table 7.15). The neuropeptide Y 
receptor family has been shown to have a diverse range of biological roles, one of 
which is the regulation of body weight and control of food intake (Naveilhan et al., 
1999). Also of interest, due to its link to AD, was the high correlation of presenilin 
enhancer 2 (PSENEN) with NUDT19 (Table 7.16). Psenen is the most recently 
identified component of the $-secretase complex, which is an enzyme intimately 
involved in A" production and a key regulator of the relative abundance of the most 







7.3 Discussion  
To further our findings from chapters 4 and 5, we have used microarray 
analyses in this chapter to identify transcriptional changes occuring in the brains of 
HFD induced insulin resistance mice. We have also investigated the effect APOE 
genotype has on cortical gene expression alone, and in combination with HFD. 
We identified firstly 32 genes, which we believed were altered as a response to 
the deletion of murine APOE, a further 5 genes that were altered as a response to the 
presence of human APOE transgenes, with a further 10 and 6 being altered by the 
presence of APOE!3 and APOE!4 respectively. Of the 32 genes altered in response to 
the absence of APOE, the most interesting finding was the downregulation of a number 
of genes involved in apoptosis, as this is a prominent feature of AD. VOPP1 (vesicular, 
overexpressed in cancer, prosurvival protein 1) is associated with apoptotic response 
and BOK induces apoptosis. ApoE plays an important role in lipid homeostasis within 
the CNS and is synthesised in large amounts in response to neuronal cell damage or 
traumatic brain injury (Boyles et al., 1989). Additionally, neurodegeneration is 
increased during aging by apoE deficiency (Masliah et al., 1995). Research by Hayashi 
et al have shown that apoE containing lipoproteins protects apoptosis in neurons via 
phospholipase C$1 activation (Hayashi et al., 2007, 2009) and thus may explain the 
upregulation of apoptosis associated genes when apoE expression is absent. Another 
interesting finding was the downregulation of the WDFY1 gene (WD repeat and FYVE 
domain containing 1), a protein localised on endosomes. Wdfy1 contains a FYVE 
domain that mediates the recruitment of proteins involved in cell signalling and also 
trafficking of proteins to phosphatidylinositol 3-phosphate containing membranes. 
APOE has been reported to activate Akt phosphorylation via the PI3K pathway in 
Neuro-2a cells (Laffont et al., 2002) and was suggested to affect neuronal cell 
metabolism. The downregulation of WDFY1 in the absence of APOE identified in our 
list suggests activation of the Akt pathway is reduced, which may interfere with cellular 
metabolism in neurons. Also noteworthy was the downregulation of PSG16 in mice 
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expressing either APOE!3 or APOE!4. PSG16 is a member of the carcinoembryonic 
antigen gene family, which is a member of the immunoglobulin gene superfamily. The 
function of this group of proteins is unclear, however evidence suggests they induce 
the secretion of some cytokines, including the interleukins IL-6, IL-10 and TGF-". It is 
thus plausible that the introduction of human APOE transgenes may reduce 
inflammatory events in the brain.  
Although we were able to identify highly significant changes in gene expression 
that occurred in response to changes in APOE genotype, we did not identify any genes 
that passed our stringent FDR correction when comparing the effect of diet on gene 
expression, within each genotype. This was likely due to a number of reasons, 
including the low power of the study, the brain region examined, and the likelihood that 
changes associated with diet would be more subtle. Despite this, we looked at the 50 
most significant genes in the uncorrected data. Uncorrected p-values still highlight 
genes that are altered but must be analysed with caution, hence we limited the 
analysis to just the top 50 genes. Within each genotype, comparing LFD with HFD 
revealed transcripts with many diverse functions. Some of these genes are diet or 
feeding related, however they have not been shown to have direct effects on the brain. 
For example, in WT mice fed HFD compared to LFD, FURIN was downregulated, 
which is involved in the processing of progrehlin, the precursor for grehlin, a hormone 
that stimulates hunger (Takahashi et al., 2009); DIO1 (deiodinase, iodothyronine, type 
I), which is upregulated in the liver of an mouse model resistant to diet-induced obesity 
(Kalaany et al., 2005) and MT2 (metallothionein 2), which has been shown to prevent 
HFD induced cardiac contractile dysfunction (Dong et al., 2007). Additionally, in 
APOE!4 mice, genes associated with diet include Il-7R (interleukin 7 receptor) the 
expression of which was decreased in blood mononuclear cells of humans that 
consumed a mediterranean diet (Konstantinidou et al., 2010) and decreased 
expression of CLDN5 (claudin 5) which is related to impaired blood brain barrier (BBB) 
integrity in rats that are fed a high energy diet (Kanoski et al., 2010). This is particularly 
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interesting in the context of this study as BBB integrity is reduced in chronic 
neurodegenerative diseases, such as AD, for which T2DM is a risk factor.  Another 
gene associated with feeding, which we expected to be altered in expression levels 
was neuropeptide Y (Beck et al., 1990). Although neuropeptide Y is widespread in the 
brain (Larhammar et al., 1987), it is plausible that this gene may be upregulated in 
other brain regions that are more susceptible to dietary changes, such as the 
hypothalamus.  
It was interesting to see an upregulation of the cholesterol transporter ABCA1 in 
APOE KO animals which highlights the association between these two proteins. ABCA 
is a subfamily of the large superfamily of ABC transporters responsible for the 
translocation of various substrates across the plasma membrane by using energy from 
ATP hydrolysis (Luciani et al., 1994). The ABCA1 transporter mediates cholesterol and 
phospholipid efflux to lipid poor lipoprotein particles. ABCA1 is transcriptionally 
regulated by the Liver X Receptor and is required for the generation and lipidation of 
apoE (Koldamova et al., 2003). In the brain and cerebrospinal fluid (CSF) of ABCA1 
knockout mice, levels of cholesterol and apoE are reduced (Kim et al., 2007; Wahrle et 
al., 2004) and the presence of small, poorly lipidated and unstable apoE containing 
lipoproteins in the CSF and that secreted from primary astrocytes indicated impaired 
cholesterol and phospholipid efflux to apoE. This role of ABCA1 in the lipidation of 
apoE and the formation of lipoprotein particles was also observed in human primary 
neurons (Kim et al., 2007). A series of reports have also revealed the role of ABCA1 in 
A" clearance and deposition. Deletion of ABCA1 in APP/PS1, APP23 or PDAPP mice, 
was shown to increase A" deposition and cerebral amyloid angiopathy with no change 
in APP processing or A" production therefore suggesting an impairment in A" 
clearance (Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005; Wahrle et al., 
2005). These observations were reversed in the PDAPP/ABCA1 double transgenic 
mouse model by Holtzman’s group (Wahrle et al., 2008). The overexpression of 
ABCA1 in the brain driven by the mouse prion promoter resulted in almost complete 
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absence of A" plaques and less A" deposition in the hippocampal dentate gyrus, a 
phenotype resembling PDAPP/APOE-/- mice. In addition, CSF and conditioned media 
from the primary astrocytes of these mice increased lipidation of apoE-containing 
particles. Taken together, it was concluded that ABCA1 mediated lipidation of apoE 
can reduce A" burden in the brain and that increasing ABCA1 function may have a 
therapeutic effect in AD. In humans, genetic studies have reported the possibility for an 
association of some of the ABCA1 genetic variants with risk for AD (Koldamova et al., 
2010) (for review). More recently, the ABCA7 member of the ABCA subfamily has been 
identified in a genome wide association study as a new susceptibility locus for AD 
(Hollingworth et al., 2011). 
 Intriguingly in APOE!4 mice, HFD upregulated ADRA2A encoding the #2A-
adrenergic receptor. #2A-adrenergic receptors mediate adrenergic suppression of 
insulin secretion (Fagerholm et al., 2004), thus insulin secretion is enhanced in 
ADRA2A KO mice (Devedjian et al., 2000). Recently, Rosengren et al identified a 
genomic 1.4 Mb locus linking impaired insulin granule docking at the plasma 
membrane and reduce "-cell exocytosis in diabetic Goto-Kakizaki rats (Rosengren et 
al., 2010). In this locus ADRA2A, was significantly overexpressed. Antagonists to the 
receptor, silencing of the receptor expression or blockade of downstream effectors 
rescued insulin secretion in the "-cells. Rosengren and colleagues further identified a 
single-nucleotide polymorphism (SNP) in the human ADRA2A gene which causes its 
overexpression and increases the risk for T2DM (Rosengren et al., 2010). The 
upregulation of this gene in APOE!4 mice fed HFD, but not in any other genotypes 
may support findings that patients with the APOE!4 genotype have a high risk of 
developing T2DM (Irie et al., 2008; Peila et al., 2002). Linking to these findings, 
Ronnemaa and colleagues recently reported that impaired insulin secretion increase 
the risk of AD (Ronnemaa et al., 2008). Taken together, this could mean the reduction 
in insulin secretion or insulin deficiency, specifically in APOE!4 carriers with T2DM, can 
induce impairment of downstream insulin signalling effects including A" trafficking and 
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accumulation, tau hyperphosphorylation and cognition. For example, insulin stimulates 
the uptake of apoE-enriched lipoproteins via the LRP receptor (Descamps et al., 1993) 
and apoE binds and facilitates the cellular degradation of soluble A" peptides (Jiang et 
al., 2008; Koistinaho et al., 2004). A reduction in insulin could result in reduced 
degradation of A" peptides by microglia leading to A" accumulation and formation of 
A" plaques. 
APOE!4 transgenic mice fed HFD had altered expression of many genes 
associated with cytoskeletal organisation compared to APOE!3 mice fed HFD. 
Although these genes did not meet the vigorous FDR correction, they still demonstrate 
important functional changes occurring in the cortex. Cytoskeletal changes are 
required for the formation of synapses during learning and memory. The 
downregulation of actin and microtubule related proteins in the brain, particularly within 
neurons, may be associated with the cognitive impairments observed in APOE!4 mice 
compared to APOE!3 mice (Grootendorst et al., 2005; Wang et al., 2005). In vitro 
studies have demonstrated APOE isoform specific effects on neurite outgrowth and 
microtubule depolymerisation; apoE4 depolymerises microtubules and inhibits neurite 
outgrowth (Nathan et al., 1995). Our network analysis by IPA revealed an indirect 
relationship between microtubule associated proteins with Erk1/2 and Igf1 signalling 
via Akt and Cnpase (2',3'-cyclic nucleotide 3' phosphodiesterase). Interestingly, the 
serine/threonine phosphatase calcineurin, and the kinases p38 MAPK and JNK, all of 
which are able to target tau (Goedert et al., 1997; Goto et al., 1985; Reynolds et al., 
1997a; Reynolds et al., 1997b) are also present in the network. This analysis suggests 
that the Erk1/2, p38 MAPK, JNK and calcinerin may play a role in the tau 
phosphorylation changes we previously described in chapter 5. Further experiments 
are needed to determine whether there is a direct link between these pathways and tau 
phosphorylation.  
Robust changes in gene expression were observed in both APOE!3 and 
APOE!4 mice fed HFD compared to WT fed HFD, even when data was corrected for 
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multiple testing. Many transcripts were altered similarly in both APOE!3 and APOE!4 
mice, indicating these may not be allele-dependent.  
Two of the most differentially expressed genes of interest, in the absence of 
murine APOE or introduction of human APOE, regardless of diet, were WDFY1 and 
NUDT19. Both genes have been previously identified in the AD11 mouse model as 
potential biomarkers for AD (Arisi et al., 2011). In this study, NUDT19 was 
downregulated and was identified as a brain marker of early (1-3 months) disease, 
whilst WDFY1 was upregulated in the brain in both early and late (6-15 months) 
stages, across multiple brain regions. Wdfy1 and Nudt19 are both associated with 
mitochondria. The FYVE domain of Wdfy1 recruits cell signalling proteins to 
phosphatidylinositol 3-phosphate containing membranes (He et al., 2009). Nudt19 is a 
coenzyme A diphosphatase that converts CoA esters into fatty-acyl-CoA esters for "-
oxidation and has recently been identified in a kidney proteomic study of diabetic 
patients (Zhang et al., 2011a). Our study demonstrates that these two genes are 
differentially expressed in the opposite direction when mice are insulin resistant. More 
importantly, our study clearly demonstrates that expression of these candidate genes 
are not APOE genotype specific, which is important in the context of Arisi and 
colleagues in vivo AD biomarker work; as all APOE variants are relatively common, an 
allele specific effect on WDFY1 and NUDT19 would significantly diminish the 
translatability of their work to human studies. These two genes may also be relevant to 
the peripheral insulin resistance-induced processes within the brain. Our webQTL 
analysis associated WDFY1 with the NPY2R gene. Although neuropeptide Y receptors 
are associated with stimulation of food intake, recent research has suggested they may 
have a protective role in the CNS, inhibiting release of the neurotransmitter glutamate 
during excitotoxic insults (Silva et al., 2005). Additionally, Nudt19 was significantly 
correlated to Psenen, a component of the $-secretase complex. This finding may 
support the idea that the impaired insulin signalling activates GSK-3, which 
subsequently dysregulates A" generation by $-secretase activity (Phiel et al., 2003). Of 
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further interest, the promoter sequences of WDFY1 and NUDT19 were entered into the 
DNAstar software application, Genequest, and found that both genes contain PPAR$1 
and PPAR$2 sites in their promoter regions, indicating that both genes may be possible 
targets of thiazolidinediones.  
There were more genes uniquely dysregulated in APOE!4 mice fed HFD, than 
in APOE!3 mice fed HFD, compared to WT mice fed HFD. Particularly noteworthy was 
the downregulation of the transferrin receptor 2 (TRFR2) gene, which may result in the 
disruption of iron homeostasis in mitochondria (Horowitz and Greenamyre, 2010). 
Mitochondrial dysfunction is frequently described in AD brain (Eckert et al., 2011), and 
is believed to be caused by oxidative stress due to the release of reactive oxygen 
species (ROS), such as O2- and OH-. Since neurons are highly sensitive to free 
radicals due to their post-mitotic nature, ROS is a major cause of neuronal cell death. 
Mitochondria dysfunction has been shown to cause tau phosphorylation and iron has 
been found to contribute to the development of A" plaques and has been detected in 
neurofibrillary tangles (Good et al., 1992; Mantyh et al., 1993). In addition, two vesicle 
transporters syntaxin 17 (STX17) and adaptor protein complex AP-1, $2 subunit 
(AP1G2) were downregulated. Disruption of these may disrupt protein trafficking and 
could cause the build up of proteins leading to their aggregation, For example, syntaxin 
5 has been shown to be involved in the secretion of A" peptides (Suga et al., 2005).  
In summary, transcriptomic analysis suggests that the tau phosphorylation 
changes observed previously in chapter 5 might be associated with Erk1/2, p38 MAPK, 
JNK and calcineurin. It also highlights the association between APOE and ABCA1 and 
the role in lipidation of lipoproteins and A" clearance. Transcriptomic analysis also 
suggests the ADRA2A gene, which mediates insulin secretion, may provide an 
underlying link between the APOE!4 isoform and the risk of developing T2DM. 
Furthermore the observation that the two genes WDFY1 and NUDT19 both have 
PPAR binding sites in their regulatory elements suggest they may be targeted by 
PPAR$ directed drugs such as the pioglitazones. Further work will be required to 
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validate some of these genes and the pathways, with relation to tau phosphorylation. 
The expression of individual genes is routinely assayed using real-time PCR (RT-
PCR). It would be of particular interest to examine the expression of the two common 
genes WDFY1 and NUDT19 in the brains of mice treated with pioglitazone in chapter 
5, across multiple brain regions, and particularly to look for correlations between 
expression and the degree of tau phosphorylation. We would also use RT-PCR to 
determine whether the feeding associated genes neuropeptide Y and leptin, which 
were not differentially expressed in the cortex of mice fed HFD compared to LFD, are 
in fact altered in other brain regions. Moreover, the expression of a gene does not 
always correlate with its protein expression and there are other approaches to 
transcript analysis including exon arrays which identifies splice variants (resulting from 
alternative splicing of mRNA), next generation sequencing-a high through-put DNA 
sequencing process and exome resequencing which selectively sequences the coding 
regions of the human genome and can potentially identify genes associated with 































The overall aim of this thesis was to investigate what effects activation of 
peroxisome proliferator-activated receptor-$ (PPAR$) signalling might have on 
Alzheimer’s disease (AD)-like pathologies resulting from experimentally induced insulin 
resistance, in the hope of identifying the molecular mechanisms underlying the action 
of both insulin and PPAR$ in this regard. Specifically, my working hypothesis was that 
diet-induced insulin resistance would cause APOE isoform-dependent effects on AD 
pathology and the subsequent treatment with the PPAR$ agonist, pioglitazone, would 
reverse diet-induced insulin resistance as well as AD pathology, possibly in an APOE 
isoform-dependent manner. 
The concept that the AD brain is in an insulin resistant state and that impaired 
insulin signalling contributes to pathology has generated a great deal of research effort. 
The evidence supporting an increased risk of AD in patients with type 2 diabetes 
mellitus (T2DM) has led the search to find therapeutics that restore brain insulin 
signalling. Recently, the thiazolidinediones (TZDs) rosiglitazone and pioglitazone have 
both been shown to improve cognitive function in patients with AD and in animal 
models. Since a definite diagnosis of AD can only be by the examination of the brain at 
autopsy, using animals has the advantage of gaining insight into the effects of drug 
action on brain pathology. However, it is unclear if APOE genotype, a well established 
risk factor of AD, has any effect on brain insulin resistance or how the APOE genotype 
affects the intervention of TZDs on the development of AD-like pathologies.  
Firstly, in this study, insulin resistance was induced in WT, APOE KO, APOE!3 
and APOE!4 mice by feeding a high fat diet (HFD). Mice manifested key features of 
T2DM; obesity, insulin resistance and impaired glucose metabolism. In the cortical 
region of the brain, tau phosphorylation was consistently reduced at three phospho-tau 
epitopes, in all insulin resistant mice, independent of APOE genotype. APP metabolism 
was not altered (as determined by A" ELISAs and measures of relative amounts of 
APP C-terminal fragments). Surprisingly, examination of some of the components of 
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the insulin signalling pathway, including the tau kinases GSK-3 and Cdk5 or the 
phosphatase PP2A were also not altered. 
I went on to show that 3 weeks pioglitazone treatment, in insulin resistant mice 
significantly altered tau phosphorylation in an APOE-dependent manner at one of the 
phospho-tau epitopes (Ser202/Thr205) examined. A significant reduction in tau 
phosphorylation at this epitope was observed in APOE!3 mice whilst, the reverse, a 
significant increase in tau phosphorylation at the same epitope was seen in the 
APOE!4 mice. Although changes in tau phosphorylation were observed, components 
of the insulin signalling pathway, the tau kinases GSK-3 and Cdk5, and also the tau 
phosphatase PP2A were again unaltered. Further to this, pioglitazone treatment 
reduced #-processing (non-amyloidogenic) in APOE!3 mice. The soluble levels of A"40 
and A"42 were not altered in pioglitazone treated compared to non-treated mice. 
However, in the APOE KO mice fed HFD and treated with or without pioglitazone, the 
soluble levels of A"40 and A"42 appeared to be higher compared to all other animals.  
I then investigated the effects of the apoE isoforms and pioglitazone treatment 
on tau phosphorylation and cholesterol biosynthesis in vitro. I investigated this by 
treating primary cortical neurons with Chinese hamster ovary (CHO)-apoE3 or CHO-
apoE4 conditioned media (CM). In both cases, improved cell viability relative to the 
neurons incubated with WT CHO CM was observed. In neurons incubated with CHO-
apoE3 CM tau phosphorylation was significantly reduced however this did not correlate 
to a change in GSK-3 activity. In neurons incubated with CHO-apoE3 or CHO-apoE4 
CM and treated with pioglitazone, no change in tau phosphorylation was observed. 
Furthermore, pioglitazone treatment in neurons incubated with CHO-apoE3 or CHO-
apoE4 CM did not alter cholesterol biosynthesis when measured by qRT-PCR.  
Finally, I examined the effects of diet and genotype on the cortical 
transcriptome of WT, APOE KO, APOE!3 and APOE!4 mice. A number of differences 
were observed. I found that feeding HFD in APOE KO mice increased the expression 
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of the cholesterol transporter ABCA1. In HFD fed APOE!4 mice, the expression of 
ADRA2A, a gene encoding the #2A-adrenergic receptor was increased which is known 
to be involved in T2DM. In the genotype comparisons, APOE!3 vs APOE!4 mice fed 
HFD revealed differentially expressed genes related to cytoskeletal organisation, post-
investigation with the ingenuity pathway analysis (IPA) revealed that these were related 
to the axonal guidance signalling pathway. The IPA network showed microtubule 
changes relating to insulin growth factor 1 (Igf1), p38 MAPK, Erk1/2, Akt, JNK and 
calcineurin. The comparisons of WT vs APOE!3 and WT vs APOE!4 mice all fed HFD, 
revealed two interesting genes in common, WDFY1 and NUDT19, being decreased 
and increased in expression respectively in both APOE!3 and APOE!4 mice. Genes 
differentially expressed in the APOE!4 mice as compared to WT controls included; 
transferrin receptor 2 (TRFR2), syntaxin 17 (SYX17) and adaptor-related protein 
complex 1, $2 (AP1G2), the expression of each being reduced in the APOE!4 mice.  
Our observation that diet-induced insulin resistance reduces tau 
phosphorylation, in all mice, independent of APOE genotype is contrary to many other 
published findings. Diabetes-like symptoms can be induced experimentally by a range 
of techniques and the discrepancy between our findings and other published data may 
be due to differences in animal models used. For example the majority of published 
studies that mimic insulin resistance in AD use streptozotocin (STZ), a nitrosurea 
derivative isolated from Streptomyces achromogenes. STZ cannot permeate through 
the blood brain barrier (BBB) but is toxic to pancreatic "-cells; STZ enters cells via the 
glucose transporter, GLUT2, and alkaylates DNA, inducing DNA damage (Rees and 
Alcolado, 2005).  As a result, insulin resistance and glucose intolerance develop 
because "-cells are destroyed and the production of insulin is halted. The systemic 
hypoinsulinemia effect on the brain in these animal models mimics type 1 diabetes 
mellitus (T1DM); a disorder due to primary failure of the insulin generating "-cells of the 
pancreas. As there is less evidence of a link between T1DM and AD compared to 
T2DM, STZ treated animals are therefore not a good model of insulin resistance in AD 
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and are not directly comparable to our study. These animals show A" pathology or tau 
phosphorylation as a consequence of the interruption of the insulin signalling pathway 
resulting in a loss of inhibitory control of GSK-3, the predominant tau kinase. 
Additionally, STZ can be intracerebroventricularly injected into the brain. In the brain, 
GLUT2 are widely expressed (Brant et al., 1993) and can be targeted by STZ which 
selectively reduces insulin production without disturbing systemic insulin and glucose 
levels. This has been shown to cause chronic reductions in glucose and glycogen 
metabolism in the cortex and hippocampus of rats (Plaschke and Hoyer, 1993) 
accompanied with the inhibition of insulin receptor function (Hoyer et al., 2000) and 
insulin signalling (Lester-Coll et al., 2006). This impairment in the insulin signalling 
pathway was shown to cause A" pathology (Plaschke et al., 2010; Salkovic-Petrisic et 
al., 2006), tau pathology (Deng et al., 2009) and learning and memory deficits in 
rodents (Lannert and Hoyer, 1998; Salkovic-Petrisic et al., 2006). Other studies use 
spontaneous diabetic models, which have a genetic deposition to T2DM, for example 
the BBZDR/Wor rats (Li et al., 2007) and db/db mice (Kim et al., 2009a), both of which 
have shown enhanced amyloidogenic APP metabolism, A" pathology, tau 
phosphorylation and tau cleavage. Gene deletion experiments can also induce insulin 
resistance by ablating some components of the insulin signalling pathway. Examples of 
these are the neuronal insulin receptor knockout (NIRKO) (Schubert et al., 2004) and 
insulin receptor substrate 2 (IRS2) knockout mice (Killick et al., 2009; Schubert et al., 
2003). In NIRKO mice, the loss of insulin mediated activation of phosphoinositide 3-
kinase (PI3K) resulted in a reduction of phosphorylated Akt and GSK-3" which led to 
an increase in tau phosphorylation. In the IRS2 knockout mouse, an increase in tau 
phosphorylation correlated to a reduction in PP2A activity but not GSK-3 activity. 
Likewise in the APP Tg2576 mice crossed with the IRS2 knockout mice (Killick et al., 
2009), tau phosphorylation was increased due to reduced levels of PP2A. However, 
these mice also displayed a reduction in A" plaques, which correlated with an increase 
of the A" binding protein, transthyretin, which may have facilitated A" clearance from 
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the brain. This was also accompanied by improvement in cognitive function in the 
Tg2576/IRS2 knockout mice. Taken together, these findings show the deletion of 
specific steps of the insulin signalling pathway does not necessarily result in evident 
AD pathology and may act in a protective manner.  
Diet-induced models of insulin resistance, which mimic the onset of T2DM, is 
more reflective of modern lifestyles in man. However, to date only a few studies have 
used diet-induced models of insulin resistance to investigate pathological processes 
related to AD. In chapter 4 (section 4.3), the discrepancies between these published 
reports and our own were discussed; feeding regimes, age of mice, different mouse 
models including transgenic mice predisposed to amyloid pathology. Moreover, APOE 
genotype dependent changes in AD pathology observed by other groups are likely to 
be caused by the constitutive expression of apoE under different promoters for 
example, neuron-specific enolase (NSE) and glial fibrillary acidic protein (GFAP) 
expressing apoE in neurons and astrocytes respectively, may drive the pathological 
features of AD, whereas in our study APOE was driven by the mouse APOE gene 
promoter leading to the expression of human apoE with identical tissue distribution and 
levels to that of the endogenous mouse gene. In the current study, diet-induced insulin 
resistance by HFD in mice demonstrated a reduction in tau phosphorylation. This is 
contrary to the hypothesis, that insulin resistance would cause impairments in 
downstream insulin signalling and therefore the resultant loss of inhibition in GSK-3 
activity would increase tau phosphorylation and alter A" metabolism. In fact, it is 
possible that in our hyperinsulinemic mice, there was an increased entry of insulin from 
the periphery into the brain across the BBB. This increase in the levels of insulin binds 
to the insulin receptors and mediates PI3K signalling, leading to the activation of Akt 
and inhibition of GSK-3 activity. Subsequently, in the absence of insulin resistance, 
levels of phosphorylated tau are reduced as observed in the brains of HFD fed mice. In 
support of this idea, intravenous infusion of insulin was shown to increase the levels of 
cerebrospinal fluid (CSF) insulin (Wallum et al., 1987), which demonstrated that 
! (*,!
peripheral insulin can be transported into the brain. Intravenous infusion of insulin 
under euglycaemic conditions in AD patients improves memory (Craft et al., 1996), and 
indicates that peripheral insulin may have a role in rescuing the impairment of insulin 
metabolism within the brain. Furthermore, clinical studies have shown that raising brain 
insulin levels by intranasal insulin is also beneficial and improves memory in AD 
patients (Reger et al., 2008). Similarly, intranasal insulin treatment in mice improved 
cognitive performance (Francis et al., 2008). Further supporting our observations, it 
was shown in mice that peripheral insulin treatment reverses tau phosphorylation in the 
brain (Jolivalt et al., 2008). Interestingly, a very recent study similar to our study was 
carried out in humans. Bayer-Carter and colleagues studied high-saturated/high 
glycemic index (HIGH) diet or a low-saturated/low glycemic index (LOW) diet in AD 
patients, amnestic mild cognitive impairments or healthy adults for 4 weeks (Bayer-
Carter et al., 2011). The outcome measures included CSF A"42 concentrations, which 
are normally reduced in AD patients due to the deposition of A"42 peptides into 
plaques. Intriguingly, in healthy individuals LOW diet reduced CSF A"42 whilst HIGH 
diet increased CSF A"42. Although the authors proposed their observations might 
reflect the presymptomatic stage of AD in which a rise in A"42 levels occurs before 
plaque deposition, nevertheless this study shows that a HFD could account for 
differences observed between ours and other studies.   
The failure to identify changes in the components of the insulin signalling 
pathway suggests there may be other mechanisms related to the action of insulin in the 
brain. In addition to serine phosphorylation, the activity of constitutively active tau 
kinase, GSK-3, is augmented by tyrosine (Tyr) phosphorylation at residues Tyr279 
(GSK-3#) and Tyr216 (GSK-3"). The phosphorylation state of both Tyr residues were 
not investigated in this study and should be considered in future experiments. It is also 
important to further examine possible alterations of these kinases and phosphatases in 
membrane fractions and compare these to cytosolic fractions. Furthermore, combining 
HFD with mouse models lacking these kinases and phosphatases for example, GSK-3 
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double knockout mice, p35 or Cdk5 knockout mice, may confirm our observations 
showing that HFD reduces tau phosphorylation. Alternatively, it is likely that the period 
of feeding required to increase levels of insulin sufficiently to affect the brain, may have 
led to a failure to detect changes in the insulin signalling components that could have 
occurred transiently at earlier time points. Feedback mechanisms may have led to the 
establishment of steady state levels similar to that of the time points we examined. 
Furthermore, it has been recently hypothesised that a decrease in brain glucose 
metabolism may contribute to neurodegenerative mechanisms (Gong et al., 2006). Tau 
can also be posttranslationally modified by O-glycosylation. Specifically, O-
glycosylation by the attachments of the monosaccharide beta-N-acetylglucosamine (O-
GlcNAcylation). O-GlcNAcylation and phosphorylation of tau are reciprocal to each 
other, in that they can compete for the same Ser/Thr residues (Liu et al., 2004). In 
support of this hypothesis, examination of AD post-mortem brain tissue found a 
correlation between reduced O-GlcNAcylated tau and hyperphosphorylated tau (Liu et 
al., 2009a; Liu et al., 2009b; Liu et al., 2008). This finding was also observed in T2DM 
post-mortem brain tissue (Liu et al., 2009b, 2011). These authors proposed that the 
observations are due to a reduction in glucose uptake via the neuronal glucose 
transporters GLUT1 and GLUT3 (Liu et al., 2009b; Liu et al., 2008) and/or reduced 
brain insulin signalling (Liu et al., 2011). Thus, for further work, it would be interesting 
to investigate whether the reduction in tau phosphorylation detected in HFD fed APOE 
mice was due to increases in O-GlcNAcylation. 
Having shown that HFD feeding induces insulin resistance in mice and causes 
a reduction of tau phosphorylation independent of APOE genotype. We then explored 
the effects of PPAR$ agonism on diet-induced insulin resistant mice. Pioglitazone 
treatment in diet-induced insulin resistant mice caused APOE allele-dependent 
changes in tau phosphorylation. The APOE!3 mice responded to treatment which 
reduced tau phosphorylation at the Ser202/Thr205 phospho-tau epitope in comparison 
to the vehicle treated APOE!3 mice, whilst the reverse, an increase in tau 
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phosphorylation was detected in the pioglitazone treated APOE!4 mice compared to 
vehicle treated APOE!4 mice. These observations are consistent with the findings from 
an early rosiglitazone clinical trial in which treatment stabilised cognition in mild to 
moderate APOE!4 negative AD patients (Risner et al., 2006). To date, there are only 
two publications that have examined TZD treatment on tau phosphorylation in vivo. 
Rosiglitazone reduced the number of tau aggregates containing Ser202/Thr205 
phospho-tau epitope in the hippocampus of human APP (K670N/M671L and V717F) 
double transgenic mice (Escribano et al., 2010), whilst in OLETF rats, which develop 
spontaneous T2DM, rosiglitazone also reduced tau phosphorylation at Ser202/Thr205 
epitope (Yoon et al., 2010). Both of these studies, along with our own, show that the 
Ser202/Thr205 phospho-tau epitope might be a common target of TZDs. Our 
observation correlating changes in tau phosphorylation with APOE genotype points 
towards the underlying cause as due to mitochondrial defects because the apoE 
protein is cleaved by a neuronal specific protease and the apoE4 isoform is the most 
susceptible to truncation. Histopathological staining of AD brains has shown the 
appearance of truncated fragments of apoE in NFT-like inclusions in neurons and 
mitochondrial damage in AD appears greater in APOE!4 carriers. It is thought that 
truncated C-terminal fragments of apoE escapes the secretory pathway and enters the 
cytosol and then impacts upon mitochondrial function. Since a possible role of PPAR$ 
is to stimulate neuronal mitochondria biogenesis (Strum et al., 2007), the excessive 
damage inflicted on mitochondria in APOE!4 mice or APOE!4 patients therefore 
renders APOE!4 genotype less able to respond to TZD treatment. Furthermore, out of 
the apoE isoforms, apoE4 is the only one with an N- and C-terminal domain interaction, 
which is postulated to be responsible for it’s pathogenic effects. A recent paper has 
provided evidence that neuronal cultures of NSE-apoE4, significantly reduced the 
levels of all subunits of mitochondrial respiratory complexes compared to NSE-apoE3 
cultures. The fact that this observation was not found in primary cultures from 
transgenic mice expressing astrocytic apoE (GFAP-apoE3 and GFAP-apoE4) 
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demonstrates this is mitochondria damage is specific to neurons. Furthermore, apoE4 
domain interaction can be abolished by the ArgThr61 mutation and this amended 
respiratory complex levels in Neuro-2a cells, indicating mitochondrial dysfunction is 
due to domain interaction, specific to the apoE4 isoform (Chen et al., 2011).  
In response to pioglitazone treatments, the APOE-dependent changes in tau 
phosphorylation did not correlate to changes in the components of the insulin signalling 
pathway (Akt, GSK-3), the tau kinases (GSK-3, Cdk5) or the tau phosphatase PP2A. 
As we only examined phosphorylation of the serine residues (Ser21/9) in GSK-3, it is 
possible that tyrosine phosphorylation (Tyr279/216) may correlate to the APOE-
dependent changes on tau phosphorylation and this would contribute to further 
experiments. Also, it cannot be ruled out that a shift of the kinases and phosphatase 
within subcellular compartments may have occurred, that would not have been 
detected in the total lysate preparations. Since we also have the membrane fractions 
for all mice, it would be interesting to compare the amount of active kinases and 
phosphatase between cytosolic and membrane fractions.   
Interestingly, in a very recent study, Choi et al found that PPAR$ can be 
phosphorylated at the Ser273 epitope via Cdk5 upon incubation of 3T3-L1 adipocytes 
with obesity related cytokines TNF#, IL-6 and fatty acids (Choi et al., 2010). The 
expression of cytokines that are increased during obesity, activates Cdk5 by causing 
the cleavage of p35 into the more stable p25 subunit (Dhavan and Tsai, 2001). The 
observation in 3T3-L1 adipocytes was replicated in vivo; HFD fed mice that became 
obese had increased PPAR$ phosphorylation and Cdk5 activity in adipose tissue, as 
early as 7 weeks compared to mice fed the standard chow diet. Furthermore, Choi et al 
found that phosphorylation of PPAR$ at Ser273 neither activated nor suppressed 
transcriptional activity of the receptor but dysregulated the expression of a subset of 
genes, including key metabolic regulators adipsin and adiponectin. On the application 
of the PPAR$ ligands rosiglitazone (a full PPAR$ agonist) and MRL24 (a partial PPAR$ 
agonist) in vivo, phosphorylation of PPAR$ in adipose tissue was reduced, alongside 
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improvement in glucose tolerance, reduction in fasting insulin levels, and most 
importantly, no alteration in body weight. Both rosiglitazone and MRL24 reversed the 
gene expression changes. By using hydrogen/deuterium exchange linked to mass 
spectrometry, the group found that binding of PPAR$ ligands to the PPAR$ ligand 
binding domain caused conformational changes which obstructed the access of Cdk5 
to the Ser273 epitope.  
In contrast to the study by Choi et al which was carried out in adipose tissue, in 
our study we have shown that p35 and p25 levels, and therefore Cdk5 activity was not 
altered in the cytosolic brain fractions of HFD fed mice treated with or without 
pioglitazone. If further work for our study shows no differences in Cdk5 activity between 
cytosolic and membrane fractions, it may suggest that a brain-specific mechanism 
exists for PPAR$ and its ligands within the brain. Other further work would include 
examining the phosphorylation state of PPAR$ at Ser273 in brain samples of our APOE 
mice treated with or without pioglitazone and also the phosphorylation state of PPAR$ 
at Ser273 in the brain of Cdk5 knockout mice. These experiments would confirm 
whether Cdk5 has a role in PPAR$ modification in the brain. 
Following their work on showing PPAR$-based drugs are not only anti-diabetic 
as agonists for the nuclear receptor but also block obesity-linked phosphorylation of 
PPAR$ by Cdk5, Choi et al developed synthetic compounds that blocked Cdk5-
mediated phosphorylation albeit having high affinity for PPAR$ and lacking classical 
agonism (Choi et al., 2011). One of these compounds, SR1664, demonstrated anti-
diabetic activity; lowering of glucose levels, reduction of fasting insulin levels and no 
change in body weight in obese mice. SR1664 also did not cause the side effects of 
many PPAR$ drugs such as fluid retention and weight gain. This paper by Choi and 
colleagues suggests the promising potential of a new class of anti-diabetic drugs over 
the current TZD agonists which causes side effects in patients. It would be interesting 
to see how this new class of anti-diabetic drugs affects Cdk5 activity in the brain, 
specifically on tau pathology in relation to AD. 
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Having shown in vivo that diet-induced insulin resistance can reduce tau 
phosphorylation and pioglitazone has APOE-dependent effects on tau phosphorylation, 
I went on to investigate, in vitro, whether these effects are mediated through direct 
action on neurons via cholesterol related mechanisms. This was because there is 
evidence showing cholesterol metabolism is differentially affected by the isoforms of 
apoE and that the TZDs can influence cholesterol biosynthesis (discussed in section 
6.1). To investigate apoE isoform specific effects, primary neurons were incubated with 
native preparations of apoE from the CM of CHO cells stably expressing human 
APOE!3 (CHO-apoE3) or APOE!4 (CHO-apoE4). Native preparations of apoE were 
used because the biologically active form of apoE requires lipid association (LaDu et 
al., 1995). ApoE from the CHO-apoE3 or CHO-apoE4 CM were taken up by neurons, 
as demonstrated by the pulse chase-like experiment. This most likely occurred via the 
LRP receptor, the most preferentially expressed apoE receptor in neurons (Rebeck et 
al., 1993). ApoE isoform specific effects on tau phosphorylation were observed in 
neurons cultured in CHO-apoE CM; apoE3 significantly reduced tau phosphorylation in 
neurons whilst apoE4 did not. This suggests the apoE3 isoform is protective, an 
observation that has also been demonstrated by other groups. The basis for the 
neuroprotective effects of apoE3 in comparison to the apoE4 isoform was proposed to 
be due to the greater avidity of the apoE3 isoform for tau which thereby forms more 
stable complexes with tau compared to the apoE4 isoform (Strittmatter et al., 1994). In 
addition, it was shown that apoE3 binds to the microtubule domains on tau and was 
proposed to protect tau from abnormal phosphorylation, thereby reducing its propensity 
to undergo self assembly into paired helical filaments (Strittmatter et al., 1994). 
Treatment of neurons cultured in the various CHO-apoE CM plus pioglitazone for 24 h 
showed a trend towards a decreased in tau phosphorylation however this did not reach 
statistical significance. This could be due to the length of pioglitazone treatment and 
longer treatment may show more pronounced effects. Furthermore, the genes related 
to cholesterol biosynthesis were examined in neurons incubated with WT CHO, CHO-
apoE3 or CHO-apoE4 CM and pioglitazone. Whilst neurons incubated with the WT 
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CHO CM and pioglitazone revealed some changes in cholesterol gene biosynthesis as 
reported by Cocks and colleagues; a trend in increased cholesterol gene expression 
(HMGCR, MVD and LSS) at 6 h, which were subsequently reduced at 24 h, neurons 
incubated with the CHO-apoE CM and pioglitazone did not revealed any significant 
changes in genes related to cholesterol biosynthesis or apoE isoform specific effects. 
Our findings are different to those published by Michikawa and colleagues who have 
shown that the neurotoxic effects of the apoE4 isoform are mediated by suppression of 
de novo cholesterol synthesis (Michikawa and Yanagisawa, 1998). However, further 
experiments are required to confirm our findings. Additionally, the discrepancy between 
our results and findings from other groups who have reported apoE isoform specific 
differences on neuronal cultures may be due to various factors. For example, the 
preparation of apoE (some groups have used recombinant apoE), the source of apoE, 
the type of cells or neuronal cultures and the precise culture conditions (addition of A" 
may allow apoE isoforms to show more prominent effects). For future experiments, an 
alternative in vitro model would be co-cultures of astrocytes and neurons from apoE 
transgenic mice. These cultures would give a more natural source of apoE thus 
eliminating variations noted above. This may give us a clearer indication of the role 
apoE isoforms plays in cholesterol biosynthesis, in the presence of a PPAR$ agonist. 
Given that we showed a decrease in tau phosphorylation in relation to diet-
induced hyperinsulinemia and an APOE genotypic specific change in tau 
phosphorylation but did not observe changes in the known tau kinases, GSK-3, Cdk5 
or phosphatase, PP2A, we then explored signalling by measuring genome-wide 
transcriptomic changes by microarray. I firstly identified APOE genotypic changes by 
comparing WT mice with APOE KO, APOE!3 and APOE!4 transgenic mice fed low fat 
diet (LFD). To then identify diet-responsive changes, the brain transcriptome of mice 
fed a LFD with that of mice fed a HFD within each genotype was compared. I also 
investigated the APOE genotypic changes by comparing HFD WT mice with both HFD 
APOE!3 and APOE!4 transgenic mice, as well as between APOE!3 and APOE!4 
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transgenic mice fed HFD. Although I was able to identify highly significant changes in 
gene expression in response to changes in APOE genotype,  I did not identify any 
genes that passed the stringent FDR correction when comparing the effect of diet on 
gene expression, within each APOE genotype. This was likely due to a number of 
reasons, including the low power of the study, the brain region examined, and the 
likelihood that changes associated with diet would be more subtle. These set of 
experiments described below will require further studies by for example, using more 
mice and validating specific genes using qRT-PCR. 
In the identification for diet-responsive changes, although no potential tau 
related kinases or phosphatases were identified, an interesting finding was the 
comparison of APOE!4 mice fed HFD to APOE!4 mice fed LFD that revealed 
differential expression of the ADRA2A gene encoding the #2A-adrenergic receptor. 
The #2A-adrenergic receptor mediates adrenergic suppression of insulin secretion. A 
polymorphism in the ADRA2A gene increases the risk of developing T2DM (Rosengren 
et al., 2010). This finding, replicated in two clinical studies, demonstrates a synergistic 
interaction between the APOE!4 gene and T2DM (Irie et al., 2008; Peila et al., 2002). 
Additionally, glaucoma is a progressive optic neuropathy characterised by apoptotic 
retinal ganglion cell (RGC) death and recent imaging research suggests that the loss of 
RGCs and their axons may play an important role in the visual deficit in AD patients. 
Interestingly, the action of #2A-adrenergic receptor agonists was shown to be 
neuroprotective in experimental models of glaucoma (Wheeler et al., 2001), possibly by 
a neuronal anti-apoptotic mechanism (Tatton et al., 2003). Moreover, #2A-adrenergic 
receptors were shown to regulate the dendritic growth of cortical neurons by altering 
the phosphorylation state of MAP2 (Song et al., 2004) and co-immunoprecipitated with 
the amyloid precursor-like protein 1 (APLP1), a homologue of APP in a two-hybrid 
screen (Weber et al., 2006). The authors of this work proposed that APLP1 regulates 
the trafficking of #2A-adrenergic receptors and may be a mechanism that #2A-
adrenergic receptor agonists exert their protective effects. #2A-adrenergic receptors 
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also modulate prefrontal cortex neuronal activity related to spatial working memory in 
macaques and rats via the inhibition of cAMP mediated signalling (Li et al., 1999a; 
Ramos et al., 2006). These data together suggests that #2A-adrenergic signalling 
might play a protective role for AD. Our data shows the gene encoding the #2A-
adrenergic receptor is increased in APOE!4 mice fed a HFD might account for a 
decrease of protective effects with the APOE!4 genotype. By using qRT-PCR in future 
experiments, the upregulation of ADRA2A can be validated in APOE!4 mice fed HFD. 
Although we did not observe any APOE isoform-dependent effects on tau 
phosphorylation in these HFD fed mice, we went on to investigate the effects of APOE 
genotype on the cortical transcriptome. It was hoped this may be informative as to the 
possible mechanisms underlying the APOE isoform-dependent effects on tau 
phosphorylation observed in pioglitazone treated HFD fed mice, as presented in 
chapter 5. In the APOE genotypic comparison, the whole brain transcriptomic analysis 
of APOE!3 mice fed HFD compared to APOE!4 mice fed HFD, revealed reduced 
expression of microtubule associated proteins (Map7, Tubb4, Cnpase). Reduced 
expression of microtubule associated proteins are indicative of disruption in the 
microtubule dynamic network, which is likely to have a detrimental effect upon cell 
physiology. IPA analysis suggested microtubule related proteins were indirectly related 
to the following proteins Igf1, Akt, Erk1/2, p38 MAPK, JNK and calcineurin (or PP2B). 
These kinases and phosphatase may underlie the APOE genotypic effects observed in 
tau phosphorylation upon administration of pioglitazone treatment and further validation 
experiments by western blotting of brain lysates from pioglitazone treated APOE!3 
versus APOE!4 mice would confirm this finding. The presence of Igf1 and Akt are 
indicative of insulin signalling, Igf1 binds insulin receptors and activates the insulin 
signalling pathway. However, the activation state of Akt, as measured by 
phosphoimmunoreactivity at the Ser473 site was not altered. Akt may also be activated 
via phosphorylation at an another epitope, Thr308. This epitope was not investigated in 
chapter 5 and would contribute to future experiments. All three MAP kinases (Erk1/2, 
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p38 MAPK and JNK) have been shown to phosphorylate tau (Goedert et al., 1997; 
Perry et al., 1999; Reynolds et al., 1997a; Reynolds et al., 1997b).  In vivo and in vitro 
studies have shown that TZDs alter JNK and p38 MAPK activities. Rosiglitazone 
reduced tau phosphorylation in rats with T2DM but not in rats with T1DM, and in the 
human tau-transfected SHSY-5Y neuronal cell line, by reducing JNK activity (Yoon et 
al., 2010). In HEK-293 cells stably expressing IRS1 and in 3T3L1 adipocytes, 
phosphorylation of IRS1 on Ser307 and Ser612 suppressed insulin signalling and was 
reversed by rosiglitazone treatment by inhibiting the action of JNK and p38 MAPK 
(Jiang et al., 2004). Additionally, TNF#, a pro-inflammatory cytokine associated with 
insulin resistance induced the activity of p38 MAPK in primary brown adipocytes and 
upon rosiglitazone treatment, insulin signalling was restored and glucose uptake 
normalised (Hernandez et al., 2004). Also, the inhibition of p38 MAPK signalling by 
pioglitazone ameliorated microglia inflammation (Ji et al., 2010). Calcineurin, also 
present in the IPA network, is a calcium (Ca2+)-dependent phosphatase that 
dephosphorylates tau (Drewes et al., 1993; Gong et al., 1994). Recently both 
rosiglitazone and pioglitazone have been shown to inhibit different sources of Ca2+ 
influx in hippocampal neurons. Rosiglitazone reduced voltage-gated Ca2+ channel 
currents whilst pioglitazone reduced NMDA receptor-mediated currents (Pancani et al., 
2009). It was suggested the actions of these TZDs are neuroprotective in regions of the 
brain vulnerable to AD. Interestingly, NMDA receptors are crucial to the establishment 
of long-term potentiation (LTP), which is intimately coupled to Ca2+ influx and involves 
calmodulin, a protein that also activates calcineurin (Tonks and Cohen, 1983; Yang et 
al., 1982). Taken together, one might speculate that pioglitazone may regulate Ca2+ 
signalling in neurons and improve learning and memory in the diet-induced insulin 
resistant APOE mice. Additionally, calcineurin might be involved with the 
dephosphorylation of tau (in the case for APOE!3 mice) as well as LTP. For future 
studies, it would be interesting to examine learning and memory in the diet-induced 
insulin resistant APOE mice treated with pioglitazone, to investigate whether there are 
apoE isoform-dependent effects, reflective of tau phosphorylation and whether they 
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mimic rosiglitazone clinical trials. This would show the APOE-dependent effects of 
TZDs on tau phosphorylation which may associate with learning and memory.   !
Other experiments for future studies would be to examine AD biomarkers in the 
mice of the current study. In the rosiglitazone clinical trial by Risner et al, plasma 
samples from treated and control patients were analysed. The following proteins 
corresponded to memory improvement: #-2-macroglobulin, complement factor C1 
inhibitor, complement factor H and apoE (Akuffo et al., 2008). With the AD Luminex 
panels currently in development, these biomarkers could be examined in the plasma 
samples of pioglitazone treated insulin resistant APOE mice, to investigate possible 
correlations with the tau phosphorylation observed within the brain. Moreover, 
adiponectin, a peripheral marker of TZD activity has been reported to have a possible 
role as a CNS signalling molecule. In humans, low molecular weight adiponectin 
multimers have been detected in the CSF (Kusminski et al., 2007; Une et al., 2011). 
Adiponectin has been detected in CSF after its administration in the periphery in mice 
(Qi et al., 2004) and was shown to stimulated AMP-activated protein kinase (AMPK) 
activity in the hypothalamus of mice, increased food intake and decrease energy 
expenditure (Kubota et al., 2007). Signalling molecules regulated by adiponectin 
include AMPK, JNK, p38 MAPK, and PP2A (Kim et al., 2009b; Luo et al., 2005; 
Yamauchi et al., 2002b). Furthermore, adiponectin receptors have been identified in 
mouse cortical neurons (Thundyil et al., 2010),  distributed in various cortical regions of 
the rat brain (Repunte-Canonigo et al., 2010) and protected hippocampal neurons 
against excitotoxicity (Qiu et al., 2011). This leads to the speculation that adiponectin 
can act on neurons and initiate downstream signalling pathways, perhaps related to 
AD. Future in vitro experiments in cultured primary cortical neurons could readily be 
used to examine these effects using recombinant adiponectin proteins. 
In conclusion an interaction between PPAR$ activation, APOE and tau 
phosphorylation has been identified. Diet-induced insulin resistance reduced tau 
phosphorylation at specific epitopes due to peripheral hyperinsulinemia, which is 
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independent of APOE genotype. Pioglitazone treatment reduced tau phosphorylation in 
an APOE isoform-dependent manner with the APOE!3 isoform being the most 
responsive to the actions of this drug. Further studies are required to validate the 
current findings and to further elucidate the mechanism. A better understanding of the 
relative importance of brain and peripheral insulin resistance will likely greatly improve 
our understanding of the disease process and also aide the rational design of 
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